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ABSTRACT 
 
LYDIA MARIE BARRIGAN: Immune evasion strategies utilized by Francisella tularensis 
(Under the direction of Jeffrey Frelinger) 
 
Francisella tularensis is a highly pathogenic, gram-negative, facultative intracellular 
bacterium and the causative agent of tularemia.  Francisella has evolved numerous 
mechanisms to evade host immune responses.  One immune evasion mechanism utilized by 
Francisella is its ability to induce prostaglandin E2 (PGE2) secretion from infected host cells.  
We identified 20 Francisella genes necessary for the induction of PGE2 secretion in infected 
host cells.  One of the genes necessary for PGE2 induction encodes a highly conserved 
AAA+ ATPase chaperone protein, ClpB.  F. tularensis live vaccine strain (LVS) clpB is 
attenuated in vivo, despite normal intracellular growth in vitro.  LVS clpB fails to inhibit pro-
inflammatory cytokine responses in the lung early after inoculation, a process normally 
inhibited by LVS.  The adaptive immune response is also altered compared to LVS with 
increased IFN-γ or IL-17A production by T cells.  Although LVS clpB is attenuated, it 
induces an immune response that is as protective as LVS following lethal challenge 
indicating clpB is a potential target for vaccine development.  Although the primary immune 
response is altered during LVS clpB infection, there are no differences in the secondary 
immune response to LVS.  The primary immune response to LVS requires IFN-γ and IL-17A 
production to control bacterial replication.  Few Th17 cells were identified during the 
secondary response in the lung whereas there were numerous CD4+ and CD8+ T cells 
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producing IFN-γ.  IFN-γ production is required for controlling bacterial replication 
during the secondary response, but IL-17A production is dispensable for survival during re-
infection.   
 Francisella also evades host immunity by targeting innate immune cells for infection.  
Francisella infects different cell types in the lung depending on the route of inoculation; 
alveolar macrophages are infected following intranasal inoculation while interstitial 
macrophages and neutrophils are infected in the lung after intradermal inoculation.  The 
lung’s cytokine milieu is more pro-inflammatory after intradermal inoculation compared to 
intranasal inoculation, consistent with the development of a more robust IFN-γ mediated 
adaptive immune response.  A better understanding of the mechanisms of Francisella 
infection will not only result in understanding important concepts in pathogenesis, but will 
suggest key pathways to impact for the development of drugs and vaccines.  
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CHAPTER 1 
INTRODUCTION 
 
Discovery of Francisella  
In 1911, George McCoy described a plague-like disease in ground squirrels in Tulare 
County California (1).  By 1912, McCoy and Chapin had isolated a gram-negative 
coccobacillus as the causative agent of this plague-like disease and named it Bacterium 
tularense (2).  Wherry and Lamb were the first to isolate Bacterium tularense in 1914 from a 
man’s conjunctival ulcer (3).  In subsequent years, Edward Francis of the Public Health 
Service extensively studied Bacterium tularense and named the disease caused by Bacterium 
tularense tularemia (4).  During Francis’s studies, it became clear to him that Bacterium 
tularense was also the causative agent rabbit fever, deer fly fever, tick fever and lemming 
fever.  Francis determined Bacterium tularense was transmitted to humans via the bite of an 
infected insect or by handling infected animal carcasses after hunting (4).  Indeed, many of 
the early cases described by Francis were farmers who had been bitten by an infected insect.  
Laboratory workers were also at risk for contracting tularemia; Francis is reported to have 
contracted tularemia on four separate occasions (4, 5).  In a lecture given by Francis in 1927, 
he claimed tularemia was, “elucidated from beginning to end by American investigators 
alone” (5).  While early studies of Bacterium tularense were conducted by researchers within 
the Public Health Service, it is clear now that tularemia was not a disease confined to the 
U.S.  Francis serologically confirmed 3 cases of human tularemia in Japan in 1925 and there 
 
 
are earlier reports from Japan and Europe of symptoms consistent with tularemia (6, 
7). In the 1920’s Bacterium tularense was designated Pasteurella tularensis, but DNA 
hybridization studies performed by Ritter and Gerloff in 1966 indicated the bacteria were not 
closely related to Pasteurella (8).  Ritter and Gerloff’s data supported earlier groups’ work 
that certain species within the Pasteurella genus were more closely related to one another 
than to other species within the genus (9, 10).  In honor of Francis’s many contributions to 
the understanding tularemia, Pasteurella tularensis was renamed Francisella tularensis.  To 
date, Francisella remains the only genus within the family Francisellaceae (11).         
Commonly studied Francisella laboratory strains 
There are three closely related strains of Francisella that differ in pathogenicity in 
both humans and mice.  A summary of the properties of the three commonly used 
Francisella strains is shown in table 1.  The most virulent strain is F. tularensis subspecies 
(subsp.) tularensis (SchuS4).  SchuS4 has an infectious dose of 10 bacteria in humans and 
the LD100 for all inoculation routes in C57Bl/6J or BALB/c mice less than 10 colony forming 
units (CFU) (12-14).  Mice inoculated with SchuS4 succumb to infection within 5 days.  F. 
tularensis subsp. tularensis is typically found in Northern America and is classified as a Type 
A strain (15).  Type A strains can be further broken down into two clades- A1 and A2.  Clade 
A1 is found  in the eastern U.S. and California while clade A2 is predominately found in the 
western half of the U.S. (16).  The A1 clade is further broken down into A1a and A1b based 
on the genotypes of human and animal isolates using pulsed field gel electrophoresis (17).  
Epidemiologic analysis revealed infection with clade A1b causes more severe disease (24% 
mortality) than A1a (4%) or A2 (0%) (17).  It is important to note, however, that the data set 
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could be biased because isolates are more likely to be collected from severe cases of 
tularemia.             
F. tularensis subsp. holartica is a Type B strain widely distributed in Asia, Europe, 
and North America and is less virulent in mice and man compared to Type A strains (16, 18).  
The commonly used Type B laboratory strain is F. tularensis subsp. holartica (live vaccine 
strain (LVS)) (15).  The inoculation route dictates the LD50 in mice for LVS.  For intranasal 
inoculations, the LD50 is 103 CFU whereas intradermal inoculation has an LD50 of 106 CFU 
(19-21).  The infectious dose in humans has not been explicitly tested, but 90 % of humans 
given a respiratory LVS vaccine with 104 organisms developed detectable antibody titers and 
59% required no treatment during a SchuS4 challenge (22).       
The inclusion of F. novicida as a F. tularensis subspecies is controversial (23-25).  F. 
novicida (U112) is considered a separate species from Francisella tularensis due to, 
“differences in phenotype including chemotaxonomic markers, distinct ecological roles, 
different clinical and epidemiological characteristics, and differing abilities and modes of 
invasion and mechanisms of tissue damage in mammals” (23).  Huber, et al. argues that 
DNA-DNA hybridization studies and 16S rRNA and recA sequencing indicates F. novicida 
should be a subspecies within the F. tularensis species (25).  Because F. novicida has not 
been officially recognized as a subspecies, it will be referred to as a separate species here.  F. 
novicida is found in Australia and North America and is avirulent in immunocompetent 
humans (26).  In mice, however, it is highly pathogenic with infectious doses (intranasal 
LD50 approximately 10 CFU; intradermal LD50 2.4x103 CFU) and a disease course similar to 
SchuS4 (27, 28).      
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Francisella genome properties 
Despite vast differences in virulence within mouse and man, the genomes of SchuS4, 
LVS, and U112 are highly similar with >97% sequence identity (SchuS4 accession number 
NC 006570, LVS accession number NC 007880, U112 accession number NC  008601).  
Despite the high degree of sequence identity between Type A strains (SchuS4) and type B 
strains (LVS), the chromosomes are extensively rearranged compared to one another (29).  
Type A strains also demonstrate gene rearrangement compared to one another while there is 
no observed rearrangement observed between two different Type B strains (29).  The 
Francisella species’ and subspecies’ chromosome contains approximately 1.9 Mb, encodes 
about 1,700 genes, and has a low % G+C content (32%) (30, 31).  Basic genome properties 
for all three strains are summarized in table 1.  Nearly one-third of all Francisella open 
reading frames encode hypothetical proteins of unknown function (30).  F. novicida has very 
few pseudogenes (14), which may not encode functional proteins, compared to both Type A 
and Type B strains (303 and 254, respectively) (30).  The large number of pseudogenes in 
Type A and Type B strains suggests these genomes are deteriorating while F. novicida’s 
genome is intact (30).  A highly conserved region of Francisella’s chromosome between 
species and subspecies is the Francisella pathogenicity island (FPI).  The FPI encodes 19 
genes and was originally identified because of its reduced %G+C content.  Type A and Type 
B strains have two nearly identical copies of the FPI, while F. novicida only has one.  
Another difference between strains is that SchuS4 and U112 contain anmK and pdpD, while 
these genes are absent in LVS (32).  While the presence of only one FPI copy in F. novicida 
may explain its decreased virulence in humans, this strain is still highly virulent in mice.  
Both copies of FPI genes seem to be functionally redundant because deletion or transposon 
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insertion does not impact virulence; attenuation only occurs when both copies are deleted 
(33-37).  As the name suggests, the FPI is required for Francisella virulence.  The role of the 
FPI during infection will be discussed in a later section.            
Tularemia 
Individuals can contact tularemia in a variety of different ways including inhalation, 
direct contact of infected tissue through a cut in the skin, a bite from an infected arthropod 
vector, or ingesting contaminated food or water.  Tularemia has an incubation period of 3-6 
days and is sometimes difficult to diagnose because of the non-specific symptoms, such as: 
malaise, fever, chills, cough, myalgias, and headache (18, 38, 39).  Ulceroglandular tularemia 
is the most common type of tularemia (90% of cases) and presents with an ulcer, the location 
of which can help determine how the patients contracted the disease (39).  Ulceroglandular 
patients have swollen lymph nodes that are painful to the touch (40).  When an ulcer cannot 
be found, the patient has glandular tularemia (41).  In rare cases, individuals can become 
infected through the conjunctiva and develop oculoglandular tularemia.  Clinical symptoms 
of oculoglandular tularemia include swollen eyelids, ocular erythema, excessive lacrimation, 
and pain (38, 41).  Another rare form of tularemia is oropharyngeal which is caused by 
ingesting contaminated food or water.  Patients present with ulcerative-exudative stomatitis, 
pharyngitis, and swelling of the regional lymph nodes (38, 41).  Occasionally, there are 
outbreaks of oropharyngeal tularemia where contaminated water is typically found to be the 
source of Francisella (42-45).   
The most severe form of tularemia is the pneumonic form that occurs when 
Francisella is inhaled.  Individuals can contract pneumonic tularemia when working with 
hay on a farm or working as a landscaper.  In fact, several of the early cases of tularemia 
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described by Francis were men working on the farm (4).  There is also the risk of aerosol 
exposure during a bioterrorism attack.  Patients with pneumonic tularemia have symptoms 
generally associated with pneumonia- fever, headache, sore throat, cough, malaise, and 
increased respiratory rate (38, 41).  Chest x-rays are typically un-informative because they 
are similar to x-rays from patients with tuberculosis, lymphoma, or pneumococcal 
pneumonia (38, 41, 46).  Pneumonic tularemia can also be caused by bacterial dissemination 
from distal sites and lung pathology is found in approximately 30% of ulceroglandular 
tularemia patients (39).  Before the advent of antibiotics, between 30-60% of individuals with 
pneumonic tularemia caused by a Type A strain would die (41).  Today, the mortality rate is 
less than 2% (47).  To treat tularemia, streptomycin is the first drug of choice, although 
gentamicin is an acceptable alternative treatment (47).  β-lactam antibiotics are ineffective 
because Francisella encodes a β-lactamase (48).                   
Francisella as a Bioterrorism Threat  
Within a few decades of Francisella’s discovery in California, it became clear this 
bacterium could be used in a bioweapon.  Francisella was tested on prisoners by Japanese 
scientists led by Ishii Shiro and Kitano Misaji in Manchuria starting in 1932 and continuing 
until 1945 (49).  Experiments involving Francisella and other potential bioweapon agents 
were conducted at a research facility called Unit 731 that employed more than 3000 
researchers (49).  Also during World War II, tularemia outbreaks affected German and Soviet 
Union soldiers.  Ken Alibeck, a bioweapons scientist from the former Soviet Union, has 
suggested those outbreaks were intentional (50).  The United States began an offensive 
bioweapon program in 1942 with assistance from Shiro and Misaji who received immunity in 
exchange for disclosing information regarding their work in Unit 731 (51-53).  In the 1950’s, 
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volunteers were exposed to Francisella aerosols in Fort Detrick, Maryland to determine 
human susceptibility and to test potential vaccines and therapies (51).  Francisella was one 
of 7 agents weaponized by the United States (51).  In 1975, the United Nations held the 
Convention on the Prohibition of the Development, Production, and Stockpiling of 
Bacteriological (Biological) and Toxin Weapons and on Their Destruction (BWC) went into 
effect (54).  This treaty prohibited signatories from developing or stockpiling pathogens or 
toxins, “of types and in quantities that have no justification for prophylactic, protective, or 
other peaceful purposes” (55).  All U.S. offensive biological weapons programs were ended 
by President Nixon’s executive orders in 1969 and 1970 and all stocks were destroyed 
between 1971 and 1973 (51, 56).  Despite the Soviet Union acting as a signatory to the 1972 
BWC treaty, Ken Alibeck claims the Soviet Union continued to stockpile Francisella, 
engineered to be antibiotic resistant, until the 1990’s (50).                                 
The use of Francisella as the infectious agent in a bioweapon would have devastating 
consequences.  F. tularensis subsp. tularensis has a low infectious dose; as few as 10 
organisms can cause severe disease in humans via either cutaneous or aerosol exposure (12, 
13).  Pneumonic tularemia is the most severe form of disease with high rates of fatality if left 
untreated (57).  Therefore, aerosolization of Francisella has the potential to expose a large 
number of individuals via the most virulent route.  A World Health Organization (WHO) 
committee estimated in 1969 that aerosolization of 50 kilograms of F. tularensis over a 
metropolitan area with a population of 5 million people would result in 250,000 
incapacitating casualties and 19,000 deaths (58).  One risk noted by the WHO as problematic 
with Francisella was the ability of tularemia outbreaks to persist for weeks, even months, 
after the initial attack (58).  Using the model devised by the WHO, the Centers for Disease 
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Control and Prevention (CDC) estimated that such an attack would cost society $5.4 billion 
per 100,000 people exposed (59).  Because of its low infectious dose, ease of aerosolization, 
ability to persist in the environment, and high rates of morbidity and mortality, F. tularensis 
subsp. tularensis is classified as a Tier 1 Select Agent by the U.S. government.  Because F. 
tularensis subsp. holartica LVS and F. novicida have been shown to not cause severe disease 
in man, the CDC has exempted these strains from the regulations governing select agent use.   
Intracellular lifestyle of Francisella 
Francisella is a facultative intracellular pathogen that can infect a wide variety of 
hosts including amoeba, arthropod vectors, and mammals.  One inside the host, Francisella 
targets a variety of cell types for infection.  Experiments with human cell lines found 
Francisella is taken into host cells by looping phagocytosis (60).  Serum opsonization 
enhances phagocytosis of Francisella and in the absence of opsonization, the mannose 
receptor can mediate uptake of bacteria (60-64).  Complement receptor 3 (CR3), Fcγ 
receptors, scavenger receptor class A, nucleolin, and lung surfactant protein A also mediate 
uptake of Francisella in mouse and human macrophages, dendritic cells, and neutrophils (62-
70).  Opsonization of SchuS4 by human C3 increases bacterial uptake into human monocyte-
derived macrophages (hMDMs) via CR3 (64).  Importantly, C3-mediated SchuS4 uptake 
does not lead to efficient NF-κB activation or elicit a pro-inflammatory response by hMDMs 
like C3-independent uptake does (64).  C3-mediated uptake of U112 into hMDMs does elicit 
a pro-inflammatory cytokine response which could partially explain why U112 is non-
pathogenic in immunocompetent humans (64).  The lack of pro-inflammatory cytokines after 
C3-mediated SchuS4 uptake is not due to bacterial factors because C3-dependent uptake of 
paraformaldehyde-fixed SchuS4 does not lead to phosphorylation of ERK whereas C3-
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independent uptake of fixed SchuS4 does (64).  Dai, et al. proposes that C3-mediated uptake 
results in a signaling cascade that negatively regulates TLR2 activation (64).  C3-mediated 
uptake is advantageous for SchuS4 because it gains entry to the host cell, but does so in a 
“silent” fashion.                
Once inside the host cell, Francisella escapes the phagosome to avoid degradation.  
The Francisella-containing phagosome does undergo portions of the normal phagosome 
maturation process (reviewed in (71)).  Several groups have characterized Francisella’s fate 
upon phagocytosis.  Because the groups used different Francisella strains, cell lines, and 
microscopy techniques, the timing of events vary; however, broad and consistent themes 
emerged.  Francisella resides in a phagosome for up to 4 hours post-infection.  During this 
time, the phagosome fuses with early endosomes (marked by EEA1) and then late endosomes 
(marked by CD63, LAMP1/2, and Rab7 GTPase) (61, 72-77).  Francisella-containing 
phagosomes do not fully mature into phagolysosomes because they never acquire cathepsin 
D (61, 72, 75, 78).  Whether or not the Francisella-containing phagosome becomes acidified 
is not clear.  Two groups have shown limited vacuolar ATPase accumulation on LVS- or 
Schus4-containing vacuoles in J774.1 and human macrophages (61, 72, 79).  Two other 
groups have found U112- or SchuS4-containing vacuoles to contain vacuolar ATPases and 
blocking acidification delayed disruption of the phagosomal membrane and consequently 
bacterial escape (73, 76).  The disparate results by these two groups may be a consequence of 
the mechanism of bacterial uptake.  Acidification did not occur when cells were infected with 
serum opsonized bacteria but did occur when non-opsonized bacteria were used.  Further 
experiments are necessary to clarify whether acidification occurs prior to Francisella’s 
escape from the phagosome. 
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Francisella has completely escaped the phagosome within 4-8 hours post-infection 
and grows in the cytosol.  In vitro and in vivo screens have identified Francisella genes 
necessary for growth and virulence (80-92).  However, it is difficult to separate a failure to 
escape the phagosome from a failure to grow intracellularly because growth requires the 
bacteria to escape the phagosome.  Therefore, additional experiments examining intracellular 
trafficking of mutants can determine whether a gene is critical for escaping the phagosome or 
for intracellular growth.  The ability of several Francisella mutants to escape the phagosome 
has been determined by microscopy.  The best characterized mutant is iglC.  Several groups, 
including our own, have found that iglC is required for Francisella to escape the phagosome 
(36, 73, 93-95).  DotU, IglG, IglI, PdpA, PdpC, and VgrG are other FPI proteins necessary 
for phagosomal escape (95-101).  IglD is required for LVS to escape the phagosome but not 
U112 (36, 102).  MglA, FevR, and MigR are also required for phagosomal escape (36, 94, 
103, 104).  Because these proteins all regulate FPI expression, it is unlikely they directly 
disrupt the phagosomal membrane but instead drive expression of proteins that do.  Outside 
of the FPI or regulators thereof, FTT0383, FTT1103, FTT1676, and carA are required for 
phagosomal escape (86, 91, 105).  U112 acpABC and hap have been shown to be required 
for phagosomal escape; however, other groups have found them dispensable in both SchuS4 
and U112 (104, 106-108).  Additional experiments are required to resolve these differing 
results.   
As stated before, many screens have identified genes necessary for Francisella to 
grow intracellularly.  Several mutations have been well characterized and have shown a 
dissociation between intracellular growth and escape from the phagosome, i.e. Francisella 
mutants can escape the phagosome but cannot replicate in the cytosol.  One such example is 
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ripA (109). LVS ripA escaped the phagosome at the same frequency as wild-type but once in 
the cytosol, did not replicate (109).  Other well characterized examples are: FTT0369c, gtt, 
and purMCD (90, 91, 110).  Two things are necessary to further characterize the genes 
necessary for phagosomal escape or intracellular growth.  First, in-frame deletion strains 
must be made to confirm the requirement of genes identified from transposon mutant screens.  
It is possible that polar effects could alter downstream gene transcription and the construction 
of in-frame deletion strains will avoid that potential issue.  Second, phagosomal trafficking 
needs to be determined for each clean deletion strain to determine whether a gene is required 
for escape or for growth.  These studies are important for our understanding of Francisella 
pathogenesis since escape and intracellular growth are required for virulence.                                    
Francisella replicates in the cytosol of host cells until approximately 24 hours post-
inoculation until the host cell lyses and bacteria are released or the bacteria are surrounded by 
a double-membrane structure termed the Francisella-containing vacuole (FCV).  The FCV is 
marked by LAMP-1 and cathepsin D indicating fusion with endosomal and lysosomal 
vacuoles and by autophagosome markers dansylcadaverin and LC3 (77).  Despite the 
presence of lysosomal components, bacteria within the FCV remain intact and do not appear 
to become damaged (77, 111).  Strains that fail to replicate intracellularly (dipA, purMCD) 
are found in autophagic-vacuoles, but these strains are destroyed indicating wild-type 
bacteria prevent destruction by an undefined mechanism (111).  Clemens and Horwitz did 
not observe autophagic vacuoles in human monocyte-derived macrophages or THP-1 cells 
following SchuS4 inoculation (112).  They attributed the difference in the formation of 
autophagic vacuoles to the use of human versus mouse macrophages.  More recently, 
however, Chong, et al. found autophagic vacuoles did form in human macrophages (111).  It 
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is possible that the formation of autophagic vacuoles is dependent on the culture conditions.  
Autophagy is used by the host to control other intracellular infections such as Salmonella, 
Listeria, or Streptococcus (113-115).  In the case of these intracellular pathogens the 
autophagic vacuole forms early after infection; however, Francisella isn’t found in the FCV 
until 20 hours post-inoculation (77).  Because the FCV forms late in infection and doesn’t 
result in bacterial destruction, its formation could be utilized by Francisella to leave the host 
cell if the host cell does lyse.                                       
Francisella pathogenicity island  
Pathogenicity islands are regions of bacterial chromosomes that encode proteins 
necessary for virulence (reviewed in (116)).  The FPI is a 33 kb region that encodes 16-19 
open reading frames that are highly conserved between Francisella species and subspecies.  
Nano, et al. first identified the FPI in 2004 by examining partially sequenced Francisella 
genomes (32).  Even before the identification of the FPI in 2004, genes within the FPI had 
already been identified as necessary for Francisella virulence (117).  Since the initial 
characterization of the FPI, numerous studies have been conducted examining the 
requirement of genes within the pathogenicity for intracellular growth, phagosomoal escape, 
cytopathogenicity, and virulence in mice and Drosophila (see Table 2 in (118)).  All FPI 
genes have been tested for their requirement for intracellular growth and only pdpC, pdpD, 
pdpE, and amnK are dispensable for intracellular growth (118).  These four genes are also 
dispensable for virulence in Drosophila (118).  The only FPI gene not required for virulence 
in mice is pdpE (118).  Not all FPI genes have been tested for their requirement for 
phagosomal escape or cytopathogenicity but of the genes tested, pdpE is dispensable for both 
properties, while iglG is not required for phagosomal escape and iglA is not required 
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cytopathogenicity (118).  Of all genes within the FPI, only pdpE is dispensable for all aspects 
of Francisella virulence.  Further studies are necessary to define the requirement of remaining 
FPI genes for phagosomal escape and cytopathogenicity.  It is clear, however, that the FPI is 
required for Francisella to grow in its intracellular niche and to cause disease in mice.   
Type six secretion system encoded by the Francisella pathogenicity island  
Genes within the FPI share limited homology with genes encoding type six secretion 
systems (T6SS) first discovered in Vibrio cholerae (97, 100, 119-122).  The FPI is a distant 
relative of all other identified T6SS (123).  The core components of T6SS are (V. cholerae 
annotation): ClpV, DotU, Hcp, IcmF, VipA, VipB, and VgrG (118).  The most conserved 
components of the FPI are IglA, IglB, DotU, and VgrG which are homologous to V. cholerae 
VipA, VipB, DotU, and VgrG, respectively (120, 124).  Interaction between IglA and IglB 
depends on a highly conserved IglA α-helix (124).  Based on homology with other T6SS, 
IglA and IglB are hypothesized to form a transmembrane structure capable of mediating the 
transport of effector proteins into the host cell; this hypothesis still needs to be directly tested 
in Francisella (125, 126).  DotU is required for functional T6S and is thought to stabilize the 
secretion apparatus (100).  While VgrG is also highly conserved, it lacks the C-terminal 
active domain found in other homologs (100).  Francisella VgrG is predicted to contain 
multiple β-strands and structural algorithms found it to show structural similarity to 
bacteriophage tail spike proteins suggesting VgrG could be involved in forming a bridge 
between Francisella and the host cell membrane (100).  Like other VgrG homologs, 
Francisella VgrG is secreted into the cytosol of infected macrophages and broth culture 
supernatants but in a FPI-independent manner (97, 119, 127).  U112 IglI was shown by 
Barker, et al. to be secreted in an FPI- and VgrG-dependent manner but Broms, et al. only 
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found FPI-independent secretion of LVS IglI (97, 99).  It is possible the difference in 
secretion profiles could have been strain specific, however, more recent work from Broms, et 
al. demonstrated LVS IglI secretion did require the FPI (128).  Broms, et al. used two 
different approaches (CyaA or TEM beta-lactamase fusion) to determine whether LVS IglI 
was secreted so it is possible the reporter tag affected secretion and lead to differing results.  
Using TEM beta-lactamase tags, Broms, et al. determined whether all FPI proteins were 
secreted into the host cell based on cleavage of the substrate CCF2-AM (128).  They found 
secretion of IglC, IglE, IglF, IglI, IglJ, PdpA, PdpE, and VgrG was dependent on DotU, IglC, 
IglG, and VgrG (128).  All but two of the proteins identified are novel T6SS effector 
proteins.   
Whether Francisella encodes a true T6SS is still unclear because three core T6SS 
components (ClpV, IcmF, and Hcp) have only limited homology with Francisella proteins.  
Francisella IglF shares some homology with ClpV, however IglF lacks the conserved AAA+ 
ATPase domain that supplies energy to drive T6S.  PdpB contains some IcmF homology but 
lacks the Walker A boxes found in conserved IcmF homologs.  Finally, IglC has structural, 
but not sequence, homology to Pseudomonas aeruginosa Hcp and is proposed to form a 
hexameric ring structure due this homology (122).  Additional support that Francisella uses a 
T6S-like system is that all of the secreted effectors identified by Broms, et al. are unique to 
Francisella and do not share homology with other T6SS effectors (128).  More studies are 
required to determine whether the function of the proteins encoded by the FPI and whether 
Francisella effectors are secreted by a T6SS or T6S-like system.                               
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Regulation of the Francisella pathogenicity island 
FPI expression is required for intracellular growth so it is not surprising that these 
genes are up-regulated once the bacteria are inside of host cells (73, 91, 120, 129-131).  
Expression of FPI genes is regulated by at least six proteins: MglA, SspA, FevR (also 
referred to as PigR), MigR, PrmA, and Hfq (27, 103, 130, 132-136).  MglA and SspA form a 
heterodimer and interact with RNA polymerase to drive gene expression (133).  FevR 
interacts with the MglA/SspA heterodimer and this interaction is mediated by ppGpp; fevR 
expression is also enhanced by increased ppGpp (137).  The FevR regulon is identical to the 
MglA/SspA regulon except that MglA/SspA regulate fevR expression further supporting the 
importance of the interaction between FevR and MglA/SspA to drive gene expression  (132, 
137).  FevR contains a helix-turn-helix motif that shares homology with MerR transcriptional 
activators suggesting FevR could target MglA/SspA/RNA polymerase to the FPI (132).  
MigR also regulates expression of the FPI but since it is required for fevR expression, it may 
be acting indirectly through FevR (103).  PrmA regulates expression of the FPI and binds its 
own promoter and pdpD’s promoter following phosphorylation by KdpD (136).  
Phosphorylated PrmA co-immunoprecipitates with MglA and SspA suggesting these proteins 
form a complex and regulate gene expression (136).  Unlike all other discussed regulators of 
the FPI which positively regulate gene expression, Hfq represses expression of Francisella 
genes within and outside of the FPI (135).  Specifically within the FPI, Hfq represses 
expression of genes from pdpA to iglJ, but not all FPI genes leading to speculation that the 
two operons within the FPI may be regulated differentially (135).                                     
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Innate immune response to Francisella 
Macrophages 
Macrophages are targeted by Francisella for infection in vivo and in vitro 
experiments often use human or mouse primary macrophages or macrophage-like cell lines 
to examine various aspects of Francisella pathogenicity.  In vivo, Francisella infects 
peritoneal, airway, lung interstitial, and alveolar macrophages (Chapter 4, (138-141)).  
Mouse macrophages infected with LVS are unable to produce pro-inflammatory cytokines, 
even when stimulated with E. coli LPS (140, 142, 143).  Macrophages infected with LVS are 
also subject to MHCII down-regulation (144).  These results will be discussed further in the 
immune evasion section.  Macrophage activation by IFN-γ prevents intracellular growth of 
U112, LVS, and SchuS4 (36, 75, 145).  U112 does not escape the phagosome of human 
monocyte-derived macrophages activated with IFN-γ (75).  IFN-γ activation of J774.1 mouse 
macrophages decreases, but does not abolish, LVS’s ability to escape the phagosome (93).  
SchuS4 escapes the phagosome of IFN-γ activated bone marrow-derived macrophages and 
human monocyte-derived macrophages but replication in the cytosol is abrogated (145).  
Differences in experimental design could impact when replication is affected from strain to 
strain; however, it is clear that macrophage activation by IFN-γ prevents Francisella 
replication and is a mechanism by which the immune system controls the infection.   
Dendritic Cells 
Francisella also infects dendritic cells (DC) in vivo (Chapter 4, (140, 141)).  SchuS4 
also replicates in human monocyte-derived DCs (146).  DCs are professional antigen 
presenting cells and are therefore a key bridge between innate and adaptive immunity 
(reviewed in (147)).  During antigen presentation, DCs secrete cytokines that influence how 
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naïve T cells differentiate into effector T cells (147).  Because DCs are a crucial component 
of the immune response, they serve as an excellent target for immune suppression by 
Francisella.  SchuS4 actively suppresses cytokine responses and up-regulation of MHCII and 
CD86 in human and mouse DCs whereas LVS does not (66, 140, 141, 146, 148-150).  
Immune suppression in DCs will be discussed in more detail below in the immune evasion 
section.            
Natural Killer Cells 
Natural killer (NK) cells are an important component of innate immunity and have 
cytolytic activity in the absence of antigen specificity (reviewed in (151)).  NK cells produce 
perforin and IFN-γ.  Production of perforin is dispensable during a LVS infection because 
perforin-deficient mice are not more susceptible than wild-type (152).  IFN-γ is critical for 
controlling Francisella infection and is produced by NK cells following LVS infection (153-
157).    Depletion of NK cells renders mice more susceptible to intranasal LVS infection; 
however, has no effect on disease course (bacterial burdens and weight loss) during primary 
intranasal SchuS4 infection (153, 158).  It is important to note, however, that mice succumb 
so rapidly to SchuS4 infection that it may be difficult determine whether a treatment worsens 
disease course.  Crane, et al. found very few IFN-γ+ NK cells in the spleen or lung of mice 
intranasally inoculated with SchuS4 further supporting data that NK cell depletion does not 
impact survival (159).  While NK cells do not play a protective role during SchuS4 infection, 
treatment of mice with Acai polysaccharide potentiates IFN-γ production by NK cells and 
increases percent survival after SchuS4 aerosol challenge (160).  Administration of CpG 
primes NK cells in a TLR9-dependent manner and enhances their ability to control an 
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infection of BMDMs (161).  These data suggest that immunomodulating therapy targeting 
IFN-γ production by NK cells could be used to treat tularemia.           
Neutrophils 
Neutrophils are critical during infection and assist in bacterial clearance by 
phagocytosis and the production of reactive oxygen species (reviewed in (162)).  Neutrophils 
also produce chemotactic factors that recruit other innate immune cells to the site of infection 
(162).  In a Francisella infection, neutrophils are present at the site of infection in a variety 
of inoculation routes (163-165).  Depletion of neutrophils using monoclonal antibody had 
only moderate effects of bacterial burdens in an aerosolized LVS model, despite the presence 
of neutrophils present in the lungs early after infection (165).  Neutrophil depletion during 
intravenous or intradermal infection with LVS caused mice to succumb to otherwise sub-
lethal doses (166).  The differences observed in mice infected with LVS could be attributable 
to the different routes of infection.  Depletion of neutrophils had no effect on mean time to 
death compared to control mice in an aerosolized SchuS4 model, however, death occurs so 
rapidly following SchuS4 infection (5 days) that it might be difficult to shorten time to death 
(167).  Similar results were found when neutrophils were depleted during an intranasal 
infection with SchuS4 (168).  It is important to note, however, that the studies examining the 
importance of neutrophils used the monoclonal antibody RB6-8C5, which recognizes Ly6G 
and Ly6C (169).  Ly6C is also present on dendritic cells, some lymphocytes, and monocytes 
(169).  Therefore, the results are confounded by the possibility that other cell types important 
during a Francisella infection were also depleted.  To avoid depleting other cell types, 
studies should use clone 1A8 which is specific for Ly6G and will only deplete neutrophils 
(169).  The presence of neutrophils could be detrimental during infection if the neutrophils 
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severe host tissue damage.  Matrix metalloproteinase 9 (MMP9) is an enzyme that degrades 
the extracellular matrix and recruits neutrophils and macrophages by creating a gradient of 
KC.  Recruitment of neutrophils in turn leads to additional MMP9 release and amplification 
of the recruitment signal.  Mice deficient in MMP9 have increased bacterial burdens and are 
more susceptible to infection with LVS or SchuS4 (170).  Altogether, these results suggest 
that neutrophils can play a beneficial role in the immune response to Francisella, however, 
too much of a neutrophil response is detrimental to the host.   
The importance of neutrophil effector function (i.e. reactive oxygen species (ROS) 
production) has also been investigated.  LVS infection of mice deficient in phagocyte oxidase 
(p47phox-/-) have a decreased LD50 compared to wild-type mice (171).  gp91phox-/- mice exhibit 
similar survival curves as wild-type mice but do have significantly increased bacterial 
burdens (168).  It is important to note that neutrophils are not the only source of ROS; 
macrophages also produce ROS (172).  Therefore mice deficient in enzymes required to 
produce ROS affect multiple cell types and this must be taken into account when considering 
the previous data.  In human neutrophils, opsonized LVS is capable of infecting cells but 
inhibits respiratory burst and replicates in the cytoplasm (173).  katG encodes a catalase 
capable of neutralizing ROS (174).  LVS katG and SchuS4 katG are more susceptible to 
H2O2 but only LVS katG is highly attenuated in vivo (174).  The difference between katG 
strains could be caused by the difference in pathogenicity of the parental strains; LVS is 
highly attenuated compared to SchuS4 in mice.  These data indicate that Francisella has 
evolved mechanisms to include inhospitable neutrophils in its replicative niche and expressed 
proteins to combat ROS.  Francisella certainly targets neutrophils for infection; neutrophils 
comprise the dominant population infected with U112, LVS, and SchuS4 on day 3 post-
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infection in the lung (139).  We also found neutrophils to be the dominant infected cell type 
in the epidermis and dermis following intradermal inoculation (Chapter 5).  Because 
neutrophils do not reside in normal, naïve skin, we hypothesize neutrophils are recruited to 
the site of infection where they ingest invading Francisella.                   
Innate immune detection of Francisella 
Toll-like receptors 
Toll-like receptors (TLRs) are a class of pattern recognition receptors (PRRs) that 
recognize conserved microbial products (reviewed in (175)).  TLRs are expressed on the 
surface of host cells or in the endosome (176).  Signaling through TLRs requires adaptor 
proteins such as MyD88, TRIF, and TIRAP and leads to the production of type I interferon 
and pro-inflammatory cytokines (176).  TLR2 recognizes lipoproteins and is the most 
important TLR during infection with Francisella (177).  Francisella has three identified 
TLR2 ligands- LpnA (also known as Tul4), FTT_1103, and FTL_0645 (178-180).  TLR2-/- 
mice are more susceptible to LVS intranasal and intradermal infection and have increased 
bacterial burdens in the spleen, liver, and lung (177).  TLR2 signaling is required for the 
induction of pro-inflammatory cytokines in LVS infected peritoneal macrophages and 
BMDCs (181, 182).  Since TLR2 signals through the adaptor, MyD88, it is not unexpected 
that MyD88-/- mice are also more susceptible to LVS infection than wild-type mice (155, 
177).  The phenotype of MyD88-/- mice is more severe than TLR2-/- mice suggesting there 
are other PRRs that signal through MyD88.  TLR4 also signals through MyD88, however, 
TLR4-/- mice are not more susceptible to intranasal infection with U112 or LVS or 
aerosolized SchuS4 (177, 183, 184).  TLR4 recognizes lipopolysaccharide (LPS), but 
Francisella expresses an altered form of LPS that does not initiate signaling through TLR4 
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(185).  This immune evasion mechanism is discussed in more detail below.  Two TLRs have 
been shown to have no role in Francisella infection.  TLR5 recognizes flagellin, but 
Francisella does not express flagellin.  Therefore, a NF-κB luciferase reporter is not 
activated when TLR5-expressing cells are stimulated with LVS (150).  TLR9 senses CpG 
DNA in the endosome/phagosome.  TLR9-/- mice have similar bacterial burdens and survival 
curves as wild-type mice when inoculated intradermally with LVS indicating this PRR is not 
required to sense infection with Francisella (155).                     
Inflammasome  
As discussed above, Francisella escapes the phagosome and replicates in the cytosol.  
Francisella evolved the ability to live intracellularly as a way to “hide” from the immune 
response, yet in the constant dance between host and pathogens, the host has evolved 
cytosolic sensors to detect pathogens, like Francisella, that violate the sanctity of the cytosol.  
A major class of cytosolic PRRs are the NOD-like receptors (NLRs) (reviewed in (186)).  
NLRs form the inflammasome by interacting with the adapter protein, ASC, which recruits 
and then cleaves pro-caspase-1 into its active form (reviewed in (187)).  Caspase-1 can then 
process pro-IL-1β and pro-IL-18 into their active forms.  There are numerous NLRs family 
members (22 in humans; 34 in mice) that respond to a variety of signals from molecules 
associated with pathogens to self-derived molecules like cholesterol crystals (187).   
In the context of LVS or U112 infection, production of IL-1β and IL-18 requires 
ASC, caspase-1, and AIM2 but not the alternative adaptor Ipaf (101, 188-190).  Additionally, 
phagosomal escape is required for caspase-1 activation because U112 mlgA or pdpA mutants 
that do not escape are unable to cause pro-caspase-1 cleavage (101).  AIM2 co-localizes with 
bacterial DNA suggesting that lysed Francisella in the cytosol activates the AIM2 
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inflammasome (188, 189).  Mice deficient in caspase-1, ASC, or AIM2 are more susceptible 
to U112 infection compared to wild-type mice as measured by bacterial burdens and/or 
survival (101, 188, 189).  Type I interferons are also required for inflammasome activation 
because IFNAR-/- macrophages do not cleave caspase-1 or produce mature IL-1β or IL-18 
(191).  Type I interferon increases AIM2 expression supporting a mechanism by which the 
cells are sensitized to DNA recognition by type I interferon signaling.  Yet, despite the 
importance of type I inteferons for inflammasome activation in vitro and the increased 
susceptibility of mice deficient in required inflammasome components, IFNAR-/- mice are 
more resistant to U112 and LVS infection (our unpublished data and (192)).  The 
discordance in results could be explained by the finding that IFNAR-/- mice have increased 
IL-17A production and increased neutrophil numbers which could increase bacterial 
clearance, thereby promoting host survival (192).   
Immune evasion by Francisella 
Targets innate immune cells 
One immune evasion strategy utilized by pathogenic bacteria is to target innate 
immune cells for infection and subsequent killing (193).  Francisella has been shown to 
target a variety of cell types following infection including dendritic cells, macrophages, 
monocytes, neutrophils, and alveolar type II (ATII) epithelial cells (139-141, 194).  Hall, et 
al. performed a comprehensive study to identify the infected cell repertoire in the lungs of 
mice inoculated with GFP-expressing U112, LVS, or SchuS4 using flow cytometry (139).  
Alveolar macrophages compose 50-80% of all infected cells for all three Francisella strains 
one day post-infection (139).  By day 3 post-inoculation, the infected cell repertoire is very 
different with neutrophils comprising 45-80% of infected cells (139).  The experiments by 
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Hall, et al. provided insight into Francisella-host interactions later in infection, but did not 
identify the cell types that Francisella initially targeted for infection.  Bosio, et al. identified 
Francisella infected airway macrophages and lung dendritic cells one hour post-inoculation 
(140, 141).  Our laboratory has also worked to identify the infected cell repertoire in the lung 
and skin after intranasal or intradermal inoculation.  These data are presented in Chapter 4.                        
Francisella modulates macrophage function 
As indicated in the preceding section, Francisella targets a variety of immune cells 
for infection.  Once inside of these cells, Francisella is capable of modulating their cytokine 
response.  J774.1 cells infected with LVS do not secrete TNF-α or IL-1β, even when 
stimulated with E. coli LPS (142).  Bone marrow-derived macrophages (BMDM) do not 
significantly up-regulate MHCII or CD86 (co-stimulatory molecule) upon inoculation with 
LVS (140).  Additionally, infected BMDMs do not produce detectable CCL2, IL-1β, IL-6, 
IL-10, MIP-2, or TNF-α when infected with LVS (140, 143).  Human monocyte-derived 
macrophages are able to produce pro-inflammatory cytokines after infection with LVS (143).  
Alveolar macrophages purified from the lung after intratracheal inoculation with LVS 
behaved like BMDMs with no up-regulation of MHCII or CD86 and no cytokine production 
(140).  Together, these data indicate that infection with LVS does not induce phenotypic 
(antigen presentation) or functional (cytokine production) maturation of macrophages.  These 
data are summarized in table 2.     
Francisella modulates DC function 
DCs infected with Francisella also have their responses modulated.  LVS infection of 
bone marrow-derived DCs (BMDC) leads to up-regulation of MHCII and CD86 but not 
production of IL-6, IL-10, or TNF-α (140).  Therefore, unlike BMDMs, BMDCs can undergo 
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phenotypic maturation without undergoing functional maturation.  Airway DCs are infected 
with LVS following intratracheal inoculation and these cells support bacterial replication 
(140).  Like BMDCs, mouse airway and lung DCs up-regulate MHCII and CD86 upon LVS 
infection and these cells do not produce TNF-α as determined by flow cytometry (140).  
SchuS4 infection, on the other hand, does not cause MHCII or CD86 up-regulation of 
airway, lung, or lymph node DCs (141).  Furthermore, cultured lung and airway cells from 
SchuS4 infected mice do not produce levels of TNF-α or IL-12p40 that is increased 
compared to uninfected mice (141).  LVS infection of DCs also inhibits cytokine production 
when infected cells are stimulated with LPS (TLR4 agonist) or zymosan (TLR2 agonist) 
(140).  Likewise, SchuS4 infection prevents CD86 up-regulation on DCs or monocyte 
recruitment when mice are treated with intranasal LPS (141).  Both LVS and SchuS4 
infection lead to the production of the anti-inflammatory cytokine, TGF-β (140, 141).  
Together, these data indicate that infection with LVS and SchuS4 suppress host immunity by 
decreasing antigen presentation by preventing functional maturation of DCs and by inducing 
TGF-β to form an immunosuppressive environment.  As a consequence, Francisella can 
persist in the host.                        
Human monocyte-derived DCs infected with SchuS4 up-regulate MHCII and CD86 
but do not produce any pro- or anti-inflammatory cytokines (146).  SchuS4 infected cells also 
fail to respond to secondary stimulation with E. coli LPS (146).  The inhibition of cytokine 
production is an active process by SchuS4 because cells inoculated with killed SchuS4 can 
produce cytokine in response to E. coli LPS (146).  Monocyte-derived DCs express little 
surface CD14, a co-receptor for TLR2 and TLR4 (149).  Addition of soluble CD14 allows 
monocyte-derived DCs to produce cytokine after SchuS4 inoculation (149).  SchuS4 
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inoculation of monocyte-derived DCs leads to the production of IFN-β and the selective 
inhibition of IL-12p40, but not TNF-α, production (148).  Incubation of human DCs with 
SchuS4 conditioned media also resulted in a failure of those to produce cytokine after E. coli 
LPS stimulation suggesting that SchuS4 secretes molecule(s) that can inhibit cytokine 
production (146).  LVS does not have the same inhibitory effect on human monocyte-derived 
DCs.  DCs up-regulate CD40, CD86, and MHCII and produce a variety of cytokines after 
LVS inoculation (66, 150).  The ability of LVS to induce a pro-inflammatory response in 
human DCs and macrophages could indicate why LVS is not pathogenic in humans, while 
the inability of human DCs to respond to a SchuS4 infection is likely one reason SchuS4 is 
highly pathogenic in people.  These data are summarized in table 2.      
Altered LPS structure 
LPS is a pathogen associated molecular pattern (PAMP) abundantly present on the 
surface of gram negative bacteria (195).  LPS consists of 3 distinct structural regions: O-
antigen, core, and lipid A (196).  LPS lipid A signals through TLR4 to activate pro-
inflammatory immune responses (197).  MALDI-TOF mass spectrometry showed that many 
different Francisella isolates (including subsp. tularensis, holartica, and mediasiatica, and F. 
novicida) have conserved tetra-acetylated lipid A with longer carbon chains (185, 198-200).  
Purified F. novicida LPS fails to stimulate human or mouse cell lines to produce cytokines 
like IL-8, TNF-α, or IL-1β (185).  Additionally, F. novicida LPS does not act as a TLR4 
antagonist, as cells can respond to Salmonella LPS even in the presence of 100 ng/mL F. 
novicida LPS (185).  Finally, aerosol delivery of F. novicida LPS does not result in 
neutrophil recruitment to the lung like E. coli LPS does (185).  Together, these data indicate 
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that Francisella LPS does not stimulate a pro-inflammatory immune response, allowing the 
bacteria to evade TLR4 mediated detection.                  
Induction of PGE2 
SchuS4, LVS and U112 induce infected bone marrow derived macrophages to 
synthesize and secrete the lipid mediator, prostaglandin E2 (PGE2) (95, 201).  Induction of 
PGE2 synthesis and secretion alters the immune response so that Francisella can persist in 
the host.  PGE2 is a pleotropic molecule that has a variety of effects on the immune response 
depending on its local concentration and the E-prostanoid receptor (EP) that binds PGE2 
(reviewed (202)).  PGE2 is required for dendritic cell migration from the infected tissue to the 
draining lymph node (203-205).  PGE2 also effects cytokine production, and therefore naïve 
T cell differentiation, by antigen presenting cells via inhibition of IL-12 production 
(decreases Th1) and enhancement of IL-23 production (increases Th17) (206-209).  Finally, 
PGE2 signaling through E-prostainoid receptor 4 (EP4) decreases calcium flux and therefore 
early T cell activation (210).  PGE2 engagement of EP4 causes T cells produce less IL-2 
thereby decreasing T cell proliferation (210, 211).  PGE2 signaling through EP4 also causes T 
cells to produce less IFN-γ, but more IL-4 and IL-5 thus skewing the T cell response from a 
Th1 response that mediates clearance of intracellular pathogens like Francisella towards a 
Th2 response that is suited for clearing extracellular pathogens (211, 212).  Overall, PGE2 
induced by Francisella decreases the number of responding T cells and skews the T cells that 
do respond towards effector functions that are ineffective at bacterial clearance.  Intranasal 
inoculation of B6 mice with LVS increases PGE2 concentration in the lung (213).  Inhibition 
of PGE2 synthesis with indomethacin, a COX1/2 inhibitor, decreases PGE2 concentration, 
increases the number of IFN-γ producing T cells, and results in faster bacterial clearance 
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(213).  Therefore, induction of PGE2 is an effective immune evasion strategy utilized by 
Francisella to persist in the host.     
We have identified the Francisella genes necessary for induction of PGE2 synthesis 
and secretion (95).  These data are presented and discussed in Chapter 5.    
Down-regulation of MHC 
Francisella further modulates the adaptive immune response by causing down-
regulation of MHCII expression on IFN-γ activated bone marrow derived macrophages 
(144).  The ability of Francisella to decrease surface expression of MHCII is dependent on 
PGE2 synthesis by infected host cells (144).  Autocrine and/or paracrine PGE2 signaling 
through a yet unidentified EP leads to the production of a >10 kDa soluble factor, termed 
FTMØSN, that induces IL-10 production (214).  IL-10 signaling leads to increased 
expression of the ubiquitin ligase MARCH1 (214).  Ubiquitination of MHCII leads to its 
degradation and therefore decreased antigen presentation to CD4+ T cells.  The identity of 
FTMØSN remains unknown, but Hunt, et al. report it is not IL-10, TGF-β, IL-6, VEGF, 
MIP-1α, or leukemia inhibitory factor (214).  Additionally, production of FTMØSN does not 
require TLR2 signaling or caspase-1 processing (214).  Although the signaling cascade that 
leads to MHCII down-regulation is complex, it does require PGE2.  Therefore, inhibition of 
PGE2 synthesis would not only increase antigen presentation to CD4+ T cells but those T 
cells would make a more effective response, as described in a subsequent section.                             
Adaptive immune response to Francisella 
Primary response by γδ T cells 
While αβ+ TCR T cells are critical during primary and secondary infection with 
Francisella, γδ+ TCR T cells are dispensable.  γδ TCR-/- mice are not more susceptible to 
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primary intranasal or intradermal infection with LVS (215, 216).  During primary infection 
with SchuS4 in a convalescent model, γδ TCR-/- mice are not more susceptible than wild-type 
mice (159).  Additionally, γδ TCR-/- survivors of the primary infection were also not more 
susceptible than wild-type survivors during a secondary infection (159).  γδ T cells produce 
IL-17 upon intranasal infection with LVS, but since γδ TCR-/- mice are not anymore 
susceptible to infection than wild-type mice, γδ T cells and their effector functions are not 
essential in mouse models of tularemia (215, 217).         
Although γδ T cells appear to be dispensable in mice, γδ T cells respond to 
Francisella infection in humans.  In particular, Vγ9/Vδ2 γδ T cells comprise almost all 
peripheral blood γδ T cells and 30-40% of all CD3+ T cells even one month after infection 
(218, 219).  Vγ9/Vδ2 γδ T cells respond to phosphoantigens and are capable of controlling 
LVS-infected THP-1 cells (human monocyte cell line) (220).  Some, but not all patient 
Vγ9/Vδ2 γδ T cells were also capable of controlling growth of SchuS4 in THP-1 cells (220).  
Depletion of IFN-γ increased the number of intracellular LVS suggesting IFN-γ is produced 
by Vγ9/Vδ2 γδ T cells and helps control the infection (220).  Whereas Vγ9/Vδ2 γδ T cells 
tremendously expand after a naturally acquired Francisella infection, LVS vaccination by 
scarification does not cause this same expansion (218).  Unfortunately, mice lack γδ T cells 
analogous to Vγ9/Vδ2 in humans so this result cannot be studied further. 
Primary response by B cells 
Francisella has long been thought of as an intracellular pathogen that spends little 
time outside of host cells during infection.  Furthermore, when bacteria were detected in the 
blood, they were thought to reside within migrating leukocytes (221).  Forestal, et al. was the 
first to counter the long-held paradigm by showing that non-cell associated Francisella are 
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found in the plasma of infected mice (222).  Both LVS and SchuS4 were found free in the 
plasma following intranasal or intradermal inoculation indicating the phenomena was not 
specific to a specific Francisella strain or route of infection (222).  Yu, et al. also found 
U112 free in the plasma of intranasally infected mice (223).  Moreover, LVS and SchuS4 
were capable of growing in whole mouse blood indicating the blood represents another 
replicative niche for Francisella (222).  Data revealing an extracellular lifecycle stage of 
Francisella within a host highlighted the potential importance of B cells in clearance of the 
primary infection. 
 Despite an extracellular phase of infection, mice deficient in B cells are only 
moderately more susceptible to intradermal or aerosol LVS infection than wild-type mice 
suggesting B cells aren’t mediating bacterial clearance (167, 224). In a convalescent model 
of SchuS4 infection, B cell deficient mice succumb to infection 10 days after stopping 
levofloxacin treatment (159).  Francisella can adhere to and infect B cell lines or splenocytes 
and induce apoptosis (225).  Because Francisella can infect a variety of cell types, it isn’t 
surprising that B cells can be infected as well (139).  Infection of B cells also allows them to 
serve as antigen presenting cells and have another role in the infection besides antibody 
production.  In fact, during secondary infection B cells likely play a role in antigen 
presentation and/or cytokine production (discussed below) (224).   
B-1a cells, or innate immune B cells, are sources of natural antibody and respond to 
T-independent antigens.  Because they are T-independent, B-1a cells respond rapidly to 
antigen and produce antibodies within 2-3 days of vaccination.  B-1a cells can be stimulated 
with LVS LPS to produce anti-LPS antibodies (226, 227).  LVS LPS vaccination causes an 
increase in splenic and peritoneal cavity B-1a cells which peak at day 5 post-vaccination 
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(226).  Splenic B-1a cells rapidly decline after day 5 but peritoneal B-1a cells are detectable 
for up to 2 months post-vaccination (226).  In the case of a convalescent SchuS4 infection, B-
1a cells exacerbate the infection by producing IL-10 which decreases IFN-γ production by 
NK cells (228).  These data highlight another difference between LVS and SchuS4 infection 
where B-1a cells help resolve LVS infection via antibody production and B-1a cells are 
detrimental during SchuS4 infection.    
In humans, the presence of serum anti-Francisella antibodies is often used to 
diagnose tularemia.  Natural infection with Francisella induces IgM, IgG, and IgA antibodies 
that peak between 4 and 7 weeks after infection and are present in the serum for up to11 
years after infection (229-231).  When anti-Francisella titers were determined in a cohort of 
individuals in Sweden infected 25 years prior, titers were below detection limit (232).  
Intradermal vaccination with LVS also leads to peak agglutination titers between 2 and 4 
weeks post-vaccination (233, 234).  Anti-Francisella antibodies were also present when 
serum was tested 1.5 years after vaccination (233).          
Secondary response by B cells 
Early studies examining the ability of immune sera to transfer protection to naïve 
mice indicated antibodies did not confer protection upon SchuS4 challenge (235).  On the 
other hand, mice could be protected during LVS challenge by transfer of LVS immune sera 
or anti-Francisella LPS antibodies (19, 236-239).  Passive transfer of antibody from SchuS4 
infected mice treated with levofloxacin (to help resolve the primary infection) was able to 
mediate protection during lethal SchuS4 challenge (240).  Immunization with Francisella 
LPS or conjugates thereof were also protective during LVS but not SchuS4 challenge (28, 
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226, 227, 241-243).  B-1a cells produce antibodies directed against LVS O-antigen that are 
protective during LVS challenge (226, 227).      
More recent studies have vaccinated mice with inactivated LVS in the presence of 
immunostimulatory compounds like IL-12, immunostimulatory complexes (ISCOMs), or 
cholera toxin and found some protection during SchuS4 challenge (239, 244-247).  
Vaccination with heat killed LVS plus IL-12 provided 100% protection during intranasal 
LVS challenge and was dependent on IgA (244).  When mice were vaccinated with heat 
killed LVS and an IL-12-expressing viral vector, mice were protected during lethal 
intraperitoneal challenge (239).  The authors did not directly show the requirement of B cells 
but did show high IgG titers and the absence of a T cell response after vaccination, leading 
them to conclude protection was B cell-mediated (239).  While several groups have shown 
partial protection during SchuS4 challenge in mice vaccinated with inactivated LVS in the 
presence of immunostimulatory compounds, they have not shown any evidence that 
protection was antibody-dependent (245-247).  In fact, Bitsaktis, et al. found their 
vaccination regimen was protective in IgA-deficient mice indicating the B cell response was 
not required to mediate protection in their model (245).  Oral vaccination with LVS did 
confer protection during SchuS4 challenge that was mediated by CD4+ T cells and B cells 
(248).  Additional studies are necessary to identify whether B and/or T cells are mediating 
protection in vaccination studies.  A better understanding of the mechanisms underlying 
protection will assist in the rationale design of vaccines.      
During a secondary infection, B cell deficient mice are much more susceptible than 
their wild-type counterparts (224).  Susceptibility is not caused by a lack of antibody 
production because passive transfer of sera does not confer protection (224).  Instead, 
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transfer of B cells from immune mice leads to protection suggesting another role for the B 
cells besides antibody production (224).  B cells could be an important source of antigen 
presentation during the secondary infection or could produce cytokines and/or chemokines 
that influence both innate and adaptive responses.  The mechanisms that cause B cells to 
confer protection need to be further elucidated.      
Primary response by αβ T cells 
Years of Francisella research have conclusively shown the requirement of T cells for 
the clearance of a primary infection and the development of protective immunity.  Mice 
lacking all T cells such as αβ TCR-/- or nu/nu mice develop a chronic infection that they 
eventually succumb to (216, 249, 250).  When either CD4+ or CD8+ T cells are singly 
depleted, mice can resolve the primary LVS intradermal infection and can survive a lethal 
LVS secondary intraperitoneal infection (216).  Mice depleted of both CD4+ and CD8+ T 
cells develop a chronic LVS infection with steady bacterial burdens for months after 
infection (216).  The cells that control, but not are incapable of clearing, the infection are 
CD4-CD8-NK1.1-TCRαβ+Thy1.2+ double negative (DN) T cells (251, 252).  These cells are 
prevalent in the lungs of intranasally inoculated mice, but are less abundant in the spleen and 
lung after intradermal inoculation (252).  The LD50 of SchuS4 in mice is <10 CFU and 
immunocompetent mice succumb rapidly to infection (5 days) (14).  Therefore, it is not 
surprising that mice lacking T cells also succumb rapidly to SchuS4 infection (21, 159, 167).  
Chen, et al. has shown that SchuS4 infection causes thymic atrophy and decreased numbers 
of CD4+CD8+ (double positive) thymocytes (253).  T cell responses during LVS infection 
peak on day 10 post-inoculation (213).  During a convalescent SchuS4 infection, T cell 
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responses were maximal on day 7 post-inoculation (159).  The authors only examined days 7, 
14, and 21 so the peak could be a consequence of the time points analyzed (159).  
There are three key effector cytokines produce by CD4+, CD8+, and/or DN T cells 
during Francisella infection.  IFN-γ is critical for survival during primary LVS infection.  
Depletion using anti-IFN-γ antibody significantly increases bacterial burdens (156, 254).  
Additionally, IFN-γ-deficient mice succumb to sub-lethal LVS infectious doses (155).  IFN-
γR-/- mice even succumb to SchuS4 during treatment with levofloxacin, highlighting the 
importance of IFN-γ during infection (159).  To complete molecular Koch’s postulates, 
treatment with recombinant IFN-γ decreases bacterial burdens, confirming the requirement of 
IFN-γ during LVS infection (255).  While a variety of cell types produce IFN-γ during 
Francisella infection, IFN-γ production by T cells is necessary to control bacterial growth in 
infected BMDMs (157, 256).  CD8+ and DN T cells also produce IFN-γ that is capable of 
controlling bacterial growth in BMDMs but these T cell subsets don’t rely on IFN-γ as much 
as CD4+ T cells do to control infection (256).  CD8+ T cells required TNF-α to control LVS 
growth in BMDMs (256, 257).  Depletion of TNF-α significantly increases bacterial burdens 
following LVS infection (254).  In vivo, CD4+, CD8+, and DN T cells produce IFN-γ after 
intradermal and intranasal inoculation with LVS (213, 252, 258).  Another critical cytokine 
during Francisella infection is IL-17.  Intranasal inoculation with LVS leads to the expansion 
of IL-17A+ CD4+ (Th17) cells and IL-17A+ DN T cells (213, 252, 258).  Production of IL-
17A is critical for controlling infection because IL-17A- or IL-17 receptor-deficient mice 
have increased bacterial burdens during respiratory infection (217, 252).  IL-17A depletion 
also results in increased bacterial burdens and quicker mean time to death during respiratory 
infection (215, 217).  Th17 cells are only detected in the lung following intranasal infection 
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and not intradermal infection, despite similar bacterial burdens early after infection (213).  
Similar results are seen during Listeria monocytogenes infection where Th17 cells are only 
found after intranasal infection and not intravenous infection (259).  To further support the 
role of Th17 cells during intranasal but not intradermal infection, IL-17A deficient mice do 
not have higher lung or liver burdens compared to wild-type mice (252).  There is a slight, 
but statistically significant increase in spleen bacterial burdens in IL-17A-/- mice compared to 
wild-type controls (252).                                      
Without MHCI or MHCII tetramers, it has been difficult to study the responses of 
antigen-specific T cells (tetramers reviewed in (260)).  An immunodominant CD4+ epitope 
(LpnA86-99) comprises up to 20% of CD4+ T cells in B6 mice and is therefore an excellent 
candidate for the use in MHCII tetramer development (261).  T cells from mice vaccinated 
intradermally responded to purified bacterioferritin, GroEL, and KatG suggesting these 
proteins also contain CD4+ and/or CD8+ epitopes (262).  Humanized HLA-DR4 transgenic 
mice have been used to identify human MHCII epitopes (263).  FopB was identified in a 
screen and contains an epitope that human CD4+ T cells respond to; immunization with FopB 
also protected HLA-DR4 transgenic mice during lethal LVS challenge (263).  McMurry, et 
al. predicted human MHCI and MHCII epitopes using bioinformatics and then tested these 
epitopes on peripheral blood mononuclear cells (PBMCs) from individuals that had 
previously contracted tularemia (264).  Using this approach, they identified candidate 
peptides that 95% of patients responded to (264).  The authors then tested whether these 
peptides could be used in a vaccination regimen in HLA-DR4 transgenic mice and found 
some protection during lethal LVS infection (265).  Because the authors used HLA-DR4 
transgenic mice, they were only able to examine “human” CD4+ T cell responses and not 
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CD8+ T cell responses, even though the identified peptides could be stimulating both T cell 
subsets.  Further identification of CD4+ and CD8+ epitopes is important for two reasons.  
First, the ability to use tetramer will allow researchers to track Franicsella-specific T cells 
throughout the primary infection, the development of memory, and a secondary response.  
MHCII tetramer with IAb presenting LpnA86-99 is currently being developed.  Although CD8+ 
T cells clearly respond to Francisella antigen, an epitope has not yet been identified.  Epitope 
identification is also important for vaccine development so that humans could be immunized 
with peptides that induce a robust, protective immune response.  The use of humanized HLA-
A2/DR4 mice could assist in these efforts.                   
Because T cells are required for the clearance of a primary infection and the 
development of protective immunity, it is not surprising that Francisella has evolved 
mechanisms to interfere with T cell responses.  Francisella infection causes host cells to 
synthesize and secrete prostaglandin E2 (PGE2) which shifts the immune away from a Th1 
response and towards a less effective Th2 response (201, 266).  MHCII is also down-
regulated in a PGE2-dependent process (144, 214).  Both of these immune evasion 
mechanisms are discussed in more detail above.        
Secondary response by αβ T cells 
Survival of a secondary LVS infection requires CD4+ or CD8+ T cells; either subset is 
sufficient to mediate bacterial clearance (216).  Both IFN-γ and TNF-α are necessary for 
survival during secondary infection with LVS (Chapter 4, (254, 267)).  During SchuS4 
secondary infection, both CD4+ and CD8+ T cells are required for protection (21, 268, 269).  
IL-17 production in the lung correlated with protection in mice challenged with aerosolized 
SchuS4 (270).  Despite correlating with protection, depletion of IL-17 with antibody did not 
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significantly increase bacterial burdens (270).  Similarly, we found IL-17A depletion had no 
effect on weight loss or bacterial burdens in mice challenged intranasally with LVS (Chapter 
4).    
Memory T cells persist in patients that were vaccinated or naturally acquired 
tularemia.  Upon re-stimulation, T cells produced IFN-γ, IL-2, and TNF-α (271-273).  When 
the ability of T cells to produce IL-17 and IL-22 was evaluated in PBMCs from LVS 
vaccinated individuals, both IL-17 and IL-22 were detected in CD4+ T cells (274).  These 
data indicate that human infection also induces Th17 cells.  Despite the absence of detectable 
anti-Francisella antibodies in people 25 years after infection, peripheral blood did contain T 
cells that produced IFN-γ following stimulation with Francisella antigen (232).  After a 
specific outbreak of tularemia, there were very few cases for the next 25 years in the region 
these individuals lived, therefore it was unlikely they were exposed to Francisella again 
(232).  In a more recent study, T cells from peripheral blood of donors vaccinated with LVS 
by scarification up to 34 years prior were able to produce IFN-γ in response to re-stimulation 
(275).  These data indicate that T cell mediated immunity is long-lasting in humans in the 
absence of a recurring infection of vaccination booster.          
Objectives 
 Francisella has evolved several mechanisms to evade and/or suppress host immunity.  
We will focus on three immune evasion mechanisms in this dissertation: the ability to induce 
infected cells to synthesis and secrete PGE2 which suppresses the T cell response (Chapters 2 
and 5), the failure to induce pro-inflammatory cytokine production (Chapter 2), and targeting 
innate immune cells for infection (Chapter 4).  We will also examine what cytokines are 
necessary for survival during a lethal secondary infection (Chapter 3).  Overall, the work 
presented here increases our understanding of the underlying mechanisms by which  
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Francisella subverts host immunity.  This knowledge not only increases our understanding of 
Francisella pathogenesis but also identifies pathways that could be targeted during future 
vaccine or drug development.            
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Table 1. Properties of Francisella strains 
 Francisella strain 
 Francisella 
novicida 
Francisella 
tularensis subsp. 
holartica 
Francisella 
tularensis subsp. 
tularensis 
Laboratory strain name U112 LVS SchuS4 
Virulence in humans - + +++ 
Human intranasal 
infectious dose (12, 13, 22, 
26) 
Not infectiousa 104 CFU 10 CFU 
Virulence in mice +++ ++ +++ 
LD50    
Intranasal (14, 19, 20, 21, 
27) 10 CFU 10
3 CFU < 10 CFU 
Intradermal (14, 19, 28) 2.4x103 CFU 106 CFU < 10 CFU 
Genome properties (30, 31)    
Genome size (bp) 1,910,031 1,895,998 1,892,819 
Number of open reading 
frames (predicted) 1731 1380 1445 
Number of pseudogenes 14 303 254 
% G+C content 32.47 32.15 32.26 
a immunocompetent individuals 
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Table 2: Immune evasion of phenotypic and functional maturation of 
antigen presenting cells 
 Francisella strain 
 LVS SchuS4 
Mouse BMDM   
Up-regulate MHCII/CD86 (140) No ND 
Produce pro-inflammatory cytokines (140, 
143) No ND 
Alveolar macrophages   
Up-regulate MHCII/CD86 (140) No ND 
Produce pro-inflammatory cytokines (140) No ND 
Human MDM   
Up-regulate MHCII/CD86 ND ND 
Produce pro-inflammatory cytokines (143) Yes ND 
Mouse BMDC   
Up-regulate MHCII/CD86 (140) Yes ND 
Produce pro-inflammatory cytokines (140) No ND 
Mouse lung or lymph node dendritic cells   
Up-regulate MHCII/CD86 (140, 141) Yes No 
Produce pro-inflammatory cytokines (140, 
141) No No 
Human MDDC   
Up-regulate MHCII/CD86 (66, 149, 150) Yes Yes 
Produce pro-inflammatory cytokines (66, 148, 
149, 150) Yes No 
ND: not determined   
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CHAPTER 2 
INFECTION WITH FRANCISELLA TULARENSIS LVS CLPB LEADS TO AN ALTERED 
YET PROTECTIVE IMMUNE RESPONSE1,2 
 
OVERVIEW 
Bacterial attenuation is typically thought of as reduced bacterial growth in the 
presence of constant immune pressure.  Infection with Francisella tularensis elicits innate 
and adaptive immune responses.  Several in vivo screens have identified F. tularensis genes 
necessary for virulence.  Many of these mutations render F. tularensis defective for 
intracellular growth.  However, some mutations have no impact on intracellular growth 
leading us to hypothesize that these F. tularensis mutants are attenuated because they induce 
an altered host immune response.  We were particularly interested in the F. tularensis LVS 
mutant clpB (FTL_0094) because this strain was attenuated in pneumonic tularemia yet 
induced a protective immune response.  LVS clpB’s attenuation was not due to an 
intracellular growth defect as LVS clpB grew similarly to LVS in primary bone marrow 
derived macrophages and a variety of cell lines.  We therefore determined whether LVS clpB 
induced an altered immune response compared to LVS in vivo.  We found that LVS clpB 
                                                            
1 Contributing authors: Lydia M. Barrigan, Shraddha Tuladhar, Jason C. Brunton, Matthew D. Woolard, Ching-
ju Chen, Divey Saini, Richard Frothingham, Gregory D. Sempowski, Thomas H. Kawula, and Jeffrey A. 
Frelinger 
 
2 Portions of this chapter were published in Infection and Immunity.  Barrigan, et al. 2013 Jun;81(6):2028-42. 
Copyright © 2013, American Society for Microbiology. Reprinted with permission.  
 
 
 
 
induced pro-inflammatory cytokine production in the lung early after infection, a process not 
observed during LVS infection.  LVS clpB provoked a robust adaptive immune response 
similar in magnitude to LVS, but with increased IFN-γ and IL-17A production as measured 
by mean fluorescence intensity.  Altogether, our results indicate that LVS clpB is attenuated 
due to altered host immunity and not an intrinsic growth defect.  These results also indicate 
that disruption of non-essential gene(s) that are involved in bacterial immune evasion, like F. 
tularensis clpB, can serve as a model for the rational design of attenuated vaccines. 
 
INTRODUCTION 
Enormous efforts have gone into detecting bacterial mutations that result in 
diminished growth in vivo.  Many of these mutations are the result of a failure of the 
pathogen to grow in vitro, and can be attributed to defects in critical aspects of bacterial 
metabolism.  Mutations, for example, that result in auxotrophy render the bacteria incapable 
of synthesizing essential nutrients such as purines or co-enzymes and therefore cause a 
growth defect.  Relatively few mutations that cause bacterial attenuation have been 
demonstrated to be the result of a failure of the pathogen to interfere with host immune 
responses.  In this manuscript, we focus on one mutation that likely falls into this class of 
altered host immunity.   
Francisella tularensis is a gram negative coccobacillus and the causative agent of the 
zoonotic disease tularemia.  Inhalation of as few as 10 virulent type A F. tularensis 
organisms can cause fatal disease in humans (1).  This low infectious dose, ability to persist 
in the environment, ease of aerosolization, and high morbidity and mortality has earned F. 
tularensis a Category A Select Agent classification (2).  In fact, F. tularensis has been used 
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as the infectious agent in bioweapons and continues to present a real threat today (3, 4).  It is 
therefore critical to understand both infection and pathogenesis.  Many attenuating mutations 
of Francisella have been described (5-7), but little information is available on the immune 
response to attenuated mutants, beyond whether they can protect from secondary challenge 
with wild-type bacteria.   
Experiments utilizing F. tularensis as the infectious agent typically use three strains 
that differ widely for virulence in humans and mice.  F. tularensis subsp. tularensis SchuS4 
(SchuS4) is a type A strain and must be handled at BSL-3 conditions because of its low 
infectious dose and its ability to be transmitted via aerosol.  SchuS4 is highly pathogenic in 
mice with an LD100 of <10 CFU (8).  Mice inoculated with SchuS4 succumb to infection 
within 6 days of inoculation (9) making studies of the adaptive immune response in non-
manipulated mice impossible.   For our experiments, we used the type B strain, F. tularensis 
subsp. holartica live vaccine strain (LVS).  LVS is attenuated in humans and mice compared 
to SchuS4.  Although LVS was widely used in Eastern Europe as a vaccine, it is unlikely to 
ever be licensed in the United States.  LVS’s intranasal LD50 is approximately 1000 CFU in 
mice (8) allowing us to examine aspects of adaptive immunity using an intranasal inoculation 
dose of 500 CFU.  The third strain commonly used is F. novicida U112 (U112) which is 
avirulent in immunocompetent humans but is highly virulent in mice with a low infectious 
dose and rapid death similar to SchuS4.                            
The immune response to F. tularensis is multi-layered and complex, requiring 
components of both innate and adaptive immunity.  The bacterium has evolved several 
strategies to evade or subvert the host’s immune response so that it can persist in the host.  
First, F. tularensis infects a variety of innate immune cells during infection in the lung 
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including macrophages, dendritic cells, monocytes, and neutrophils (10, 11).  F. tularensis 
also expresses a form of LPS that does not efficiently stimulate TLR4 (12).  LVS does not 
stimulate functional maturation (cytokine production) of dendritic cells but does promote 
phenotypic maturation through the up-regulation of CD80 and CD86 (11).  SchuS4 does not 
induce phenotypic or functional maturation of dendritic cells, allowing the bacterium to 
persist in an immunosuppressed environment (13).  Finally, F. tularensis lives intracellularly, 
allowing the bacterium to avoid antibody and complement-mediated destruction (14).   
Because F. tularensis replicates within host cells, the T cell response is a critical 
component for bacterial clearance.  Indeed, T cells are required for clearance of F. tularensis 
and the development of protective immunity (15).  In particular, IFN-γ is required for 
controlling F. tularensis infection.  When IFN-γ is blocked by antibody, there is an increase 
in bacterial burden and mice deficient in IFN-γ succumb to an LVS inoculum dose that is 
sublethal in wild-type mice (16, 17).  Administration of recombinant IFN-γ to infected mice 
decreases bacterial burdens confirming this cytokine’s importance in control of the infection 
(18).  Th17 cells are also induced in the lung following intranasal inoculation (19).  IL-17A 
deficient mice have increased bacterial burdens compared to wild-type mice and 
administration of IL-17 neutralizing antibody also increased bacterial burdens highlighting 
this cytokine’s importance during respiratory tularemia (20, 21).         
Several in vivo screens have identified F. tularensis virulence determinants in U112, 
LVS, and SchuS4 (5-7).  A F. tularensis mutant could be attenuated if the mutation disrupts 
expression of a gene necessary for intracellular growth such as the genes within the 
pathogenicity island (22).  A F. tularensis mutant could also be attenuated if the disrupted 
gene causes the strain to become an auxotroph (5-7).  When a mutation does not cause an 
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intracellular growth defect, a strain’s attenuation could be the result of the failure to evade 
the host’s immune response.  We were interested in characterizing the immune response to 
an attenuated LVS mutant, LVS clpB (FTL_0094).  clpB encodes a highly conserved 
chaperone protein of the AAA+ superfamily of ATPases.  F. tularensis ClpB is involved in 
the response to oxidative, ethanol, and acid stresses (23).  LVS clpB and SchuS4 clpB strains 
are attenuated when delivered using intradermal, intraperitoneal, or oral inoculation routes 
(23-25).  Previous infection with LVS clpB and SchuS4 clpB provided protection during 
wild-type challenge (23-25).  However, the host’s primary immune response to LVS clpB 
that elicits protection during wild-type challenge has not yet been examined.   
In this study, we examined the innate and adaptive immune response following 
intranasal infection with LVS or LVS clpB.  Our LVS clpB strain did not show any defects in 
intracellular growth in primary bone marrow derived macrophages or several cell lines.  
Because there were no differences in growth, we hypothesized that LVS clpB’s attenuation 
was due to an altered immune response.  Indeed, LVS clpB induced altered innate and 
adaptive immune responses compared to LVS.  Other groups have shown SchuS4 clpB and 
LVS clpB are attenuated in vivo, but potential mechanism(s) causing attenuation have not 
been described (23-25).  The work presented here describes the immune response that 
contributes to LVS clpB’s attenuation.  The studies also highlight the potential use of clpB as 
a target for attenuation because milder disease is caused while still inducing a robust 
protective immune response in the lung. 
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MATERIALS AND METHODS 
Bacteria   
The live vaccine strain of Francisella tularensis subsp. holartica (LVS) was obtained 
from the CDC (Atlanta, GA).  F. tularensis subsp. tularensis (SchuS4) was obtained from 
BEI Resources (Manassas, VA).  Bacteria were grown on chocolate agar supplemented with 
1% IsoVitalex (Becton-Dickinson), brain heart infusion (BHI) broth supplemented with 1% 
IsoVitalex, or Chamberlain’s defined media (CDM) (26).  When necessary, kanamycin (10 
μg/mL) or hygromycin (200 μg/mL) was added for antibiotic selection.  Bacteria were grown 
at 37˚C.  To prepare bacterial inoculations, bacteria were removed from a lawn grown on 
chocolate agar and resuspended in sterile PBS at an OD600=1 (equivalent to 1x1010 
CFU/mL).  Appropriate dilutions were made in sterile PBS to obtain the desired bacterial 
dose.  The number of viable bacteria was quantified by serial dilution and plating on 
chocolate agar.  The LVS clpB::Tn strain was generated using the EZ-Tn5 system 
(Epicentre).  Insertion in clpB mapped to nucleotide 89763.  The LVS clpB (FTL_0094) and 
LVS dotU (FTL_0119) deletion strains were generated using the suicide vector pMP812 (27) 
containing an amplified region of clpB or dotU.   
Bacterial growth curves   
In a 96-well plate, CDM or BHI broth was inoculated with LVS, LVS clpB, or LVS 
dotU so that the starting OD600=0.01.  The OD600 was measured every 15 minutes for 48 
hours using a TECAN Infinite M200 plate reader (TECAN) capable of maintaining 37˚C and 
5% CO2 while shaking.      
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Mice   
C57Bl/6J (B6), B6.SJL-PtprcaPepcb/BoyJ (B6-CD45.1), and BALB/cByJ (BALB/c) 
mice were obtained from The Jackson Laboratory (Bar Harbor, ME).  B6.129S7-
Rag1tm1Mom/J (Rag-/-) were purchased from The Jackson Laboratory and then bred in-house.  
All mice were housed in specific-pathogen free conditions at the University of Arizona or 
Duke University in accordance with their respective Institutional Animal Care and Use 
Committees.  Female B6 and BALB/c mice used for infections were between 7 to 12 weeks 
of age.   
Cell lines and BMDM generation   
J774.1, MH-S, and A549 cells were obtained from ATCC (Manassas, VA).  J774.1 
and A549 cells were cultured in DMEM supplemented with 10% fetal bovine serum (Atlas), 
L-glutamine (HyClone), sodium pyruvate (HyClone), and penicillin/streptomycin (Life).  
MH-S cells were cultured in RPMI 1640 supplemental with 10% fetal bovine serum (Atlas), 
L-glutamine (HyClone), sodium pyruvate (HyClone), and penicillin/streptomycin (Life).  
Media was replaced with antibiotic free media 24 hours prior to inoculation with F. 
tularensis. BMDMs were generated from B6 bone marrow as previously described (28).      
In vitro growth assays   
1x106 cells/well (BMDM, J774, and MH-S) or 0.5x106 cells/well (A549) were seeded 
into a 24 well plate for intracellular growth assays and given 2 hours to adhere to the plate.  
Cells were inoculated at a multiplicity of infection (MOI) of 25:1.  Infection was facilitated 
by centrifugation at 300xg for 5 minutes.  Cells were incubated for 2 hours with bacteria and 
then media was removed.  Media containing 50 μg/mL gentamicin (Sigma) was added to kill 
extracellular bacteria.  One hour after gentamicin addition, media was removed and the cells 
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were washed twice before the addition of fresh media.  To determine intracellular growth, 
media was removed 4 or 24 hours post-infection and 1 mL of PBS was added to the cells.  
Cells were removed from the plate by scraping and pipeting vigorously up and down.  Cells 
were lysed by vortexing at maximal speed for 1 minute.  Serial 1:10 dilutions of the lysate 
were made and plated on chocolate agar.  Resulting colonies were counted 72 hours later.   
Inoculation of Mice   
Mice were anesthetized with 575 mg/kg tribromomethanol (Avertin) (Sigma) 
administered intraperitoneally.  Mice were then intranasally inoculated with 5 x 102 CFU 
LVS, 5x104 CFU LVS clpB, or 5x105 CFU LVS dotU suspended in 50 μL PBS.  For high 
dose LVS challenge experiments, mice were anesthetized with 0.25 mL of 7.5 mg/mL 
ketamine and 0.5 mg/mL xylazine cocktail in PBS.  Mice were then intranasally inoculated 
with 5x103 CFU LVS.  For SchuS4 challenge, approximately 30 CFUs of SchuS4 were 
administered via the aerosol route in a BSL-3 chamber.  Mice were weighed daily following 
all inoculations.  Mice were sacrificed if they lost more than 25% of their starting weight as 
indicated in our UA and Duke IACUC protocols.     
Determination of bacterial burdens   
Spleens, livers, and lungs were homogenized in sterile PBS using a Biojector 
(Bioject).  10-fold serial dilutions were made and plated on chocolate agar.  Resulting 
colonies were counted 72 hours later.  The limit of detection is 50 CFU per organ.       
Collection of broncheoalverolar lavage fluid   
Mice were sacrificed and the trachea exposed.  A 22 gauge catheter was inserted into 
the trachea and secured with suture.  The lungs were fully inflated with 800 μL of PBS and 
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washed three times.  Cells were removed from the lavage fluid by centrifugation.  Collected 
lavage fluid was frozen at -80˚C until Luminex analysis.   
Luminex analysis   
A multiplex luminex bead-based approach was used to quantify 
cytokines/chemokines in BAL fluid or clarified tissue homogenate.  A 20-analyte assay panel 
was performed according to the manufacturer’s protocol (Invitrogen) using a BioPlex array 
reader (Bio-Rad Laboratories).  Using integrated cytokine/chemokine standard curves, the 
assay reports pg/mL of the following analytes:  FGF basic, GM-CSF, IFN-γ, IL-1α, IL-1β, 
IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p40/p70), IL-13, IL-17, KC, MCP-1, MIG, MIP-1α, 
TNF-α, and VEGF.  A five-parameter non-linear logistic regression model was used to 
establish standard curve and to estimate the probability of occurrence of a concentration at a 
given point.  Standard outliers were removed from the analysis if the observed/expected % 
recovery was outside of the acceptable limits (70-130%).  Upper and lower levels of 
quantification were determined by the BioPlex Manager software based on goodness of fit 
and percent recovery.  Calculated pg/mL for experimental specimens were multiplied by the 
inherent assay dilution factor (df=2) and reported as final observed pg/mL. 
Depletion of IFN-γ   
Purified XMG1.2 (anti-IFN-γ) antibody was a generous gift from Mary Ann 
Accavitti-Loper at the SERCEB Mouse Monoclonal Antibody Core (University of Alabama- 
Birmingham).  Rat IgG1 isotype control antibody (anti-HRPN) was purchased from 
BioXCell (West Lebanon, NH).  Mice were administered 500 µg of depleting or control 
antibody in 200 µL PBS via intraperitoneal injection on days 0 and 2 post-inoculation.   
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Gating strategy for BALF analysis 
 The gating scheme is shown in figure 1.  Single cells were discriminated from 
doublets by plotting side scatter height (SSC-H) versus side scatter area (SSC-A).  Cells were 
then gated on by plotting SSC-A versus forward scatter area (FSC-A).  Live cells were then 
gated by plotting the live/dead stain on a 1-D histogram.  Cells from the BALF were 
discriminated from the CFSE-labeled splenocyte carries by plotting an empty channel versus 
CFSE.  CD3+, CD19+, and not B and T cells were gated on by plotting CD3 versus CD19.  
From the not B and T gate, GR-1 versus CD11b was plotted to distinguish neutrophils from 
not neutrophils.  From the not neutrophils gate, SSC-A versus F4/80 was plotted to 
distinguish F4/80+ from F4/80- cells.  From the F4/80- gate, CD11c versus FSC-A was 
plotted and dendritic cells were gated on.  From the F4/80+ gate, CD11c versus CD11b was 
plotted to distinguish alveolar macrophages (AMs) from interstitial macrophages (IMs).       
Collection of spleen and lung cells    
Spleens were harvested from mice and made into a single cell suspension.  Red blood 
cells were lysed using ammonium chloride-potassium carbonate lysis buffer.  Lungs were 
perfused with PBS to remove blood and then finely minced.  Minced lung was placed in 10 
mL of digestion buffer containing 0.5 mg/mL collagenase I (Worthington Biochemical), 0.02 
mg/mL DNase (Sigma), and 125 U/mL elastase (Worthington Biochemical) in RPMI1640 
(HyClone).  Lungs were digested for 30 minutes at 37˚C and then vigorously pipetted prior to 
filtering through a 100 µM filter.  Mononuclear cells were isolated from the single cell 
suspension by density gradient centrifugation over Lympholyte M (Cedarlane Labs).  Viable 
cells from spleen and lung were determined by trypan blue exclusion using a hemacytometer.           
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Antibodies   
The following directly conjugated antibodies were utilized for flow cytometry 
analysis: CD3 AF488 (Clone 145-2C11, eBioscience); CD3 Pacific Blue (Clone 17A2, 
Biolegend); CD4 AF700 (Clone GK1.5, Biolegend); CD8a V500 (Clone 53-6.7, BD 
Biosciences); CD11b Pacific Blue (Clone M1/70, Biolegend); CD11b V500 (Clone M1/70, 
BD Horizon); CD11c Pacific Blue (Clone N418, Biolegend); CD11c PE-Cy7 (Clone N418, 
Biolegend); CD19 Pacific Blue (Clone 6D5, Biolegend); CD19 PerCP-Cy5.5 (Clone 6D5, 
Biolegend); CD45.1 PE-Cy7 (Clone A20, Biolegend); F4/80 Pacific Blue (Clone BM8, 
Biolegend); F4/80 PE (Clone BM8, eBioscience); GR-1 (Ly-6G) eFluor 450 (Clone RB6-
8C5, eBioscience); GR-1 AF700 (clone RB6-8C5, eBioscience); IFN-γ PE (Clone XMG1.2, 
BD Biosciences); IL-17A AF647 (Clone TC11-18H10.1, Biolegend); NK1.1 Pacific Blue 
(Clone PK136, Biolegend); TCR γδ PerCP-Cy5.5 (Clone GL3, Biolegend).   All antibodies 
were titrated on normal B6 splenocytes prior to use.   
Intracellular cytokine staining    
Splenocytes from B6-CD45.1 mice were used as antigen presenting cells.  B6-
CD45.1 cells were added at 2x106/well in a 24 well plate or 0.5x106/well in a 48 well plate 
and infected with LVS at an MOI of 200:1 or mock infected.  Two hours post-infection, the 
media was removed and 5 μg/mL gentamicin was added to kill any extracellular bacteria.  
Splenocytes were cultured overnight in the presence of gentamicin.  Prior to co-culture with 
cells isolated from infected mice, antigen presenting cells were washed extensively to 
remove any cytokine or PGE2 that could interfere with the co-culture.  Cells isolated from 
mice were co-cultured at a 1:1 ratio with infected or mock infected splenocytes for 24 hours.  
During the last 4 hours of culture, 10 µg/mL Brefeldin A (Sigma) was added to each well to 
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stop cytokine secretion.  Cells were removed from the plate and stained with Pacific Blue 
succimidyl ester (Invitrogen) to distinguish live and dead cells.  Cells were then stained with 
antibodies for surface markers.  Following fixation and permeabilization of the cells, cells 
were stained for IFN-γ and IL-17A.  Cells were washed extensively after each staining step 
to remove residual unbound antibody.               
Gating strategy for intracellular cytokine staining analysis   
The gating scheme is shown in figure 2.  Single cells were discriminated from 
doublets by plotting side scatter linear versus side scatter area.  Cells were then selected by 
plotting side scatter area versus forward scatter area.  Live CD3+ T cells were then selected 
by plotting CD3 versus the Pacific Blue channel which included the live/dead stain and 
markers for antigen presenting cells.  From the CD3+ gate, CD4+ and CD8+ T cells were 
selected.  Gates for IFN-γ and IL-17A positive cells were set based on isotype control 
staining.  Delta mean fluorescent intensity (∆MFI) for each sample was determined by 
subtracting the cytokine negative population from the cytokine positive population.  FlowJo 
v7.6 (Treestar) was used for all flow cytometry analysis.       
Determination of IFN-γ and IL-17A secretion by purified CD4+ T cells   
B6 splenocytes were depleted of T cells using Mouse Thy1.2 Dynabeads (Life 
Technologies) and used as antigen presenting cells.  5x104/well T cell depleted splenocytes 
were seeded in a 96 well plate and then infected with LVS at an MOI of 200:1 or mock 
infected.  Two hours post-infection, the media was removed and 5 μg/mL gentamicin was 
added to kill any extracellular bacteria.  T cell depleted splenocytes were cultured overnight 
in the presence of gentamicin.  Prior to co-culture with purified CD4+ T cells from infected 
mice, antigen presenting cells were washed extensively to remove any cytokine or PGE2 that 
79
 
 
 
could interfere with the co-culture.  CD4+ T cells were enriched from single cell suspension 
of lung cells or splenocytes using a Dynabeads Untouched Mouse CD4 Cells Kit (Life 
Technologies).  Enriched CD4+ T cells were co-cultured at a 1:1 ratio with T cell depleted 
LVS infected or mock infected splenocytes for 24 hours.  Culture supernatant was then 
removed and stored at -20°C until ELISA analysis.  Each sample was tested in triplicate.  
IFN-γ concentration was determined using a Mouse IFN-γ Instant ELISA (eBioscience) and 
IL-17A concentration was determined using a Mouse IL-17A Ready-Set-Go ELISA 
(eBioscience).  T cell depletion and CD4+ T cell enrichment was determined using flow 
cytometry analysis.  IFN-γ and IL-17A concentrations were normalized based on the number 
of CD4+ T cells in the culture as determined by flow cytometry.   
Statistical analysis   
Data were analyzed using a one-way ANOVA with Tukey’s post-test for cytokine 
levels and flow cytometry results.  Bacterial burdens were log transformed and then a 
Student’s t-test or ANOVA with Tukey’s post-test was applied.  For LVS protection studies, 
a Chi-square test with Yates’ correction was applied.  GraphPad Prism (v5.04) was used for 
analysis.  Error bars show standard error of the mean.  Significance levels are indicated as 
follows: * p < 0.05; ** p < 0.01, *** p < 0.001, **** p < 0.0001. 
 
RESULTS 
LVS clpB is attenuated in mouse pneumonic tularemia   
Several groups have shown that LVS clpB or SchuS4 clpB strains are attenuated 
following either intradermal, intraperitoneal, or oral inoculation in either BALB/c or 
C3H/HeN mice (23-25).  We were interested in determining whether LVS clpB was also 
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attenuated in a pneumonic tularemia model in C57Bl/6J (B6) mice.  For this study, we 
produced two LVS clpB mutant strains.  One strain carried a transposon (Tn) insertion in the 
clpB gene and the other was an in frame deletion of the clpB coding sequence.  The 
mutations were confirmed by DNA sequencing.  Although transposon mutations can have 
polar effects, we did not expect any from the transposon insertion in clpB because 
bioinformatic analysis indicated that clpB is not located in an operon (23).  Indeed, we found 
the clpB::Tn mutant and the deletion strain behaved identically in all experiments.  We have 
therefore combined all data and will simply refer to infection with either strain as LVS clpB.   
Initial experiments demonstrated that LVS clpB did not disseminate to the spleen and 
liver in all mice when an inoculation dose of 500 CFU was used, despite this dose causing 
disease following LVS inoculation (figure 3).  We therefore conducted preliminary 
experiments to establish the dose of LVS clpB that produced a similar peak bacteremia in the 
spleen so that mice were exposed to similar antigen levels.  Similar antigen load is important 
because in other infection models, the magnitude of the primary adaptive immune response 
was influenced by the peak bacterial load and not the duration of infection (29-31).  As a 
control for inoculation with a bacterial strain that failed to grow intracellularly, we selected 
LVS dotU (32).  We achieved similar burdens for LVS and LVS clpB but since LVS dotU 
fails to grow intracellularly (32), this strain was inoculated at the highest practical dose.  
Seven to twelve week old B6 mice were intranasally inoculated with 5x102 CFU LVS, 5x104 
CFU LVS clpB, or 5x105 CFU LVS dotU.  To determine bacterial growth in vivo, mice were 
euthanized on days 3, 7, and 10 post-inoculation and bacterial burdens were determined in 
the spleen, liver, and lung by plating serial dilutions of tissue homogenate on chocolate agar 
(figure 4A-C). While LVS clpB and LVS bacterial burdens were not significantly different 3 
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days post-inoculation in the spleen and liver, LVS clpB was cleared much faster than LVS 
from all organs tested.  Few LVS clpB colonies were recovered 10 days post-inoculation 
while LVS-infected mice still had high bacterial loads, particularly in the lung.  LVS clpB 
was also attenuated in BALB/c mice compared to LVS (figure 5A-C).  Like B6 mice, LVS 
and LVS clpB burdens are similar in the spleen and liver of BALB/c mice on day 3 post-
inoculation and LVS clpB is cleared faster than LVS.   
Despite the 1000-fold higher dose of LVS dotU compared to LVS, the number of 
colonies recovered from the lungs 3 days post-inoculation was 1000-fold less than LVS.  
Viable LVS dotU organisms were recovered from isolated lung cells from LVS dotU 
infected mice harvested 3 days post-inoculation cultured in gentamicin for 1 hour 
demonstrating that LVS dotU was internalized and the bacteria had not simply persisted in 
the extracellular space (figure 6).  Despite its intracellular location, LVS dotU failed to leave 
the lung and transit to the spleen and liver and was effectively cleared by 7 days post-
inoculation in all organs tested.  Because LVS dotU was not found in distal organs on day 3 
post-inoculation, but infected cells were still present in the lung, these data suggest that 
infected cells were not the primary method of dissemination.  Alternatively, the LVS dotU 
infected cells were not activated in a manner that caused them to leave the primary site of 
infection.  To confirm that rapid clearance of LVS clpB and LVS dotU was specifically due 
to the absence of these genes, the strains were trans-complemented.  B6 mice were 
intranasally inoculated with 5x102 CFU of LVS clpB complement or LVS dotU complement.  
We used the same dose as LVS since transcomplementation should return these strains to 
wild-type LVS virulence levels.  Indeed, transcomplementation of  LVS clpB and LVS dotU 
led to bacterial burdens comparable to LVS in the spleen, liver, and lungs 3 days post-
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inoculation (figure 7).  Overall, these results demonstrate that LVS clpB is attenuated in a 
pneumonic model of tularemia, just as other groups have shown for LVS clpB and SchuS4 
clpB by different routes of inoculation (23-25).       
We also wanted to understand if the extent of disease caused by LVS clpB was 
similar to LVS induced disease.  As a measure of overall health, body weight change is a 
reasonable measure of clinical status.  Infected B6 and BALB/c mice were weighed daily and 
weight loss as a percentage of starting weight is reported (figure 8).  LVS infected mice lost 
approximately 15% of their starting weight by day 7 and then slowly regained weight. In 
contrast to LVS, LVS clpB infected mice only lost approximately 10% of their starting 
weight and began to regain weight 5 days post-inoculation.  LVS clpB mice regained their 
lost weight more rapidly than LVS infected mice which correlated with faster bacterial 
clearance.  Mice infected with LVS dotU did not lose any weight, an expected result given 
the bacteria failed to grow in vivo.  Together these results indicate the LVS clpB is attenuated 
in pneumonic tularemia and lead to a weight loss profile that differed from LVS infection. 
Previous infection with LVS clpB protects against lethal LVS intranasal challenge   
We next sought to determine whether previous intranasal inoculation with LVS, LVS 
clpB, or LVS dotU elicits an immune response that was protective against subsequent lethal 
LVS intranasal challenge.  Mice were intranasally inoculated with 5x102 CFU LVS, 5x104 
CFU LVS clpB, or 5x105 CFU LVS dotU.  To examine the early memory response, mice 
were challenged with 5x103 CFU (approximately 5 LD50 (8)) LVS intranasally 28 days after 
the initial infection.  All mice vaccinated with LVS or LVS clpB survived lethal LVS 
challenge (figure 9A).  LVS and LVS clpB vaccinated mice lost little weight following lethal 
LVS challenge and quickly returned to their starting weight (figure 9B).  Naïve and LVS 
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dotU vaccinated mice continued to lose weight after LVS and LVS clpB vaccinated mice 
began their recovery.  The abrupt change in the weight loss curve for the LVS dotU group is 
due to the one surviving mouse.  Naïve mice fell below the weight loss threshold 6 or 7 days 
post-re-challenge.  5 of 6 LVS dotU vaccinated mice succumbed to infection 6 days after the 
lethal dose challenge.  There was no significant difference in survival when LVS dotU 
vaccinated mice were compared to the naïve group.  The surviving LVS dotU vaccinated 
mouse lost more than 20% of its starting weight, but never fell below the 25% threshold after 
challenge with LVS.  Despite sustained illness indicated by weight loss in this mouse, there 
were no colonies recovered from the spleen, liver, or lung 14 days following the lethal 
challenge, similar to mice following primary exposure to LVS.   
When naïve and LVS dotU vaccinated mice were sacrificed upon losing >25% of their 
starting weight (day 6 post-re-challenge), we harvested spleen, liver, and lung and 
determined bacterial burdens (figure 9C-E).  We also harvested spleen, liver, and lungs from 
LVS and LVS clpB vaccinated mice on day 6 post-infection and determined bacterial 
burdens for comparison purposes (figure 9C-E).  Naïve and LVS dotU vaccinated mice had 
high bacterial burdens in the spleen and liver with means exceeding 105 CFU.  Even higher 
bacterial burdens were observed in the lungs of naïve and LVS dotU vaccinated mice (means 
>107 CFU).   LVS and LVS clpB vaccinated mice had few or no colonies recovered from the 
spleen, liver, and lung.  For example, no colonies were recovered from the lungs of LVS 
vaccinated mice and 4 of 6 LVS clpB vaccinated mice.       
We were also interested in whether LVS clpB would confer long-lived protection 
against lethal LVS challenge.  Mice were intranasally innoculated with 5x102 CFU LVS, 
5x104 CFU LVS clpB, or 5x105 CFU LVS dotU and then challenged with 5x103 CFU LVS 
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intranasally 120 days after the initial infection.  All LVS and LVS clpB vaccinated mice 
survived lethal LVS challenge (figure 10A).  All naïve mice succumbed to their infection by 
day 7.  Over half of the LVS dotU vaccinated mice succumbed to their infection by day 7 and 
all but one mouse succumbed by day 14.  The surviving LVS dotU vaccinated mouse lost 
more than 20% of its starting weight but never fell below the 25% threshold for sacrifice.  
This mouse was sacrificed on day 14 and the bacterial burdens were determined in the 
spleen, liver, and lung.  125 CFUs were recovered from the spleen, zero CFUs were 
recovered in the liver, and 425 CFUs were recovered from the lung indicating this mouse was 
clearing the high dose LVS challenge.  When mice were challenged 120 days after 
vaccination, the LVS and LVS clpB vaccinated groups lost more weight (approximately 10-
15% of starting weight) compared to the same groups challenged 28 days after vaccination 
(figure 10B).  LVS and LVS clpB vaccinated mice not only showed equivalent weight loss 
after high-dose LVS challenge but also regained their lost weight at a similar pace.  Naïve 
and LVS dotU vaccinated mice also show similar weight loss profiles compared to each 
other.  Figure 2E also shows the surviving LVS dotU vaccinated mouse exhibited extreme 
weight loss but did rapidly gain weight on days 13 and 14.   
When naïve and LVS dotU vaccinated mice fell below the weight loss threshold on 
day 6, four mice per group were sacrificed and bacterial burdens were determined for the 
spleen, liver and lung (figure 10C-E).  Naïve and LVS dotU vaccinated mice had high 
bacterial burdens that were comparable to the burdens found when mice were challenged 28 
days after vaccination with means exceeding 105 in the spleen and liver and 107 in the lung..  
LVS and LVS clpB vaccinated mice had approximately 104 CFU in their lungs on day 6 after 
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the high-dose LVS challenge but few, if any, CFUs in the spleen and liver.  These results 
clearly indicate that LVS clpB protects against subsequent lethal LVS challenge.   
Since LVS clpB induced a robust adaptive immune response that protected against a 
lethal LVS challenge, we next wanted to determine whether LVS clpB could protect against 
aerosolized highly virulent SchuS4.  Mice were intranasally innoculated with 5x102 CFU 
LVS, 5x104 CFU LVS clpB, or 5x105 CFU LVS dotU and then challenged with 30 CFU 
SchuS4 (measured as dose retained  in the lungs at one hour, approximately 30 LD100 (8)) via 
the aerosol route 28 days after the initial infection.  The use of aerosolized SchuS4 in B6 
mice is a very stringent test of whether LVS clpB infection confers protection.  Previous 
vaccination with LVS protected 2 of 7 mice and LVS clpB vaccination protected 1 of 8.  
These results are consistent with the findings of others who have also shown that previous 
LVS infection does not fully protect against SchuS4 challenge in B6 mice (33, 34).  Naïve 
and LVS dotU vaccinated mice succumbed to SchuS4 infection 5 days post-infection.  While 
neither LVS nor LVS clpB vaccination provided complete protection against subsequent 
SchuS4 infection, these infections significantly increased the median survival time from 5 
days (naïve) to 9 (LVS clpB) or 10 (LVS) days (figure 11).  A Mantel-Cox log-rank test was 
used to compare survival of the vaccinated groups to the naïve group.  LVS dotU vaccination 
was not statistically different from the naïve group but LVS and LVS clpB vaccination 
significantly increased survival after SchuS4 challenge (p ≤ 0.001). 
LVS clpB does not exhibit an intracellular growth defect   
A bacterial strain’s attenuation could be the result of a growth defect or an altered 
immune response that is more effective at bacterial clearance.  We therefore sought to 
determine whether our LVS clpB or LVS dotU strains had a growth defect in broth or 
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intracellularly that could explain their attenuation in vivo.  We initially examined the ability 
of LVS, LVS clpB, and LVS dotU to grow in either CDM (minimal) or BHI (rich) broth.   
We inoculated cultures with log phase bacteria and monitored the OD600 every 15 minutes for 
48 hours.  The growth rates of the three strains in CDM and BHI are nearly identical (figure 
12A-B).  Therefore, there is no inherent growth difference in vitro. 
We next determined whether LVS clpB or LVS dotU had an intracellular growth 
defect in primary BMDMs or the cell lines: A549 (human alveolar type II epithelial), J774 
(mouse macrophage), and MH-S (mouse alveolar macrophage).  Cells were inoculated with 
LVS or LVS clpB at an MOI of 25:1 for 120 minutes to allow internalization.  Cells were 
then treated with gentamicin to kill extracellular bacteria.  To determine bacterial 
internalization, cells were lysed 4 hours after inoculation and serial dilutions of the lysate 
were plated on chocolate agar.  We recovered a similar number of both LVS and LVS clpB 
CFUs within each different cell type at 4 hours post-inoculation indicating that LVS clpB is 
not defective for internalization (figure 13A-D).  To determine the ability of LVS clpB to 
grow in BMDMs, we lysed infected cells 24 hours post-inoculation and plated serial dilutions 
of the lysate on chocolate agar.  We found a similar increase in the number of CFUs 
recovered for LVS and LVS clpB within each cell line indicating LVS clpB has no 
intracellular growth defect (figure 13A-D).  Because LVS clpB grows in a variety of cell 
lines, these data indicate the ability of LVS clpB to grow intracellularly is generalizable and 
not specific to a certain cell type.  Although LVS dotU infects all cells tested so that it is 
protected from gentamicin similarly to LVS 4 hours post-inoculation, this strain failed to 
grow and a similar number or even fewer CFUs were recovered 24 hours post-inoculation 
(figure 13A-D).  We can rescue the intracellular growth defect seen with LVS dotU by trans-
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complementation (figure 14).  These results indicate the in vivo attenuation of LVS dotU is 
likely a consequence of this strain’s inability to grow intracellularly.  Indeed, LVS dotU and 
U112 dotU fail to escape the phagosome (32, 35) to reach the cytosol- Francisella’s 
replicative niche.  However, since LVS clpB has no intracellular growth defect, its 
attenuation may be caused by an altered immune response that is more effective at bacterial 
clearance.   
LVS clpB fails to inhibit early pro-inflammatory cytokine production in the lung   
Because LVS clpB did not exhibit an intracellular growth defect, we hypothesized 
that this strain’s attenuation was due to an altered immune response that was more effective 
at bacterial clearance.  To test our hypothesis, we first examined cytokine production in the 
lung BALF on day 3 post-inoculation using a 20-plex mouse cytokine Luminex assay.  
Despite higher lung bacterial burdens in LVS infected B6 mice on day 3 post-inoculation 
compared to LVS clpB infected B6 mice (figure 4A), the BALF of LVS infected B6 mice 
contained less pro-inflammatory cytokines and chemokines compared to LVS clpB infected 
B6 mice (figure 15).  LVS clpB also induced a similar profile of pro-inflammatory cytokines 
and chemokines in the lungs of BALB/c mice on day 3 post-inoculation whereas LVS did not 
(figure 15).  BALB/c mice also had significantly higher day 3 post-inoculation lung LVS 
burdens compared to LVS clpB (figure 5A).  Clearly, LVS clpB failed to suppress early pro-
inflammatory cytokine production in the lung which is in stark contrast to LVS infection 
which does not induce pro-inflammatory cytokine production in the lung (figure 15 and 
(11)).  Additionally, the failure of LVS clpB to suppress pro-inflammatory cytokine 
production is not specific to a particular mouse strain as the same effect is seen in B6 and 
BALB/c mice.  Despite the high inoculum dose of LVS dotU, this strain did not elicit any 
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detectable pro-inflammatory cytokine production in the lungs of B6 or BALB/c infected mice 
(data not shown).    
Depletion of IFN-γ early after LVS clpB inoculation increases bacterial burdens   
To confirm that pro-inflammatory cytokine production early after LVS clpB 
inoculation was important innate-mediated bacterial clearance, we treated B6 mice with 500 
µg of XMG1.2 (anti-IFN-γ) or rat IgG1 isotype antibody on day 0 and day 2 post-
inoculation.  On day 3 post-inoculation, mice were sacrificed and bacterial burdens were 
determined in the spleen, liver, and lung.  Mice receiving IFN-γ depleting antibody had 
significantly higher bacterial burdens than mice receiving isotype control antibody in all 
organs (figure 16A-C).  We confirmed IFN-γ depletion by subjecting clarified tissue 
homogenates to Luminex analysis.  All mice receiving anti-IFN-γ depleting antibody had 
IFN-γ levels below the detection limit whereas isotype control animals had high levels of 
lung IFN-γ (figure 16D).  These data indicate pro-inflammatory cytokine production, such as 
IFN-γ, early after LVS clpB inoculation help control bacterial replication.   
LVS clpB infection alters the cellular composition of the BALF  
The presence of pro-inflammatory cytokines/chemokines in the BALF on day 3 post-
inoculation suggested that the cellular composition of the BALF could be altered in LVS 
clpB infected mice.  First, we determined the overall cellularity of the BALF for uninfected, 
LVS, LVS clpB, or LVS dotU infected B6 mice.  LVS clpB infected mice have significantly 
more cells in the BALF compared to uninfected, LVS, and LVS dotU infected mice (figure 
17A).  We then used flow cytometry to identify alveolar macrophages, dendritic cells, 
interstitial macrophages, and neutrophils.  Because the total cellularity of LVS clpB BALF 
was significantly higher than all other groups, the total number of each individual cell 
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population is also increased.  We therefore focused on whether the composition of the 
response is changing (figure 17B-E).  We did not detect a significant increase in any of the 
analyzed cell populations except for neutrophils.  In LVS clpB infected mice, neutrophils 
comprise approximately 40% of all BALF cells; neutrophils are only approximately 10% of 
BALF cells in LVS infected mice.  The difference in the composition is not surprising given 
the presence of neutrophil chemoattractants like MIG and KC in the BALF of LVS clpB 
infected mice (figure 15).             
 We also determined the BALF cellularity of uninfected, LVS, LVS clpB, or LVS 
dotU infected BALB/c mice on day 3 post-inoculation.  Like B6 mice infected with LVS 
clpB, BALB/c mice also had significantly more cells in the BALF upon LVS clpB infection 
(figure 18).  BALB/c mice express high levels of GR-1 on all myeloid cells; therefore, we 
could not unambiguously define the cellular composition of the BALF as we did in B6 mice.  
Despite being unable to define the cellular composition of BALB/c BALF, we did observe 
increased cellularity in LVS clpB infected mice, data consistent with increased pro-
inflammatory cytokine and chemokine levels as determined by Luminex (figure 15).          
MyD88 and TLR2 signaling are required for LVS clpB clearance  
 We next sought to determine the signaling pathways involved in mediating LVS clpB 
clearance.  Signaling through MyD88 is required for survival during LVS infection (16, 36).  
To determine whether MyD88 signaling is required for clearance of LVS clpB, we 
intranasally inoculated MyD88-/- or B6 mice with 5x104 CFU LVS clpB and determined 
bacterial burdens in the spleen, liver, and lung on days 3 and 7 post-inoculation.  MyD88-/- 
mice have significantly higher bacterial burden in the lung, but not the spleen or liver, on day 
3 post-inoculation (figure 19A-C).  These data suggest that MyD88 signaling is necessary for 
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control of bacterial growth at the site of primary infection, but not distal sites, early after 
inoculation.  On day 7 post-inoculation, bacterial burdens in all three organs exceeded 108 
CFU (figure 19A-C).  This increase in bacterial burdens indicates MyD88 signaling is 
necessary for a productive innate immune response capable of controlling LVS clpB 
infection.  Despite the high bacterial burdens, MyD88-/- mice do not lose any weight until 
days 6 and 7 post-inoculation when bacterial burdens are very high (figure 19D).  The 
absence of weight loss in earlier after inoculation in MyD88-/- mice suggests there is little 
production of cytokines like IL-1, IL-6, and TNF-α.     
 TLR2 signaling is required for survival following intranasal or intradermal 
inoculation with LVS (36).  TLR2 requires MyD88 to progagate the signaling cascade (37).  
To determine whether the failure of MyD88-/- mice to control LVS clpB infection was due 
solely to the failure to propagate signals initiated by TLR2, we infected TLR2-/- or B6 mice 
with 5x104 CFU LVS clpB and determined bacterial burdens in the spleen, liver, and lung on 
days 3 and 7 post-inoculation.  On day 3 post-inoculation, B6 and TLR2-/- had identical 
burdens in the spleen, liver, and lung indicating TLR2 signaling is not necessary for early 
control of LVS clpB (figure 20A-C).  On day 7 post-inoculation, TLR2-/- mice have 
significantly higher bacterial burdens in the lung and liver compared to B6 mice; spleen 
bacterial burdens are not different between the two groups (figure 20A-C).  Lung TLR2 
signaling is particularly important for controlling the infection because bacterial burdens are 
approximately 100-fold increased in the lungs of TLR2-/- mice compared to B6 (figure 20C).  
TLR2-/- mice have similar weight loss profiles as B6 mice until days 6 and 7 post-inoculation 
where they fail to gain weight at the same rate as B6 mice (figure 20D).  These weight loss 
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data suggest that there are TLR2-independent pathways mediating cytokine production that 
causes weight loss early after inoculation.                                                        
TLR2 signaling is required for production of some pro-inflammatory cytokines after 
LVS clpB infection  
 Three Francisella lipoproteins have been identified as TLR2 ligands- LpnA, 
FTT_1103, and FTL_0645 (38-40).  TLR2 signaling is necessary for the production of pro-
inflammatory cytokines in peritoneal macrophages infected with LVS (36, 41).  Therefore, it 
was possible that TLR2-/- mice fail to control LVS clpB infection because of defective 
cytokine/chemokine production.  We isolated BALF from uninfected or LVS clpB infected 
B6 and TLR2-/- mice on day 3 post-inoculation and determined cytokine and chemokine 
concentrations using Luminex analysis.  TLR2-/- mice were able to produce several pro-
inflammatory cytokines/chemokines after LVS clpB infection at significantly higher levels 
compared to uninfected mice (IL-12, IP-10, KC, MIG, and GM-CSF) (figure 21).  Despite 
the ability of TLR2-/- mice to produce these cytokines/chemokines, they did not produce as 
much cytokine/chemokine as B6 mice (with the exception of GM-CSF where equivalent 
amounts were produced) (figure 21).  These data suggest that LVS clpB stimulates both 
TLR2-independent and TLR2-dependent pathways that lead to pro-inflammatory cytokine 
production.  The production of IL-1α, IL-1β, IL-2, IL-6, IL-17, MIP-1α, and TNF-α required 
TLR2 signaling as these cytokines/chemokines were not found at significantly higher levels 
in LVS clpB infected TLR2-/- mice compared to uninfected mice (figure 21).  Of note, IFN-γ 
was 28-fold higher in LVS clpB infected TLR2-/- mice compared to uninfected mice but this 
was not a statistically significant increase (figure 21).  Although GM-CSF and IFN-γ were 
produced at higher levels in B6 and TLR2-/- mice than uninfected mice, there was no 
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difference between the LVS clpB infected B6 and TLR2-/- mice suggesting their induction is 
TLR2-independent.  Altogether, these data indicate that LVS clpB stimulates the innate 
immune system via TLR2-independent and -dependent mechanisms that lead to pro-
inflammatory cytokine and chemokine production. 
TLR2 signaling is not required for neutrophil influx into the BALF   
 The differential cytokine and chemokine concentrations in the BALF of LVS clpB 
infected B6 and TLR2-/- mice could affect cellular recruitment to the lungs and therefore the 
cellular composition of the BALF.  We first determined the total number of cells present in 
the BALF and found LVS clpB infected B6 mice had significantly more BALF cells than 
both uninfected and LVS clpB infected TLR2-/- mice (figure 22A).  LVS clpB infected TLR2-
/- mice did have significantly more BALF cells than uninfected mice indicating TLR2-
independent pathways are involved in cellular recruitment (figure 22A).  These data are 
consistent with decreased, but not absent, cytokines and chemokines in the BALF which 
could cause a decrease in cellular recruitment (figure 21).  Despite recovering fewer cells 
from the BALF of LVS clpB infected TLR2-/- mice, the cellular composition is nearly 
identical to B6 mice in terms of the percentage of BALF cells that are alveolar macrophages, 
dendritic cells, or neutrophils (figure 22B-E).  There was a statistically significant increase in 
the percentage of interstitial macrophages in LVS clpB infected TLR2-/- mice compared to 
B6 mice (figure 22D).  While statistically significant, we do not believe the increase to be 
biologically significant because the percentage of all cells is low and amounts to just a few 
hundred cells.  Together, these data indicate that while TLR2-/- mice have decreased total 
BALF cellularity compared to B6 mice, the composition of the BALF is equivalent.             
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Adaptive immunity is required for LVS clpB clearance   
LVS clearance requires adaptive immunity (15).  Because LVS clpB induced a robust 
innate immune response and was nearly cleared from the host prior to the peak of the 
adaptive immune response (day 10 post-inoculation (19)), this raised the possibility that the 
innate immune system alone was capable of controlling the infection and mediating bacterial 
clearance without the requirement of adaptive immunity even though the adaptive response 
was vigorous (see below).  To test this possibility, we infected B6 and Rag-/- with 5x104 CFU 
LVS clpB.  On days 3 and 7 post-infection, B6 and Rag-/- mice had equivalent bacterial 
burdens in the lung indicating that innate immunity was capable of controlling the infection 
initially (figure 23A).  We next infected Rag-/- and B6 mice with 5x104 CFU LVS clpB and 
harvested organs 28 days post-inoculation.  No bacteria were recovered from the B6 mice but 
LVS clpB persisted in the lungs of Rag-/- mice (figure 23A).  The same trend was seen in the 
spleen and liver (figure 23B-C).  Despite persistent bacteremia with LVS clpB in Rag-/- mice, 
weight loss profiles were identical in Rag-/- and B6 mice (figure 23D).  Since LVS clpB 
persisted in Rag-/- mice, this result indicates that adaptive immunity is required for LVS clpB 
clearance similar to LVS (15); the robust innate response is not sufficient to clear LVS clpB.  
It further suggests that the innate immune response is responsible for the early weight loss 
profile observed in LVS clpB inoculated mice.   
LVS clpB infection induces altered immune expansion   
After determining that adaptive immunity is required for LVS clpB clearance, we 
characterized the adaptive immune response to this strain.  First we determined the total 
number of cells recovered from the spleen and lung on days 7 and 10 post-inoculation (figure 
24).  LVS and LVS clpB infected mice had similar increases in spleen cellularity with an 
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approximately 2-3 fold increase in total cells compared to uninfected mice on days 7 and 10 
post-inoculation (figure 24A-B).  LVS and LVS clpB infected mice also had increased lung 
cellularity of 2-5 fold over uninfected mice on days 7 and 10 post-inoculation (figure 24C-
D).  When spleen cellularity of LVS and LVS clpB infected mice was compared, there was 
no significant difference on day 7 or 10 post-inoculation (figure 24A-B).  However, lung 
cellularity was decreased significantly in LVS clpB infected mice compared to LVS infected 
mice on days 7 and 10 post-inoculation (figure 24C-D).  The difference in lung cellularity is 
likely due to the contraction of the immune response following LVS clpB clearance.  While 
the LVS clpB infection was nearly cleared on day 10 post-inoculation, LVS infected mice 
still had high bacterial burdens and an on-going infection likely drives sustained lung 
cellularity.  Because LVS dotU failed to grow in vivo, it was not surprising that LVS dotU 
infected mice did not have any increase in spleen or lung cellularity compared to uninfected 
mice and exhibited no immune expansion from day 7 to 10 (figure 24A-D).        
LVS clpB infection induced a robust IFN-γ mediated immune response similar in 
magnitude to LVS infection  
Given the strong innate response, we suspected that in spite of the earlier clearance of 
LVS clpB, we would still observe a robust adaptive response.  We therefore examined 
whether IFN-γ production by CD4+ T cells was altered after LVS clpB infection in terms of 
absolute number and frequency (Figure 25A-H).  We identified IFN-γ producing T cells 
using intracellular cytokine staining following co-culture with LVS infected congenic B6-
CD45.1 splenocytes as antigen presenting cells.  The gating scheme used for all flow 
cytometry analysis is shown in figure 2.  We found no statistically significant difference in 
the number of CD4+ T cells producing IFN-γ in LVS and LVS clpB infected mice on day 7 in 
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the spleen and lung (figure 25A-B).  On day 10 post-inoculation, the number of splenic CD4+ 
IFN-γ+ T cells was not significantly different between LVS and LVS clpB infected mice in 
spite of lower bacterial burdens in LVS clpB infected mice (figure 25C).  In the lung, 
however, there was a significant decrease in the number of CD4+ IFN-γ+ T cells in LVS clpB 
infected mice compared to LVS infected mice (figure 25D).  While the frequency of IFN-γ+ 
cells in the CD4+ T cell pool in LVS clpB infected mice was higher than LVS infected mice 
(41.6% versus 35.8%), the difference did not reach statistical significance (figure 25H).  
Because the frequency of IFN-γ+ cells of CD4+ T cells was similar in the lungs of LVS and 
LVS clpB infected mice, the difference in the absolute number was due to fewer total cells in 
the lungs of LVS clpB infected mice on day 10 post-inoculation (figure 24D).  The frequency 
of splenic IFN-γ+ CD4+ T cells in LVS infected mice was significantly increased compared 
uninfected and LVS dotU infected mice on days 7 and 10 post-inoculation (figure 25E, G).  
LVS clpB infected mice did not have a statistically significant increase in the frequency of 
IFN-γ+ CD4+ T cells compared to uninfected mice in the spleen on day 7 or 10 post-
inoculation, but the frequency trends higher (figure 25E, G).  LVS and LVS clpB infected 
mice had significantly more IFN-γ+ CD4+ T cells in the lung on day 7 post-inoculation 
compared to uninfected and LVS dotU infected mice (figure 25F).  We did not detect an 
increase in the number or frequency of splenic or lung CD4+ IFN-γ+ cells in LVS dotU 
infected mice compared to uninfected mice (figure 25A-H).         
CD8+ T cells showed a similar pattern of IFN-γ production as CD4+ T cells (figure 
26A-H).  There was no statistical difference in the number of CD8+ IFN-γ+ T cells in the 
spleen or lungs of LVS and LVS clpB infected mice on day 7 post-inoculation (figure 26A-
B).  On day 10 post-inoculation, there were equivalent numbers of CD8+ T cells producing 
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IFN-γ in the spleens of LVS clpB and LVS infected mice (figure 26C).  There was, however, 
a significant decrease in the number of IFN-γ+ CD8+ T cells in the lungs of LVS clpB 
infected mice on day 10 post-inoculation compared to LVS infected mice (figure 26D).  
Again, the percentages of IFN-γ+ cells in the CD8+ T cell pool remained the same, therefore 
any decrease in absolute number on day 10 is due to decreased lung cellularity in LVS clpB 
infected mice (figure 26H).  There was a significant decrease in the frequency of IFN-γ+ 
CD8+ T cells in the lungs of LVS clpB infected mice compared to LVS infected mice on day 
7 post-inoculation in the lung (figure 26F).  The difference in the frequency of IFN-γ+ CD8+ 
T cells between LVS and LVS clpB infected mice in the lung on day 7 post-inoculation has 
been overcome by LVS clpB infected mice by day 10 post-inoculation (figure 26F, H).  In 
the spleen, the frequency of IFN-γ+ CD8+ T cells are similar for all groups on day 7 post-
inoculation (figure 26E).  By day 10 post-infection, LVS and LVS clpB infected mice have 
significantly higher frequencies of IFN-γ+ CD8+ T cells compared to uninfected or LVS dotU 
infected mice (figure 26G).  Uninfected and LVS dotU infected mice were similar to each 
other in terms of the absolute number and frequency of CD8+ IFN-γ+ cells in the spleen and 
lungs on days 7 and 10 post-inoculation (figure 26A-D).      
We found an approximate 2-fold increase in the number of IFN- γ+ CD4+ T cells in 
the spleens of LVS and LVS clpB infected mice between days 7 and 10 post-inoculation 
(figure 25A, C).  There was at least a 10-fold expansion of IFN- γ+ CD4+ T cells in the lungs 
of LVS and LVS clpB infected mice between days 7 and 10 post-inoculation (figure 25B, D).  
LVS clpB infected mice, however, did not show the degree of expansion seen in LVS 
infected mice (10-fold versus 35-fold).  The frequency of IFN-γ+ CD4+ T cells also increased 
from day 7 to day 10 post-inoculation in the lungs of LVS and LVS clpB infected mice 
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(figure 25F, H).  There was no change in the number of IFN-γ+ CD8+ T cells in the spleens of 
LVS or LVS clpB infected mice between days 7 and 10 post-inoculation (figure 26A, C).  
There was, however, an approximate 10-fold increase in the number of responding IFN-γ+ 
CD8+ T cells in the lungs of both LVS and LVS clpB infected mice between days 7 and 10 
(figure 26B, D).  Like CD4+ T cells, the frequency of IFN-γ+ CD8+ T cells increased in the 
lungs of LVS and LVS clpB infected mice from day 7 to day 10 post-inoculation (figure 26F, 
H)  Together these results indicate that LVS clpB infection induced a similar number and 
frequency of IFN- γ+ CD4+ and CD8+ T cells as LVS infection.     
LVS clpB infection led to increased IFN-γ expression by responding T cells compared to 
LVS infection   
We next measured the mean fluorescent intensity (MFI) of CD4+ IFN-γ+ cells 
because MFI is an indication of how much IFN-γ is expressed on a per cell basis.  We 
normalized the data by subtracting the MFI of the IFN-γ- population from the MFI of the 
IFN-γ+ population to give a change in MFI (∆MFI).  Figure 27A-D shows data for CD4+ 
IFN-γ+ ∆MFI combined from 4 independent experiments.  The differences in ∆MFI for CD4+ 
IFN-γ+ T cells on day 10 were consistent from experiment to experiment and representative 
histograms derived from the same experiment are shown (figure 27E-H).  There was a 
significant increase in the ∆MFI of CD4+ cells producing IFN-γ in the spleens and lungs 
from LVS and LVS clpB infected mice compared to either uninfected mice on day 7 and 10 
post-inoculation (figure 27A-D).  On day 7 post-inoculation, there was no significant 
difference in CD4+ IFN-γ ∆MFI from LVS infected mice as compared to LVS clpB infected 
mice for both the spleen and lung (figure 27A-B).  However, on day 10, there was a 
significant increase in IFN-γ ∆MFI from LVS clpB infected mice compared to LVS infected 
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mice in both the spleen and lung (figure 27C-D).  To further investigate IFN-γ production by 
CD4+ T cells, we enriched CD4+ T cells from the spleen and lung on day 10 post-inoculation.  
We chose day 10 because this time point had more responding CD4+ T cells than day 7 and 
also exhibited differences in IFN-γ expression as measured by ΔMFI.  Enriched lung and 
spleen CD4+ T cells were re-stimulated using LVS infected T cell-depleted splenocytes.  The 
concentration of IFN-γ in the culture supernatant was determined by ELISA 24 hours after 
the start of the co-culture and normalized to the number of CD4+ T cells in each sample 
(figure 28).  There was no difference in the IFN-γ concentration following re-stimulation of 
enriched lung or spleen CD4+ T cells from LVS or LVS clpB infected mice.  It is possible 
that we did not see the difference in IFN-γ production by CD4+ T cells because of IFN-γ 
turnover during the culture.  Additionally, intracellular cytokine staining is a much more 
sensitive technique than ELISA analysis of culture supernatant.                  
The IFN-γ ∆MFI trend for CD8+ T cells is similar to the CD4+ T cell subset.  
Measurement of IFN-γ ∆MFI in the spleen and lung showed similar expression of IFN-γ on 7 
days post-inoculation in LVS and LVS clpB infected mice (figure 29A-B).   There was a 
significant increase in the ∆MFI of IFN-γ+ in the CD8+ T cells in LVS clpB infected mice 
compared to LVS infected mice in the spleen and lung on day 10 post-inoculation (figure 
29C-D).  Representative histograms derived from the same experiment for IFN-γ+ CD8+ T 
cells from LVS and LVS clpB infected mice are shown (figure 29E-H).  The IFN-γ ∆MFI in 
CD8+ T cells indicates that like CD4+ T cells, the cells from LVS clpB infected mice express 
more IFN-γ than cells isolated from LVS infected mice, even though fewer cells are present.                   
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LVS clpB infection increases IL-17 expression compared to LVS infection   
Th17 cells are also involved in the immune response during pneumonic tularemia (19, 
20).  Although there was no significant change on day 7 post-inoculation, by day 10 post-
inoculation there was a significant increase in the absolute number of CD4+ IL-17A+ T cells 
in the lungs of LVS infected mice compared to uninfected mice (figure 30C, D).  LVS clpB 
infected mice trended towards more CD4+ IL-17A+ T cells in the lungs on day 10 post-
inoculation than uninfected mice but the difference did not reach statistical significance 
(figure 30D).  There was no significant difference in the absolute number of Th17 cells in the 
lungs of LVS and LVS clpB infected mice on day 10 post-inoculation (figure 30D).  There 
was also an expansion of Th17 cells in the lung between days 7 and 10 post-inoculation for 
LVS and LVS clpB infected mice with nearly a 10-fold increase in cell number (figure 30C-
D).  The absolute number and frequency of splenic CD4+ T cells producing IL-17A was 
similar on days 7 and 10 post-inoculation among uninfected, LVS, LVS clpB, and LVS dotU 
infected mice indicating Th17 cells are not responding to infection in the spleen (figure 30A-
B).  On day 7 post-inoculation, the lungs of LVS infected mice have a significant increase in 
the frequency of IL-17A+ CD4+ T cells compared to uninfected mice (figure 30G).  LVS 
clpB infected mice have a significant increase in the frequency of IL-17A+ CD4+ T cells in 
the lung on day 10 post-inoculation compared to uninfected and LVS dotU infected mice 
(figure 30H).     
There was a significant increase in IL-17A ∆MFI in the lung of LVS clpB infected 
mice on day 10 post-inoculation in the lung compared to LVS (figure 31D).    There was also 
no significant difference in the splenic IL-17A ∆MFI when all groups of mice are compared 
(figure 31A-B).  Representative histograms of IL-17A+ CD4+ T cells are shown (figure 31E-
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H).  We also determined IL-17 secretion by enriched CD4+ T cells from the lung and spleen 
on day 10.  These cells were re-stimulated with LVS infected T cell depleted splenocytes and 
the concentration of IL-17 was determined using ELISA (figure 32).  Enriched CD4+ T cells 
from the lungs of LVS and LVS clpB infected mice secreted similar amounts of IL-17A.  
Overall, our results suggest that Th17 expansion largely occurs at the site of primary 
infection.     
LVS clpB induces an altered innate and adaptive immune response compared to LVS 
infection 
Altogether, our results demonstrate that LVS clpB infection induces altered host 
immunity compared to wild-type LVS infection.  First, we saw early pro-inflammatory 
cytokine production in the lungs of LVS clpB infected mice, a process that was inhibited 
during LVS infection.  The production of these pro-inflammatory cytokines was partially 
dependent on TLR2 signaling.  Additionally, LVS clpB infected mice produced at least 
equivalent expansion of Th1, Th17, and CD8+ T cell responses as LVS infected mice, with 
lower bacterial burdens and a shorter duration of infection. 
 
DISCUSSION 
Bacterial attenuation can be the consequence of a strain’s failure to grow, as in the 
case of auxotrophs, or by a strain’s failure to inhibit components of host immunity.  Both in 
vitro and in vivo screens have identified Francisella virulence determinants and several of 
those screens identified clpB as a gene required for virulence (5-7, 42).  While several groups 
describe a slight intracellular growth defect for clpB strains (23, 43, 44), we did not see an 
intracellular growth defect for our LVS clpB strains in the cell types we tested.  This result 
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suggested that something else was responsible for clpB’s attenuation in animal models of 
infection (23-25).  We therefore hypothesized that LVS clpB induces an altered immune 
response that mediates faster bacterial clearance. 
To test our hypothesis, we first confirmed that our LVS clpB strain was attenuated in 
a pneumonic model of tularemia.  In order to achieve similar bacterial burdens early after 
infection, we inoculated mice with a 100-fold higher dose of LVS clpB compared to LVS.  
Ideally, we would have used the same inoculation dose for both bacterial strains.  However, 
LVS clpB not only failed to disseminate to the spleen and liver in all mice but the bacterial 
burdens were also significantly lower in all organs tested on day 3 post-inoculation at an 
inoculation dose of 5x102 CFU.  An inoculation dose of 5x104 CFU of LVS clpB led to 
similar bacterial burdens as LVS 3 days post-inoculation and allowed us to examine 
differences in the adaptive immune response in the absence of large differences in overall 
antigen load.  Despite similar bacterial burdens early after inoculation, we observed rapid 
clearance of LVS clpB.  Even though LVS clpB was cleared rapidly from the host, this strain 
did elicit an adaptive immune response that developed into protective memory.  Importantly, 
previous infection with LVS clpB provided equivalent protection as LVS against subsequent 
lethal LVS intranasal inoculation.  The bacterial burdens in LVS and LVS clpB vaccinated 
mice infected 120 days after vaccination were higher than the same groups challenged 28 
days after vaccination.  The increase in bacterial burden was consistent with the increased 
weight loss seen when mice were challenged 120 days after vaccination.  Because the 
number of antigen-specific T cells decreases over time, we hypothesize the increased 
bacterial burdens seen upon challenge 120 days after vaccination was due to fewer 
responding T cells compared to day 28.  However, we cannot directly address this hypothesis 
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by quantifying the number of Francisella-specific T cells because MHCI or MHCII tetramer 
is not yet available.  Previous LVS clpB infection did not provide complete protection against 
aerosolized SchuS4 administered 28 days after LVS clpB infection.  LVS clpB infection did 
however, increase the median survival time.  One mouse previously inoculated with LVS 
dotU survived lethal LVS challenge; however, we do not know if that was the result of a 
secondary immune response.  This result was surprising given that our intracellular cytokine 
staining showed LVS dotU infected mice behaved much like naïve mice with similar low 
numbers of IFN-γ producing T cells.  However, LVS dotU persisted intracellularly in some 
mice until at least day 7 post-inoculation, allowing time for a F. tularensis specific T cell 
response to be primed.   The protection was incomplete and indicates a LVS dotU mutant 
would not be effective vaccine.  Overall, our LVS clpB strain was attenuated in pneumonic 
tularemia while providing 100% protection against subsequent lethal infection just as other 
groups had shown using other models of tularemia (23-25).   
After confirming the attenuation of LVS clpB in pneumonic tularemia, we examined 
the innate immune response in the lung.  LVS infection does not elicit a pro-inflammatory 
cytokine response in the lung despite promoting phenotypic maturation of dendritic cells 
(11).  We also found that LVS infection did not elicit a pro-inflammatory cytokine response 
in the lung despite very high bacterial burdens on day 3 post-inoculation.  LVS clpB, in 
contrast, did elicit a robust pro-inflammatory cytokine response in the lungs of both B6 and 
BALB/c mice.  The failure of LVS clpB to inhibit early cytokine production could explain 
why lower inoculation doses resulted in poor dissemination to the spleen and liver, in spite of 
no intracellular growth defect.  Because antibody depletion of IFN-γ increased lung LVS 
clpB burdens, these data suggest that the high concentration of pro-inflammatory cytokines 
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and chemokines in the lung are responsible for the decrease in bacterial burdens compared to 
LVS we observe on day 3 post-inoculation. 
Maximal weight loss occurs two days earlier in LVS clpB infected mice compared to 
LVS infected mice and corresponds to the same time period where there are high levels of 
pro-inflammatory cytokines in the BALF.  We therefore hypothesize that the earlier weight 
loss in LVS clpB infected mice is caused by the pro-inflammatory cytokine response and not 
bacterial burdens or the adaptive immune response.  Rag-/- mice infected with LVS clpB have 
identical weight loss profiles as B6 mice, despite the presence of a chronic infection, 
suggesting weight loss is not caused by bacterial burdens.  We have not determined whether 
Rag-/- mice are capable of producing pro-inflammatory cytokines/chemokines after LVS clpB 
infection, however, Rag-/- mice have an intact innate immune system so we predict these 
mice would produce cytokines upon infection.  LVS clpB infected MyD88-/- mice do not lose 
weight between days 2-5 post-inoculation and only begin to lose weight when they have 
extremely high bacterial burdens and are therefore likely experiencing organ failure.  We 
have not determined whether MyD88-/- mice can produce pro-inflammatory 
cytokines/chemokines after LVS clpB infection, however we predict that they cannot based 
on their failure to lose weight and the requirement of MyD88 for all TLR signaling, except 
TLR3.  The production of pro-inflammatory cytokines during LVS clpB infection was only 
partially dependent on TLR2 signaling.  Francisella has three identified TLR2 ligands and 
TLR2-signalling has been reported to be important for survival during intranasal and 
intradermal inoculation with LVS (36, 38-40).  TLR2-/- mice were able to produce some pro-
inflammatory cytokines and chemokines in response to LVS clpB infection but did not 
induce the levels that were found in wild-type mice inoculated with LVS clpB.  LVS clpB 
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infected TLR2-/- mice fail to regain weight at the same rate as B6 mice and have higher 
bacterial burdens on day 7 post-inoculation.  These data suggest that TLR2-/- mice have a 
defect in the development of adaptive immunity.  To support this idea, LVS clpB infected 
TLR2-/- mice had a significantly lower concentration of IL-12 in the BALF on day 3 post-
inoculation compared to LVS infected mice.  IL-12 production by dendritic cells or 
macrophages directs naïve T cells towards a Th1 (IFN-γ producing) fate upon antigen 
encounter (45, 46).  This question could be addressed in the context of LVS clpB infection 
with simple intracellular cytokine staining experiments to determine whether TLR2-/- mice 
have an altered T cell response compared to B6 mice.                   
Despite a robust pro-inflammatory innate immune response to LVS clpB, the innate 
response was not sufficient to mediate bacterial clearance alone.  Additionally, we knew 
from our protection studies that there was priming of the adaptive immune response because 
mice previously infected with LVS clpB were protected from lethal LVS challenge.  We then 
began to characterize the adaptive immune response to LVS clpB.  When overall immune 
expansion is compared, LVS and LVS clpB infection led to a similar increase in the number 
of cells found in the spleen on days 7 and 10.  We found a significant decrease in the number 
of cells isolated from the lungs of LVS clpB infected mice on days 7 and 10 post-inoculation 
compared to LVS infected mice.  This decrease was likely due to contraction of the immune 
response as LVS clpB was rapidly cleared from the host while LVS infected mice maintain 
high bacterial burdens.  To further support this, the percentages of CD4+ and CD8+ T cells in 
the lungs were the same in LVS and LVS clpB infected mice indicating that while the 
magnitude of the response was changing, the composition of the response remained 
unchanged.  When we examined the effector function of cells in the spleen, we found 
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equivalent numbers of CD4+ and CD8+ T cells producing IFN-γ in LVS and LVS clpB 
infected mice.  The absolute number of CD4+ and CD8+ T cells in the lung of LVS clpB 
infected mice was decreased compared to LVS infected mice but the percentage of cells 
producing IFN-γ remained the same.   
Although we found similar frequencies of IFN-γ producing CD4+ and CD8+ T cells 
after LVS or LVS clpB infection, we did find altered expression levels of IFN-γ as measured 
by ∆MFI.  There was a significant increase in the amount of IFN-γ expressed by T cells from 
LVS clpB infected mice compared to LVS infected mice in both the spleen and lung as 
measured by ∆MFI.  Since IFN-γ is critical for LVS clearance and administration of 
recombinant IFN-γ decreased bacterial burdens, the increased production of IFN-γ by T cells 
in LVS clpB infected mice is consistent with faster clearance of LVS clpB (18).              
The IL-17 response is also important during pneumonic tularemia.  We have 
previously shown that LVS intranasal, but not intradermal, inoculation induces Th17 cells in 
the lung (19).  IL-17 production following F. tularensis infection has been shown to promote 
IL-12 production by dendritic cells and indirectly promote a Th1 immune response (20).  
Although infection with LVS or LVS clpB led to similar numbers of Th17 cells in the lungs 
of infected mice, Th17 cells from LVS clpB infected mice expressed significantly more IL-
17A as measured by ∆MFI.  The increase in IL-17 expression by LVS clpB infected mice is 
consistent with the finding by Lin et al, where the Th1 response was promoted by IL-17 (20).   
We also measured IFN-γ and IL-17 concentration in the BALF, 7 and 10 days post-
inoculation.  We did not detect increased concentration of either cytokine in BALF from 
LVS clpB infected mice compared to LVS mice.  Although these data are not in agreement 
with the flow ∆MFI data, we attribute the difference to differential distribution of immune 
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cells between airspace and lung parenchyma.  Cytokines in the BALF are secreted 
predominantly by cells within the airspace, and represent production by a variety of immune 
cells.  In contrast, our intracellular cytokine staining experiments measure IFN-γ and IL-17 in 
the entire lung, but this analysis is limited only to T cells.  When we enriched CD4+ T cells 
from the lung and spleen on day 10 post-inoculation and re-stimulated them ex vivo with 
LVS infected T cell-depleted splenocytes, we did not detect differences in IFN-γ or IL-17A 
secretion into the culture supernatant.  Differences between the read-out of the flow 
cytometry and ELISA assays could also account for disparate result.  At a minimum, 
however, CD4+ T cells isolated from LVS clpB infected mice are able to produce equivalent 
amounts of cytokine compared to T cells from LVS infected mice.   
The increase in IFN-γ production by T cells in LVS clpB infected mice could be 
caused by differences in lung prostaglandin E2 (PGE2) concentration.  PGE2 suppresses IFN-
γ production by T cells in LVS infected mice (19).  U112 clpB fails to induce PGE2 in 
BMDMs (35) and LVS clpB induced significantly less PGE2 than wild-type LVS in BMDMs 
(figure 33).   LVS clpB infected mice have significantly lower PGE2 concentrations in the 
lavage fluid on day 7 and 10 post-inoculation compared to LVS infected mice (figure 34).  
The high concentration of PGE2 in LVS infected mice decreases IFN-γ production by 
responding T cells, an inhibitory process not present in LVS clpB infected mice.  Increased 
IFN-γ production in LVS clpB infected mice is also consistent with increased IL-17 
expression by T cells in LVS clpB infected mice based on the finding by Lin et al where the 
Th1 response was promoted by IL-17 (20).  However, PGE2 has been shown to promote IL-
23 production which drives the development of Th17 cells (47-50).  In LVS clpB infected 
mice, there was little PGE2 present in the BALF suggesting there is another mechanism 
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driving Th17 accumulation since this cell subset was present in equivalent numbers in LVS 
and LVS clpB infected mice despite dramatic differences in PGE2 levels.   
Although we are still in the process of identifying the F. tularensis effector molecule 
responsible for inducing PGE2, it seems unlikely that ClpB directly induces PGE2.  ClpB is 
an intracellular chaperone protein that is unlikely to be sensed by the host.  Proteomic 
analysis by Meibom, et al of a membrane-enriched protein fraction from a LVS clpB mutant 
identified 5 proteins with decreased expression compared to LVS at elevated temperature 
conditions (23).  None of the identified targets of ClpB are required for PGE2 induction (35) 
therefore ClpB must have another target that is involved in PGE2 induction.  We speculate 
clpB was identified as a gene necessary for PGE2 induction because ClpB plays a role in 
assembly of the type VI secretion system that is responsible for secreting the unknown PGE2 
inducer.  Studies to identify the mechanim(s) utilized by F. tularensis to induce PGE2 
synthesis are ongoing.                        
ClpB is a highly conserved chaperone protein present not only in prokaryotes but also 
in eukaryotes and plants (51).  Due to ClpB’s conserved nature and the finding that 
disruption of clpB attenuates F. tularensis as well as other bacteria (52-56), this gene is an 
excellent candidate target for attenuation of pathogenic bacteria for vaccine development.  In 
the case of F. tularensis, LVS clpB infection was cleared faster than LVS yet induced a 
robust IFN-γ mediated immune response that was protective in both short- and long-term 
secondary infections.  Therefore, clpB serves as an advantageous target for F. tularensis 
attenuation for future vaccine development.  This work also highlights the importance of 
examining the immune response to attenuated mutants, particularly in the course of vaccine 
development.  
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Figure 1.  Gating scheme for BALF analysis.  Single cells were discriminated from 
doublets by plotting side scatter height (SSC-H) versus side scatter area (SSC-A).  Cells 
were then gated on by plotting SSC-A versus forward scatter area (FSC-A).  Live cells 
were then gated by plotting the live/dead stain on a 1-D histogram.  Cells from the BALF 
were discriminated from the CFSE-labeled splenocyte carries by plotting an empty 
channel versus CFSE.  CD3+, CD19+, and not B and T cells were gated on by plotting 
CD3 versus CD19.  From the not B and T gate, GR-1 versus CD11b was plotted to 
distinguish neutrophils from not neutrophils.  From the not neutrophils gate, SSC-A versus 
F4/80 was plotted to distinguish F4/80+ from F4/80- cells.  From the F4/80- gate, CD11c 
versus FSC-A was plotted and dendritic cells were gated on.  From the F4/80+ gate, 
CD11c versus CD11b was plotted to distinguish alveolar macrophages (AMs) from 
interstitial macrophages (IMs).  For each gate, the percent of the parent gate is indicated in 
bold (for example, AMs are 66.84% of the F4/80+ gate). 
109
Figure 2
Figure 2.  Gating scheme for intracellular cytokine staining analysis.  Single cells were 
discriminated from doublets by plotting side scatter linear versus side scatter area.  Cells 
were then selected by plotting side scatter area versus forward scatter area.  Live CD3+ T 
cells were then selected by plotting CD3 versus the Pacific Blue channel which included 
the live/dead stain and markers for antigen presenting cells.  CD45.1- CD3+ cells were 
gated on by plotting CD3 versus CD45.1.  From the CD45.1- CD3+ gate, CD4+ and CD8+ 
T cells were selected.  Gates for IFN-γ and IL-17A positive cells were set based on isotype 
control staining.  For simplicity, only CD4+ IFN-γ is shown.  Change in mean fluorescent 
intensity (ΔMFI) for each sample was determined by subtracting the cytokine negative 
population from the cytokine positive population.  For each gate, the percent of the parent 
gate is indicated in bold (for example, CD3+ cells are 15.10% of the cells gate).    
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Figure 3.  LVS clpB does not disseminate when a low inoculation dose is used.  B6 mice 
were intranasally inoculated with 5x102 CFU LVS, 5x102 CFU LVS clpB, or 5x104 CFU 
LVS clpB.  On day 3 post-inoculation, bacterial burdens were determined in the A) spleen, 
B) liver, and C) lung by plating serial dilutions of organ homogenate on chocolate agar.  
n=6-10 mice/group.  Data are combined from at least 2 independent experiments.  The 
dashed line indicates the limit of detection of 50 CFUs.  Statistical significance was 
determined on log-transformed data using ANOVA with Tukey's post-test.    
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Figure 4.  LVS clpB infected B6 mice clear bacteria faster.  B6 mice were intranasally 
inoculated with LVS (5x102 CFU), LVS clpB (5x104 CFU), or LVS dotU (5x105 CFU).  
On days 3, 7, and 10 post-inoculation, bacterial burdens were determined in the A) lung, B) 
liver, and C) spleen by plating serial dilutions of organ homogenate on chocolate agar.  
n=5-12 mice/group.  Data are combined from at least 4 independent experiments per time 
point.  The dashed line indicates the limit of detection of 50 CFUs.  Statistical significance 
was determined on log-transformed data using ANOVA with Tukey's post-test (day 3 and 
7) or a Student's t-test (day 10).  
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Figure 5.  LVS clpB infected BALB/c mice clear bacteria faster.  BALB/c mice were 
intranasally inoculated with LVS (5x102 CFU), LVS clpB (5x104 CFU), or LVS dotU 
(5x105 CFU).  On days 3, 7, and 10 post-inoculation, bacterial burdens were determined in 
the A) lung, B) liver, and C) spleen by plating serial dilutions of organ homogenate on 
chocolate agar.  n=4-6 mice/group.  Data are combined from 2 independent experiments 
per time point.  The dashed line indicates the limit of detection of 50 CFUs.  Statistical 
significance was determined on log-transformed data using ANOVA with Tukey's post-test 
(day 3 and 7) or a Student's t-test (day 10).   
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Figure 6
Figure 6.  LVS dotU is internalized by lung cells following intranasal inoculation.  B6 
mice were intranasally inoculated with 5x105 CFU LVS dotU.  3 days post-inoculation, 
lungs were removed and digested into a single cell suspension.  Samples were then divided 
in half and one half was treated with 50 µg/mL gentamicin for 45 minutes to kill 
extracellular bacteria.  Cells were washed to remove antibiotic and then plated directly on 
chocolate agar without lysis.  The number of bacterial colonies in the untreated half and 
gentamicin-treated half were determined.  n=3 mice.  Data are from 1 experiment.    
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Figure 7
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Figure 7.  Trans-complementation of LVS clpB or LVS dotU restores bacterial virulence 
to LVS levels.  B6 mice were intranasally inoculated with 5x102 CFU LVS, LVS clpB, LVS 
clpB complement, or LVS dotU complement or 5x105 LVS dotU.  Bacterial burdens were 
determined in the lung for A) LVS clpB or B) LVS dotU on days 3 post-inoculation by 
plating serial dilutions of organ homogenate on chocolate agar.  The dashed line indicates 
the limit of detection of 50 CFUs.  Statistical significance was determined using an 
ANOVA with Tukey's post-test on log-transformed data.  n=3-4 mice/group.  Data are from 
1 experiment.    
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Figure 8.  LVS clpB infected B6 and BALB/c mice exhibit less disease.  B6 and BALB/c 
mice were intranasally inoculated with LVS (5x102 CFU), LVS clpB (5x104 CFU), or LVS 
dotU (5x105 CFU).  Mouse weight was determined daily and is reported as the percentage 
of starting weight for A) B6 or B) BALB/c mice.  n=25-32 mice/group (B6) or n=4-6 
mice/group (BALB/c).       
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Figure 9.  LVS clpB protects against a lethal LVS secondary challenge 28 after primary 
infection.  B6 mice were intranasally inoculated with LVS (5x102 CFU), LVS clpB (5x104 
CFU), or LVS dotU (5x105 CFU), or left uninfected.  A) 28 days after primary infection, 
mice were challenged intranasally with 5x103 CFU LVS and survival was measured.  n=6-
12 mice/group.  Data are combined from 2 independent experiments.  A Chi-square test 
with Yate's correction was used to compare survival of the vaccinated groups to the naïve 
group: Naïve versus LVS: p ≤ 0.001; Naïve versus LVS clpB: p ≤ 0.0001; Naïve versus 
LVS dotU: ns.  B) Mice were weighed daily following secondary infection with LVS and 
weight loss is reported as a percentage of starting weight.  Weight loss by the surviving 
LVS dotU vaccinated mouse is reported.  n=6-12 mice/group.  Data are combined from 2 
independent experiments.  Bacterial burdens in the C) spleen, D) liver, and E) lung on day 
6 post-rechallenge were determined by plating serial dilutions of tissue homogenate on 
chocolate agar.  n=5-7 mice/group.  Data are combined from 2 independent experiments.  
The dashed line indicates the limit of detection of 50 CFUs.  Statistical significance was 
determined on log-transformed data using ANOVA with Tukey's post-test.  
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Figure 10.  LVS clpB protects against a lethal LVS secondary challenge 120 after 
primary infection.  B6 mice were intranasally inoculated with LVS (5x102 CFU), LVS 
clpB (5x104 CFU), or LVS dotU (5x105 CFU), or left uninfected.  A) 120 days after 
primary infection, mice were challenged intranasally with 5x103 CFU LVS and survival 
was measured.  n=6-12 mice/group.  Data are combined from 2 independent experiments.  
A Chi-square test with Yate's correction was used to compare survival of the vaccinated 
groups to the naïve group: Naïve versus LVS: p ≤ 0.001; Naïve versus LVS clpB: p ≤ 
0.0001; Naïve versus LVS dotU: ns.  B) Mice were weighed daily following secondary 
infection with LVS and weight loss is reported as a percentage of starting weight.  Weight 
loss by the surviving LVS dotU vaccinated mouse is reported.  n=12-15 mice/group.  Data 
are combined from 2 independent experiments.  Bacterial burdens in the C) spleen, D) 
liver, and E) lung on day 6 post-rechallenge were determined by plating serial dilutions of 
tissue homogenate on chocolate agar.  n=6-8 mice/group.  Data are combined from 2 
independent experiments.  The dashed line indicates the limit of detection of 50 CFUs.  
Statistical significance was determined on log-transformed data using ANOVA with 
Tukey's post-test.  
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Figure 11
Figure 11.  Previous infection with LVS clpB increases median survival time after lethal 
SchuS4 aerosol challenge.  B6 mice were intranasally inoculated with LVS (5x102 CFU), 
LVS clpB (5x104 CFU), or LVS dotU (5x105 CFU), or left uninfected.  28 days after 
primary infection, mice were challenged with 30 CFU of aerosolized SchuS4.  A Mantel-
Cox log-rank test was used to compare survival of the vaccinated groups to the naïve 
group.  n=8 mice/group.  Data are from 1 experiment.  Naïve versus LVS: p ≤ 0.001; 
Naïve versus LVS clpB: p ≤ 0.0001; Naïve versus LVS dotU: ns.  
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Figure 12.  LVS clpB does not exhibit a broth growth defect.  LVS, LVS clpB and LVS 
dotU growth in A) CDM or B) BHI broth was determined using a TECAN Infinite M200 
plate reader by measuring the OD600 every 15 minutes for 48 hours.  Data shown are the 
average of triplicate wells and are representative of at least 3 independent experiments per 
strain.  
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Figure 13
Figure 13.  LVS clpB does not exhibit an intracellular growth defect.  A) B6 bone 
marrow derived macrophages (BMDMs), B) A549, C) J774, or D) MHS cells were 
infected with LVS, LVS clpB, or LVS dotU at an MOI of 25:1.  Cells were lysed either 4 or 
24 hours post-infection and serial dilutions of the lysate were plated on chocolate agar to 
determine the number of bacteria present.  Cells were infected with each strain in triplicate 
and lysates from each sample were plated in duplicate.  Data are representative of at least 2 
independent experiments.  
A  B
C D
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Figure 14
Figure 14.  Trans-complementation of LVS dotU restores intracellular growth.  B6 bone 
marrow derived macrophages (BMDMs) were inoculated with LVS, LVS dotU, or LVS 
dotU complement at an MOI of 25:1.  BMDMs were lysed either 4 or 24 hours post-
inoculation and serial dilutions of the lysate were plated on chocolate agar to determine the 
number of bacteria present.  BMDMs were inoculated with each strain in triplicate and 
lysates from each sample were plated in duplicate.  Data are representative of 3 
independent experiments. 
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Figure 15
Figure 15.  LVS clpB induces a pro-inflammatory response in the lung early after 
infection.  B6 or BALB/c mice were intranasally inoculated with LVS (5x102 CFU) or 
LVS clpB (5x104 CFU), or left uninfected.  3 days post-inoculation, BALF was collected 
and cytokine and chemokine concentrations were determined using a Luminex-based 
assay.  Cytokine and chemokines levels were first normalized to the levels in uninfected 
mice and then the fold increase in cytokine or chemokine concentration from LVS clpB 
infected mice over LVS infected mice was determined for each infected group and values 
are indicated in bold if they exceeded 2 fold.  n=4-7 mice/group.  Data are combined from 
at least 2 independent experiments per mouse strain.  ANOVA with Tukey's post-test was 
used to determine significant changes in cytokine and chemokine concentrations within 
each mouse strain.  LVS clpB levels were significantly higher (p ≤ 0.05) than LVS in both 
mouse strains for IP-10, KC, IL-12, and TNF-α.  LVS clpB levels were significantly 
higher (p ≤ 0.05) than LVS levels in B6 mice for IFN-γ, IL-6, and GM-CSF.  LVS clpB 
levels were significantly higher (p ≤ 0.05) than LVS levels in BALB/c mice for MIG.
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Figure 16.  IFN-γ depletion increases bacterial burdens after LVS clpB inoculation.  B6 
mice were intranasally inoculated with LVS clpB (5x104 CFU).  Mice were treated with 
500 μg anti-IFN-γ or rat IgG1 isotype control antibody on day 0 and 2 post-inoculation.  
Bacterial burdens in the A) spleen, B) liver, and C) lung were determined on day 3 post-
inoculation by plating serial dilutions of tissue homogenate on chocolate agar.  n=8 
mice/group.  Data are compiled from 2 independent experiments.  The dashed line indicates 
the limit of detection of 50 CFUs.  Statistical significance was determined on log-
transformed data using a Student's t-test.  D) Lung tissue homogenate was clarified and 
IFN-γ concentration determined by Luminex analysis.   n=8 mice/group.  Data are compiled 
from 2 independent experiments.  The dashed line indicates the limit of detection of 20 
pg/mL.  Statistical significance was determined using a Student's t-test.    
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Figure 17.  LVS clpB infection of B6 mice leads to increased mBAL cellularity and 
altered mBAL cellular composition.  B6 mice were intranasally inoculated with LVS 
(5x102 CFU), LVS clpB (5x104 CFU), or LVS dotU (5x105 CFU), or left uninfected.  A) 
On day 3 post-inoculation, the total number of cells in the mBAL was determined.  The % 
B) alveolar macrophages, C) dendritic cells, D) interstitial macrophages, and e) neutrophils 
of all cells in the mBAL was determined by flow cytometry.  n=4-7 mice/group.  Data are 
combined from 2 independent experiments.       
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Figure 18
Figure 18.  LVS clpB infection of BALB/c mice leads to increased mBAL cellularity.  
BALB/c mice were intranasally inoculated with LVS (5x102 CFU), LVS clpB (5x104 
CFU), or LVS dotU (5x105 CFU), or left uninfected.  On day 3 post-inoculation, the total 
number of cells in the mBAL was determined. n=5-7 mice/group.  Data are combined from 
2 independent experiments.       
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Figure 19.  MyD88 signaling is required to control LVS clpB infection.  B6 or MyD88-/- 
mice were intranasally inoculated with LVS clpB (5x104 CFU).  On days 3 and 7 post-
inoculation, bacterial burdens were determined in the A) spleen, B) liver, and C) lung by 
plating serial dilutions of organ homogenate on chocolate agar.  n=5-9 mice/group.  Data 
are combined from 2 independent experiments per time point.  The dashed line indicates 
the limit of detection of 50 CFUs.  Statistical significance was determined on log-
transformed data using a Student's t-test.  
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Figure 20
Figure 20.  TLR2 signaling is required to control LVS clpB infection.  B6 or TLR2-/- 
mice were intranasally inoculated with LVS clpB (5x104 CFU).  On days 3 and 7 post-
inoculation, bacterial burdens were determined in the A) spleen, B) liver, and C) lung by 
plating serial dilutions of organ homogenate on chocolate agar.  n=3-8 mice/group.  Data 
are from 1 experiment for day 3 and combined from 2 independent experiments for day 7.  
The dashed line indicates the limit of detection of 50 CFUs.  Statistical significance was 
determined on log-transformed data using a Student's t-test.  D) Weight loss was 
determined daily and is reported as a percentage of the starting weight.   
D
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Figure 21.  TLR2 signaling is required for maximal pro-inflammatory cytokine 
production following LVS clpB infection.  B6 or TLR2-/- mice were intranasally 
inoculated with LVS clpB (5x104 CFU).  On day 3 post-inoculation, BALF was collected 
and cytokine and chemokine concentrations were determined using a Luminex-based assay 
and fold increases for each pair of groups is reported.  n=3-5 mice/group.  Uninfected mice 
are combined B6 and TLR2-/-.  Data are from 1 experiment.  An ANOVA with Tukey's 
post-test was used to determine statisical significance for each cytokine or chemokine.  
Statistical significance is indicated by stars after the fold change when two groups differed.        
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Figure 22.  LVS clpB infection of B6 and TLR2-/- mice leads to increased BALF 
cellularity and altered BALF cellular composition.  B6 or TLR2-/- mice were intranasally 
inoculated with LVS clpB (5x104 CFU) or left uninfected.  A) On day 3 post-inoculation, 
the total number of cells in the BALF was determined.  The % B) alveolar macrophages, 
C) dendritic cells, D) interstitial macrophages, and e) neutrophils of all cells in the BALF 
was determined by flow cytometry.  n=3-5 mice/group.  Data are from 1 experiment.  
Statistical significance was determined using ANOVA with Tukey's post-test.        
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Figure 23.  Adaptive immunity is required for LVS clpB clearance.  B6 or Rag-/- mice 
were intranasally inoculated with 5x104 CFU LVS clpB.  Bacterial burdens were 
determined in the A) lung, B) spleen, and C) liver on days 3, 7, 10, and 28 post-inoculation 
by plating serial dilutions of organ homogenate on chocolate agar.  n=6-8 mice/group for 
each time point.  Data are combined from 2 independent experiments for each time point.  
The dashed line indicates the limit of detection of 50 CFUs.  Statistical significance was 
determined on log-transformed data using a Student's t-test.  D) Mouse weight was 
determined daily and is reported as the percentage of starting weight.  n=6-8 mice/group.  
Data are combined from 2 independent experiments.
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Figure 24. LVS and LVS clpB infection leads to increased spleen and lung cellularity.  
B6 mice were intranasally inoculated with LVS (5x102 CFU), LVS clpB (5x104 CFU), or 
LVS dotU (5x105 CFU), or left uninfected.  The total number of cells in the spleen or lung 
was determined on day 7 and 10 post-inoculation by trypan blue exclusion.  Total number 
of cells in the spleen on day A) 7 or B) 10 post-inoculation.  Total number of cells in the 
lung on day C) 7 or D) 10 post-inoculation.  n=4-9 mice/group.  Data are combined from at 
least 4 independent experiments.  Statistical significance was determined using an ANOVA 
with Tukey's post-test.    
132
AFigure 25
Figure 25.  LVS and LVS clpB infection leads to increased IFN-γ+ CD4+ T cells.  B6 
mice were intranasally inoculated with LVS (5x102 CFU), LVS clpB (5x104 CFU), or LVS 
dotU (5x105 CFU), or left uninfected.  On days 7 and 10 post-inoculation, splenocytes or 
isolated lung cells were re-stimulated with LVS infected B6-CD45.1 antigen presenting 
cells for 24 hours.  Brefeldin A was added during the last 4 hours of co-culture.  n=4-9 
mice/group.  Data are combined from at least 4 independent experiments.  Statistical 
significance was determined using an ANOVA with Tukey's post-test.  Number of IFN-γ 
producing CD4+ in the A) spleen or B) lung on day 7 post-inoculation.  Number of IFN-γ 
producing CD4+ in the C) spleen or D) lung on day 10 post-inoculation.  % IFN-γ+ of 
CD4+ in the E) spleen or F) lung on day 7 post-inoculation.  % IFN-γ+ of CD4+ in the G) 
spleen or H) lung on day 10 post-inoculation.  
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Figure 26.  LVS and LVS clpB infection leads to increased IFN-γ+ CD8+ T cells.  B6 
mice were intranasally inoculated with LVS (5x102 CFU), LVS clpB (5x104 CFU), or LVS 
dotU (5x105 CFU), or left uninfected.  On days 7 and 10 post-inoculation, splenocytes or 
isolated lung cells were re-stimulated with LVS infected B6-CD45.1 antigen presenting 
cells for 24 hours.  Brefeldin A was added during the last 4 hours of co-culture.  n=4-9 
mice/group.  Data are combined from at least 4 independent experiments.  Statistical 
significance was determined using an ANOVA with Tukey's post-test.  Number of IFN-γ 
producing CD8+ in the A) spleen or B) lung on day 7 post-inoculation.  Number of IFN-γ 
producing CD8+ in the C) spleen or D) lung on day 10 post-inoculation.  % IFN-γ+ of 
CD8+ in the E) spleen or F) lung on day 7 post-inoculation.  % IFN-γ+ of CD8+ in the G) 
spleen or H) lung on day 10 post-inoculation.   
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Figure 27. CD4+ T cells from LVS clpB infected mice express more IFN-γ per cell than LVS 
infected mice.  B6 mice were intranasally inoculated with LVS (5x102 CFU), LVS clpB (5x104 
CFU), or LVS dotU (5x105 CFU), or left uninfected.  On days 7 and 10 post-inoculation, 
splenocytes or isolated lung cells were re-stimulated with LVS infected B6-CD45.1 antigen 
presenting cells for 24 hours.  Brefeldin A was added during the last 4 hours of co-culture.  To 
determine the change in mean fluorescent intensity (ΔMFI) for each sample, the MFI of the IFN-γ 
negative population was subtracted from the MFI of the IFN-γ positive population.  n=4-9 
mice/group.  Data are combined from at least 4 independent experiments.  Statistical significance 
was determined using an ANOVA with Tukey's post-test.  IFN-γ ΔMFI for CD4+ T cells in the A) 
spleen or B) lung on day 7 post-inoculation.  IFN-γ ΔMFI for CD4+ T cells in the C) spleen or D) 
lung on day 10 post-inoculation.  Representative histograms of the IFN-γ+ CD4+ T cells from LVS 
(solid line) and LVS clpB (dotted line) infected mice in the E) spleen or F) lung on day 7 post-
inoculation.  Representative histograms of the IFN-γ+ CD4+ T cells from LVS (solid line) and LVS 
clpB (dotted line) infected mice in the G) spleen or H) lung on day 10 post-inoculation. 
135
Figure 28
A
B
Figure 28.  CD4+ T cells from LVS or LVS clpB infected mice secrete similar amounts 
of IFN-γ.  B6 mice were intranasally inoculated with LVS (5x102 CFU), LVS clpB (5x104 
CFU), or left uninfected.  10 days post-infection, CD4+ T cells were enriched from the A) 
spleen and B) lung and re-stimulated with LVS or mock infected T cell-depleted 
splenocytes.  Cells were stimulated with PMA/Ionomycin as a positive control or left 
untreated as a negative control.  IFN-γ secretion into the culture supernatant was measured 
by ELISA.  Each sample was analyzed in triplicate.  n=4 mice/group.  Data are combined 
from two independent experiments.   
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Figure 29. CD8+ T cells from LVS clpB infected mice express more IFN-γ per cell than LVS 
infected mice.  B6 mice were intranasally inoculated with LVS (5x102 CFU), LVS clpB (5x104 
CFU), or LVS dotU (5x105 CFU), or left uninfected.  On days 7 and 10 post-inoculation, 
splenocytes or isolated lung cells were re-stimulated with LVS infected B6-CD45.1 antigen 
presenting cells for 24 hours.  Brefeldin A was added during the last 4 hours of co-culture.  To 
determine the change in mean fluorescent intensity (ΔMFI) for each sample, the MFI of the IFN-γ 
negative population was subtracted from the MFI of the IFN-γ positive population.  n=4-9 
mice/group.  Data are combined from at least 4 independent experiments.  Statistical significance 
was determined using an ANOVA with Tukey's post-test.  IFN-γ ΔMFI for CD8+ T cells in the A) 
spleen or B) lung on day 7 post-inoculation.  IFN-γ ΔMFI for CD8+ T cells in the C) spleen or D) 
lung on day 10 post-inoculation.  Representative histograms of the IFN-γ+ CD8+ T cells from LVS 
(solid line) and LVS clpB (dotted line) infected mice in the E) spleen or F) lung on day 7 post-
inoculation.  Representative histograms of the IFN-γ+ CD8+ T cells from LVS (solid line) and LVS 
clpB (dotted line) infected mice in the G) spleen or H) lung on day 10 post-inoculation. 
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Figure 30.  Th17 cells expand in the lungs of LVS and LVS clpB infected mice.  B6 mice 
were intranasally inoculated with LVS (5x102 CFU), LVS clpB (5x104 CFU), or LVS dotU 
(5x105 CFU), or left uninfected.  On days 7 and 10 post-infection, splenocytes or isolated 
lung cells were re-stimulated with LVS infected B6-CD45.1 antigen presenting cells for 24 
hours.  Brefeldin A was added during the last 4 hours of co-culture.  n=4-9 mice/group.  
Data are combined from at least 4 independent experiments.  Statistical significance was 
determined using an ANOVA with Tukey's post-test.  Number of IL-17A producing CD4+ 
in the spleen on A) day 7 or B) day 10 post-infection.  Number of IL-17A producing CD4+ 
in the lung on C) day 7 or D) day 10 post-infection.  % IL-17A+ of CD4+ in the spleen on 
E) day 7 or F) day 10 post-inoculation.  % IL-17A+ of CD4+ in the lung on G) day 7 or H) 
day 10 post-inoculation. 
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Figure 31.  Th17 cells from LVS clpB infected mice express more IL-17 than cells from 
LVS infected mice.  B6 mice were intranasally inoculated with LVS (5x102 CFU), LVS 
clpB (5x104 CFU), or LVS dotU (5x105 CFU), or left uninfected.  On days 7 and 10 post-
infection, splenocytes or isolated lung cells were re-stimulated with LVS infected B6-
CD45.1 antigen presenting cells for 24 hours.  Brefeldin A was added during the last 4 
hours of co-culture.  To determine the change in mean fluorescent intensity (ΔMFI), the 
MFI of the IL-17A negative population was subtracted from the MFI of the IL-17A 
positive population.  n=4-9 mice/group.  Data are combined from at least 4 independent 
experiments.  Statistical significance was determined using an ANOVA with Tukey's post-
test.  IL-17A ΔMFI for CD4+ T cells in the spleen on A) day 7 or B) day 10 post-infection.  
IL-17A ΔMFI for CD4+ T cells in the lung on C) day 7 or D) day 10 post-infection.  
Representative histograms of the IL-17A+ CD4+ T cells from LVS (solid line) and LVS 
clpB (dotted line) infected mice in the spleen on E) day 7 or F) day 10 post-infection.  
Representative histograms of the IL-17A+ CD4+ T cells from LVS (solid line) and LVS 
clpB (dotted line) infected mice in the lung on G) day 7 or H) day 10 post-infection.    
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Figure 32.  CD4+ T cells from LVS or LVS clpB infected mice secrete similar amounts of 
IL-17A.  B6 mice were intranasally inoculated with LVS (5x102 CFU), LVS clpB (5x104 
CFU), or left uninfected.  10 days post-inoculation, CD4+ T cells were enriched from the 
A) spleen and B) lung and re-stimulated with LVS or mock infected T cell-depleted 
splenocytes.  Cells were stimulated with PMA/Ionomycin as a positive control or left 
untreated as a negative control.  IL-17A secretion into the culture supernatant was 
measured by ELISA.  The dashed line indicates the limit of detection of 6 pg/mL.  Each 
sample was analyzed in triplicate.  n=4 mice/group.  Data are combined from two 
independent experiments.  
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Figure 33
Figure 33.  LVS clpB induces less PGE2 synthesis and secretion from bone marrow-
derived macrophages compared to LVS.  1x105 B6 BMDMs were inoculated at an MOI of 
500:1, 250:1, or 125:1 with LVS, LVS clpB, or LVS dotU.  24 hours post-inoculation, 
culture supernatants were collected and the concentration of PGE2 was determined using 
an ELISA.  BMDMs were infected with each strain in triplicate.  Uninfected BMDMs 
produced 38.58 +/- 1.62 pg/mL PGE2 and LPS treated BMDMs (positive control) 
produced 672.58 +/- 172.01 pg/mL PGE2.  Data are representative of 3 independent 
experiments.  Statistical significance was determined using ANOVA with Tukey's post-test 
to compare the strains at each MOI: 500:1: LVS versus LVS clpB: p ≤ 0.001; LVS versus 
LVS dotU: p ≤ 0.001; LVS clpB versus LVS dotU: p ≤ 0.01. 250:1: LVS versus LVS clpB: 
p ≤ 0.05; LVS versus LVS dotU: p ≤ 0.01; LVS clpB versus LVS dotU: ns. 125:1: LVS 
versus LVS clpB: p ≤ 0.01; LVS versus LVS dotU: p ≤ 0.001; LVS clpB versus LVS dotU: 
ns.   
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Figure 34
Figure 34.  LVS clpB infected mice produce less PGE2 than LVS infected mice.  B6 mice 
were intranasally inoculated with LVS (5x102 CFU), LVS clpB (5x104 CFU), or left 
uninfected.  On days A) 3, B) 7, and C) 10 days post-inoculation BALF was collected and 
the concentration of PGE2 was determined by ELISA.  n=5-10 mice/group for each time 
point.  Data are combined from at least two independent experiments per time point.  
Statistical significance was determined using ANOVA with Tukey's post-test.    
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CHAPTER 3 
IFN-γ, BUT NOT IL-17A, IS REQUIRED FOR SURVIVAL DURING SECONDARY 
PULMONARY FRANCISELLA TULARENSIS LVS INFECTION1 
 
OVERVIEW 
 
IL-17 production by T cells is critical following intranasal inoculation with the highly 
pathogenic bacterium, Francisella tularensis Live Vaccine Strain (LVS).  In the absence of IL-17, 
mice have higher bacterial burdens and produce less IFN-γ, a cytokine required for F. tularensis 
clearance.  While the importance of both Th1 and Th17 cells during primary intranasal F. tularensis 
infection is clear, the importance of these cells isn’t understood during the memory response.  Using 
intracellular cytokine staining, we measured the number of CD4+ T cells producing IFN-γ or IL-17 in 
vaccinated mice on day 4 of the secondary response.  Because there were so few bacteria in the spleen 
after secondary challenge, we also measured the local immune response in the lung where bacterial 
loads were higher.  Although there was a robust Th1 response, Th17 cells are not present at higher 
numbers in the lungs of vaccinated mice compared to unvaccinated mice.  These data show that the 
lung is the dominant site of the secondary infection and the immune response.   Furthermore, these 
data suggest Th17 cells are not required for survival after secondary challenge.  To further investigate 
the importance of IFN-γ and IL-17 during the secondary response to F. tularensis, we depleted either 
IFN-γ or IL-17 in vivo using monoclonal antibody treatment.  Vaccinated mice treated with IFN-γ 
depleting antibody lost more weight and had higher bacterial burdens compared to vaccinated mice 
treated with isotype control antibody.  In contrast, treatment with anti-IL-17 antibody did not alter 
                                                            
1 Contributing authors: Lydia Barrigan, Shraddha Tuladhar, Deepa Jamwal, and Jeffrey Frelinger 
 
 
 
weight loss profiles or bacterial burdens compared to mice treated with isotype control antibody.  
Altogether, these results suggest that IFN-γ is required both during primary and secondary intranasal 
F. tularensis infection.  IL-17, on the other hand, is critical during the primary response to intranasal 
F. tularensis but dispensable during the secondary response. 
 
INTRODUCTION 
Tularemia, or rabbit fever, is caused by the gram negative coccobacillus, Francisella 
tularensis.  Francisella is highly pathogenic and causes severe disease in humans, leading the 
U.S. government to categorize Francisella as a Tier 1 Select Agent (1).  While the CDC 
reports approximately 120 cases of naturally-acquired tularemia each year in the U.S., 
Francisella has been used as the infectious agent in bioweapons and continues to pose a 
realistic threat today (2-4).  The potential of a bioterrorism attack utilizing F. tularensis as 
the infection agent underscores the need for an effective vaccine.  Although the Francisella 
Live Vaccine Strain (LVS) was widely used as a vaccine in Europe where tularemia is much 
more common, the mechanisms of attenuation are undefined, preventing the FDA from 
licensing this vaccine in the U.S. (1).         
Three different strains of Francisella are commonly studied in the laboratory.  F. 
tularensis subsp. tularensis SchuS4 (SchuS4) is a highly virulent Type A strain.  As few as 
10 organisms can cause severe disease in humans with a 30-60% fatality rate if antibiotics 
are not administered (5).  The LD100 in mice is <10 CFU for all inoculation routes and mice 
succumb to infection within 5-6 days (6, 7).  SchuS4 is handled at BSL-3 due to its ease of 
aersolization and low infectious dose in humans.  Because unmanipulated mice succumb to 
SchuS4 infection before the development of an adaptive immune response, F. tularensis 
subsp. holartica LVS is used to study components of adaptive immunity.  LVS is less 
151
 
 
virulent in both mouse and man; the LD50 for mice varies widely depending on the 
inoculation route.  The LD50 for intraperitoneal inoculation is <1 CFU, intranasal inoculation 
is 103 CFU, and intradermal inoculation has an LD50 of >105 CFU (8).  The final commonly 
studied strain of Francisella is F. novicida U112 (U112).  U112 is avirulent in 
immunocompetent humans but highly virulent in mice with a low infectious dose (LD100 < 
10 CFU) and rapid death similar to SchuS4.                
The T cell response is required to mediate F. tularensis clearance because the 
bacterium lives within infected cells (9).  IFN-γ is required to control LVS infection.  IFN-γ 
depletion increases systemic bacterial burdens and mice deficient in IFN-γ succumb to an 
otherwise sublethal LVS infection for wild-type mice (10, 11).   Treatment with exogenous 
recombinant IFN-γ decreases bacterial burdens further confirming the importance of IFN-γ 
for bacterial control (12).  The route of primary infection influences the T cell response.  
When B6 mice are inoculated intranasally with LVS, there are significantly fewer responding 
T cells producing IFN-γ in the lung compared to intradermally inoculated mice even though 
bacterial burdens (i.e. antigen loads) are similar early after infection (13).  The increased 
IFN-γ production observed in intradermally inoculated mice correlates with faster bacterial 
clearance compared to mice inoculated intranasally.  Intranasal inoculation with LVS also 
induces expansion of lung Th17 cells, a response not seen in intradermally inoculated mice 
(13).  IL-17A is also important for bacterial control following intranasal inoculation as IL17-/- 
mice have increased lung LVS burdens compared to wild-type B6 mice (14).  In primary 
infections with LVS, treatment with IL-17A depleting antibody increases lung bacterial 
burdens compared to mice treated with isotype control antibody and decreases the mean time 
to death (14, 15).         
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Previous infection with LVS or the attenuated mutant, LVS clpB, provides 100% 
protection against lethal LVS challenge and T cells are required for the development of 
protective immunity (9, 16).  While the importance of IFN-γ and IL-17A during primary 
pneumonic tularemia are clear (10-12, 14, 15), the nature of the T cell response during 
secondary pneumonic tularemia remains unknown.  We sought to determine whether IFN-γ 
producing CD4+ and CD8+ T cells and/or Th17 cells are elicited during the secondary 
response using intracellular cytokine staining.  We further determined if IFN-γ and/or IL-
17A are important during the secondary response using antibody depletion.  Additionally, we 
were interested in comparing the memory responses in LVS and LVS clpB vaccinated mice 
because both strains completely protected during a lethal challenge, despite differences in the 
primary T cell response.  We found LVS and LVS clpB vaccinated mice have nearly 
identical T cell responses during a secondary infection and that IFN-γ is absolutely required 
for survival during re-challenge whereas IL-17A is dispensable.  Understanding what T cell 
responses are crucial for protective memory will inform further vaccine development.         
 
MATERIALS AND METHODS 
Bacteria   
The live vaccine strain of Francisella tularensis subsp. holartica (LVS) was obtained 
from the CDC (Atlanta, GA).  Bacteria were grown at 37˚C on chocolate agar supplemented 
with 1% IsoVitalex (Becton-Dickinson).  To prepare bacterial inoculations, bacteria were 
removed from a lawn grown on chocolate agar and resuspended in sterile PBS at an OD600=1 
(equivalent to 1x1010 CFU/mL).  Appropriate dilutions were made in sterile PBS to obtain 
the desired bacterial dose.  The actual number of viable bacteria was determined by serial 
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dilution and plating on chocolate agar.  The LVS clpB (FTL_0094) deletion strain was 
generated using the suicide vector pMP812 (17) containing an amplified region of clpB.   
Mice   
C57Bl/6J (B6) and B6.SJL-PtprcaPepcb/BoyJ (B6-CD45.1) mice were obtained from 
The Jackson Laboratory (Bar Harbor, ME).  All mice were housed in specific-pathogen free 
conditions at the University of Arizona in accordance with the Institutional Animal Care and 
Use Committee (IACUC).  Female B6 mice used for infections were between 7 to 12 weeks 
of age.   
Inoculation of Mice   
Mice were anesthetized with 575 mg/kg tribromomethanol (Avertin) (Sigma) 
administered intraperitoneally.  Mice were then intranasally inoculated with 5 x 102 CFU 
LVS or 5x104 CFU LVS clpB suspended in 50 μL PBS.  Mice were weighed daily following 
all inoculations.  For lethal LVS challenge experiments, mice were anesthetized with 0.25 
mL of 7.5 mg/mL ketamine and 0.5 mg/mL xylazine cocktail in PBS.  Mice were then 
intranasally inoculated with 5x103 CFU (5 x LD50) LVS in 50 µL PBS.  Mice were weighed 
daily following all inoculations.  Mice were sacrificed if they lost more than 25% of their 
starting weight as indicated in our IACUC protocol.           
Determination of serum IgG titers   
LVS lysate was made by lysing mid-log phase LVS grown in brain heart infusion 
(BHI) broth using RIPA buffer.  The amount of protein in the LVS lysate was quantified 
using a Bio-Rad DC Protein Assay (Bio-Rad).  High binding ELISA plates (Costar) were 
coated overnight with 0.25 µg/well LVS lysate in 100 mM sodium carbonate/bicarbonate 
buffer (pH 9.6).  Coated plates were washed with 1x PBS containing 0.05% Tween-20 and 
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then blocked with 5% BSA (w/v) in PBS for 1 hour at room temperature.  100 µL/well of 1:2 
serial dilutions of mouse serum starting at 1:100 was added to the plate and incubated at 
room temperature for 2 hours.  Plates were then washed with 1x PBS containing 0.05% 
Tween-20.  100 µL/well of anti-mouse IgG conjugated to alkaline phosphatase (1:1000) 
(Life) was added to the plate and incubated at room temperature for 1 hour.  Plates were 
washed with 1x PBS containing 0.05% Tween-20.  100 µL/well para –Nitrophenylphosphate 
(pNpp) (Life) was added to the plate and incubated for 30 minutes at room temperature.  A405 
and A570 were measured using a plate reader (Molecular Devices).  A570 was subtracted from 
A405 to normalize and half-maximal titers were determined for each mouse.  Each serum 
sample was analyzed in duplicate.      
Western blots detecting LVS specific antibodies   
10, 20, and 40 µg of LVS lysate were loaded in a 4-12% Bis-Tris SDS 
polyacrylamide gel (Life).  A molecular weight marker ranging from 10-250 kDa was also 
loaded on the gel (Licor).  Proteins were separated by subjecting the gel to 150 volts for 
approximately 2 hours.  Proteins were then transferred onto a PVDF membrane by subjecting 
the transfer apparatus to 25 volts for 60 minutes.  The membrane was then blocked with 5% 
BSA in TBST buffer (w/v) for 1 hour at room temperature.  Mouse sera from naïve, LVS, or 
LVS clpB infected mice collected 28 days post-inoculation was diluted 1:2000 in 5% BSA in 
TBST buffer (w/v) and incubated on the membrane overnight at 4°C.  The membrane was 
then washed thoroughly with TBST buffer.  Goat anti-mouse IgG conjugated to IRDye 
800CW (Licor) was diluted 1:5000 in 5% milk in TBST and incubated with the membrane 
for 1 hour at room temperature.  The membrane was then washed thoroughly and then bands 
were visualized using the Odyssey Infrared Imaging System (Licor).                        
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Determination of bacterial burdens   
Spleens, livers, and lungs were homogenized in sterile PBS using a Biojector 
(Bioject) as previously described (13).  10-fold serial dilutions were made and plated on 
chocolate agar.  Resulting colonies were counted 72 hours later.  The limit of detection is 50 
CFU per organ.       
Collection of spleen and lung cells   
Spleens were harvested from mice and made into a single cell suspension.  Red blood 
cells were lysed using ammonium chloride-potassium carbonate lysis buffer.  Lungs were 
perfused with PBS to remove blood and then finely minced.  Minced lung was placed in 10 
mL of digestion buffer containing 0.5 mg/mL collagenase I (Worthington Biochemical), 0.02 
mg/mL DNase (Sigma), and 125 U/mL elastase (Worthington Biochemical) in RPMI1640 
(HyClone).  Lungs were digested for 30 minutes at 37˚C and then vigorously pipetted prior to 
filtering through a 100 µM filter.  Mononuclear cells were isolated from the single cell 
suspension by density gradient centrifugation over Lympholyte M (Cedarlane Labs).  Viable 
cells from spleen and lung were determined by trypan blue exclusion using a hemacytometer.           
Antibodies   
The following directly conjugated antibodies were utilized for flow cytometry 
analysis: CD3 AF488 (Clone 145-2C11, eBioscience); CD4 AF700 (Clone GK1.5, 
Biolegend); CD8a V500 (Clone 53-6.7, BD Biosciences); CD45.1 PE-Cy7 (Clone A20, 
Biolegend); TCR γδ PerCP-Cy5.5 (Clone GL3, Biolegend); IFN-γ PE (Clone XMG1.2, BD 
Biosciences); IL-17A AF647 (Clone TC11-18H10.1, Biolegend); CD11b Pacific Blue (Clone 
M1/70, Biolegend); CD11c Pacific Blue (Clone N418, Biolegend); CD19 Pacific Blue 
(Clone 6D5, Biolegend); F4/80 Pacific Blue (Clone BM8, Biolegend); GR-1 (Ly-6G) eFluor 
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450 (Clone RB6-8C5, eBioscience); NK1.1 Pacific Blue (Clone PK136, Biolegend).   All 
antibodies were titrated on normal B6 splenocytes prior to use.   
Intracellular cytokine staining   
Splenocytes from B6-CD45.1 were used as antigen presenting cells.  B6-CD45.1 cells 
were added at 2x106/well in a 24 well plate or 0.5x106/well in a 48 well plate and infected 
with LVS at an MOI of 200:1 or mock infected.  Two hours post-infection, the media was 
removed and 5 μg/mL gentamicin was added to kill any extracellular bacteria.  Splenocytes 
were cultured overnight in the presence of gentamicin to allow antigen processing and 
presentation.  Prior to co-culture with cells isolated from infected mice, antigen presenting 
cells were washed extensively to remove any cytokine or PGE2 that could interfere with the 
co-culture.  Cells isolated from mice were co-cultured at a 1:1 ratio with infected or mock 
infected splenocytes for 24 hours.  During the last 4 hours of culture, 10 µg/mL Brefeldin A 
(Sigma) was added to each well to stop cytokine secretion.  Cells were removed from the 
plate and stained with Pacific Blue succimidyl ester (Invitrogen) to distinguish live and dead 
cells.  Cells were then stained with antibodies for surface markers.  Following fixation and 
permeabilization of the cells, cells were stained for IFN-γ and IL-17A.  Cells were washed 
extensively after each staining step to remove residual unbound antibody.               
Gating Strategy for T cell Analysis   
The gating scheme is shown in figure 1.  Single cells were discriminated from 
doublets by plotting side scatter linear versus side scatter area.  Cells were then selected by 
plotting side scatter area versus forward scatter area.  Live CD3+ T cells were then selected 
by plotting CD3 versus the Pacific Blue channel which included the live/dead stain and 
markers for antigen presenting cells.  From the CD3+ gate, CD4+ and CD8+ T cells were 
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selected.  Gates for IFN-γ and IL-17A positive cells were set based on isotype control 
staining.  Change in mean fluorescent intensity (∆MFI) for each sample was determined by 
subtracting the cytokine negative population from the cytokine positive population.  FlowJo 
v7.6 (Treestar) was used for all flow cytometry analysis.       
Depletion of IFN-γ or IL-17A   
Anti-IFN-γ (clone XMG1.2) was a generous gift from Mary Ann Accavitti-Loper 
(University  of Alabama- Birmingham).  Rat IgG1 isotype control antibody (clone HRPN), 
anti-IL-17A (clone 17F3), and mouse IgG1 isotype control antibody (clone MOPC-21) were 
purchased from BioXCell (West Lebanon, NH).  Mice were administered 500 µg of anti-
IFN-γ or rat IgG1 isotype control or 100 ug of anti-IL-17A or mouse IgG1 in 200 µL PBS 
via intraperitoneal injection on days 0, 2, and 4 post-inoculation.   
Luminex analysis   
A multiplex luminex bead-based approach was used to quantify 
cytokines/chemokines in BAL fluid or clarified tissue homogenate.  A 20-analyte assay panel 
was performed according to the manufacturer’s protocol (Invitrogen) using a BioPlex array 
reader (Bio-Rad Laboratories).  Using integrated cytokine/chemokine standard curves, the 
assay reports pg/mL of the following analytes:  FGF basic, GM-CSF, IFN-γ, IL-1α, IL-1β, 
IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p40/p70), IL-13, IL-17, KC, MCP-1, MIG, MIP-1α, 
TNF-α, and VEGF.  A five-parameter non-linear logistic regression model was used to 
establish standard curve and to estimate the probability of occurrence of a concentration at a 
given point.  Standard outliers were removed from the analysis if the observed/expected % 
recovery was outside of the acceptable limits (70-130%).  Upper and lower levels of 
quantification were determined by the BioPlex Manager software based on goodness of fit 
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and percent recovery.  Calculated pg/mL for experimental specimens were multiplied by the 
inherent assay dilution factor (df=2) and reported as final observed pg/mL. 
Statistical analysis   
Statistical significance of flow cytometry data was determined using a Kruskal-Wallis 
with Dunn’s post-test.  Bacterial burdens were log transformed and then a one-way ANOVA 
with Tukey’s post-test was applied.  A Mann-Whitney test was used for IgG titer data.  
GraphPad Prism (v5.04) was used for analysis.  Error bars show standard error of the mean.  
Significance levels are indicated as follows: * p < 0.05; ** p < 0.01, *** p < 0.001, **** p < 
0.0001.   
 
RESULTS 
Do differences in the adaptive immune response to LVS and LVS clpB translate to 
differences in the memory response?   
We have previously shown that LVS clpB is attenuated, not because of an intrinsic 
growth defect, but instead by inducing altered innate and adaptive immunity (16).  The 
kinetics of the T cell response during primary infection with LVS and LVS clpB differs (16).  
To briefly summarize, LVS and LVS clpB infected mice have similar immune responses on 
day 7 post-inoculation, i.e. the total spleen and lung cellularity are similar as are the number 
of CD4+ T cells producing IFN-γ or IL-17A or CD8+ T cells producing IFN-γ (Chapter 2 
figures 24-26).  Additionally, the amount of cytokine produced by responding T cells is 
similar on day 7 post-inoculation as measured by delta mean fluorescence intensity (ΔMFI) 
(Chapter 2 figures 27 and 29).  The immune responses between LVS and LVS clpB infected 
mice differ 10 days post-inoculation.  LVS infected mice have significantly higher spleen and 
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lung cellularity on day 10 post-inoculation than LVS clpB infection (Chapter 2 figure 24).  
The differences in cellularity are likely a consequence of immune response contraction 
because LVS clpB was nearly cleared from the host on day 10 post-inoculation (Chapter 2 
figure 4).  Although there is a significant decrease in the number of T cells responding in 
LVS clpB infected mice, the responding T cells produced significantly more IFN-γ and IL-
17A as measured by ΔMFI (Chapter 2 figures 25-27, 29-31).  Despite LVS clpB’s 
attenuation, inoculation with this strain induced a robust adaptive immune response that was 
required for bacterial clearance (Chapter 2 figure 23).  Previous infection with LVS or LVS 
clpB induced a protective immune response during lethal LVS challenge early (day 28) or 
late (day 120) post-initial infection (Chapter 2 figures 9, 10).  We next sought to determine 
whether the secondary immune response was similar in LVS and LVS clpB vaccinated mice.             
LVS and LVS clpB infected mice have similar antibody responses   
B cell deficient mice are not more susceptible to primary infection with LVS, 
however they are 100-fold more susceptible during secondary infection (18).  Therefore, 
while differences in the primary antibody response to LVS or LVS clpB were unlikely to 
affect bacterial clearance during the first infection, differences in the antibody response may 
impact clearance, and therefore survival, during a second infection.  We therefore determined 
anti-Francisella IgG titers in LVS and LVS clpB infected mice 28 and 120 days post-
inoculation.  Mice were inoculated with 5x102 CFU LVS or 5x104 CFU LVS clpB.  On days 
28 and 120 post-inoculation, sera was obtained from naïve, LVS or LVS clpB vaccinated 
mice and half-maximal IgG titers were determined by ELISA.  LVS and LVS clpB 
vaccinated mice had similar IgG titers on day 28 or day 120 post-inoculation (figure 2A-D).  
Naïve mouse sera did not contain LVS-specific IgG antibodies (figure 2A, C).  In addition to 
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similar IgG titers, sera from LVS and LVS clpB infected mice produced similar, but not 
identical, banding patterns when used to probe LVS lysate indicating infection with LVS or 
LVS clpB results in recognition of similar Francisella antigens (figure 2E).  Together, these 
data indicate that infection with either LVS or LVS clpB elicits a similar antibody response 
in terms of total IgG levels as well as antibody specificity.  Additionally, these data 
suggested that survival of LVS and LVS clpB vaccinated mice during lethal LVS challenge is 
not a consequence of a more robust B cell response in one vaccinated group compared to the 
other.                  
Previous infection with LVS and LVS clpB decreases bacterial burdens during 
secondary infection   
We next examined the T cell response in LVS and LVS clpB vaccinated mice to 
determine whether differences in the primary response translated to differences in the 
memory response.  We chose to look at the T cell memory response on day 4 post-
rechallenge because the secondary response occurs more rapidly than the primary response 
and this time point was also before unvaccinated mice began to succumb to infection (16).  
We first determined bacterial burdens in the spleen, liver, and lung on day 4 post-rechallenge 
to quantitate the amount of antigen present in each tissue.  Mice were inoculated with 5x102 
CFU LVS or 5x104 CFU LVS clpB and then challenged with 5x103 CFU LVS 120 days after 
the initial infection.  Age-matched unvaccinated mice were also inoculated with 5x103 CFU 
LVS.  As expected, bacterial burdens were significantly lower in the spleen, liver, and lung 
of LVS and LVS clpB vaccinated mice compared to unvaccinated mice (figure 3A-C).  These 
data indicate that prior infection with LVS or LVS clpB elicits an immune response that 
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controls bacterial growth at the site of primary infection (lung) as well as distal sites (spleen 
and liver).     
Spleen and lung cellularity is similar irrespective of vaccination status   
We next examined the secondary T cell response in LVS or LVS clpB vaccinated 
mice.  Mice were inoculated with 5x102 CFU LVS or 5x104 CFU LVS clpB and then 
challenged with 5x103 CFU LVS 120 days after the initial infection.  Age-matched 
unvaccinated mice were also inoculated with 5x103 CFU LVS.  On day 4 post-re-challenge, 
mice were sacrificed and the number of live cells in the spleen and lung were determined by 
trypan blue exclusion.  Unvaccinated, LVS vaccinated, and LVS clpB vaccinated mice had 
similar spleen and lung cellularity (figure 4).  It is likely that the cellular composition of 
unvaccinated and vaccinated mice is different; however, quantification of individual cell 
populations using flow cytometry was not performed.       
LVS and LVS clpB vaccinated mice have an increased lung IFN-γ-mediated immune 
response compared to unvaccinated mice   
IFN-γ+ CD4+ and CD8+ T cells respond in the lung during the primary immune 
response to LVS and LVS clpB (16).  We next determined whether memory CD4+ and/or 
CD8+ T cells were responding during the secondary infection in LVS and LVS clpB 
vaccinated mice by quantifying the number of CD4+ and CD8+ T cells producing IFN-γ in 
the lung on day 4 post-re-challenge.  LVS and LVS clpB vaccinated mice had significantly 
more IFN-γ producing CD4+ and CD8+ T cells than unvaccinated mice (figure 5A, B).  There 
was no significant difference in the number of IFN-γ producing CD4+ or CD8+ T cells in the 
lungs of LVS or LVS clpB vaccinated mice during re-challenge.  Additionally, responding 
CD4+ and CD8+ T cells from the lungs of LVS and LVS clpB vaccinated mice produced 
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significantly more IFN-γ as measured by ΔMFI compared to unvaccinated mice (figure 5C, 
D).  The IFN-γ ΔMFI for CD4+ and CD8+ T cells from LVS and LVS clpB vaccinated mice 
were not significantly different.  Together these data indicate that LVS or LVS clpB 
vaccination leads to a similar IFN-γ response in the lung during lethal re-challenge that is 
greater in magnitude than the IFN-γ response in unvaccinated mice.                
LVS and LVS clpB vaccinated mice have a similar lung IL-17A-mediated immune 
response compared to unvaccinated mice   
Primary infection with LVS and LVS clpB induces Th17 expansion in the lung (13, 
16).  We next examined whether memory Th17 cells were responding during re-challenge as 
we found for IFN-γ producing T cells (figure 5).  Using ICS, we determined the number of 
Th17 cells in the lung on day 4 post-re-challenge and found similar numbers of Th17 cells 
irrespective of vaccination status (figure 6A).  Additionally, IL-17A expression did not 
increase in vaccinated mice compared to unvaccinated mice as measured by ΔMFI (figure 
6B).  These data indicate that despite the importance of Th17 cells during the primary 
response, Th17 cells do not appear to be an important component of the memory response on 
day 4 post-re-challenge because the response in vaccinated mice is similar to unvaccinated 
mice.  
The secondary response is nearly absent in the spleens of LVS and LVS clpB vaccinated 
mice   
Bacterial burdens were near the detection limit in the spleen on day 4 post-re-
challenge (figure 3A).   It is possible that bacterial burdens were low in the spleen because 
there was a robust T cell response that controlled the infection.  Alternatively, the robust T 
cell memory response in the lung could decrease bacterial dissemination to distal organs and 
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low antigen loads will not drive a local memory response.  To distinguish between these two 
possibilities, we examined the secondary immune response in the spleen on day 4 post-re-
challenge using ICS.  Additionally, examination of the secondary response in the spleen 
would indicate whether the memory response was systemic or limited to the primary site of 
infection (lung).  There were similar absolute numbers of IFN-γ producing CD4+ or CD8+ T 
cells in LVS or LVS clpB vaccinated mice compared to unvaccinated mice (figure 7A, B).  
IFN-γ ΔMFI was significantly higher in CD4+ T cells from vaccinated mice compared to 
unvaccinated mice (figure 7C) but a significant increase in IFN-γ ΔMFI for CD8+ T cells was 
not observed in vaccinated mice compared to unvaccinated mice (figure 7D).   
Primary intranasal infection with LVS or LVS clpB does not elicit expansion of Th17 
cells in the spleen (13, 16).  Similarly, the absolute number of Th17 cells in the spleens of 
LVS or LVS clpB vaccinated mice was similar to unvaccinated mice (figure 8A).  
Additionally, IL-17A expression was not increased in vaccinated mice compared to 
unvaccinated mice as measured by ΔMFI (figure 8B).  These data indicate that, like a 
primary infection with LVS or LVS clpB, Th17 cells are not involved in the immune 
response in the spleen.     
Because we observed similar numbers of CD4+ IFN-γ+, CD8+ IFN-γ+, and Th17 cells 
in the spleens of vaccinated and unvaccinated mice on day 4 post-re-challenge, these data 
suggest that the low bacterial burdens were not a consequence of a robust T cell response.  
Instead, these data suggest that low bacterial burdens in the spleen did not drive splenic 
memory T cell expansion and that a systemic immune response does not occur following 
intranasal secondary challenge of immune mice.   
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IFN-γ production is required during the secondary response to LVS   
The secondary response in LVS and LVS clpB vaccinated mice induced IFN-γ 
producing CD4+ and CD8+ T cells in the lungs as determined by ICS.  To determine whether 
IFN-γ was required during the secondary response, we treated mice with 500 µg XMG1.2 
(anti-IFN-γ) or rat IgG1 isotype control on days 0, 2, and 4 post-re-challenge.  On day 0 mice 
were intranasally inoculated with 5x103 CFU LVS, approximately 1 hour after antibody 
treatment.  Mice were weighed daily and weight loss reported as % of starting weight (figure 
9A).  Weight loss is monitored because we have found it is a nearly perfect indicator of 
clinical status.  The weight loss profiles of LVS and LVS clpB vaccinated mice receiving 
anti-IFN-γ was similar to unvaccinated mice receiving either anti-IFN-γ or isotype control 
(figure 9A).  LVS or LVS clpB vaccinated mice receiving isotype control antibody did not 
lose as much weight as those receiving anti-IFN-γ and had begun to regain lost weight on day 
5 post-re-challenge (figure 9A) indicating they are recovering from their infection and will 
survive.  We sacrificed all vaccinated mice receiving isotype control antibody on day 6 post-
re-challenge to determine bacterial burdens and therefore could not explicitly demonstrate 
that these mice would survive the lethal challenge.  However, the weight loss profiles of 
vaccinated mice receiving isotype control antibody are nearly identical to untreated 
vaccinated mice in Barrigan, et al that did recover all lost weight and survive the same lethal 
challenge dose (16).  Therefore, we are confident that the isotype control treated vaccinated 
mice would have survived the lethal challenge.             
We next examined bacterial burdens in the spleen, liver, and lung on day 6 post-re-
challenge following administration of anti-IFN-γ or isotype control antibody.  We selected 
day 6 because unvaccinated mice begin to succumb to the lethal LVS inoculation at this time 
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point.  LVS and LVS clpB vaccinated mice receiving anti-IFN-γ had significantly higher 
bacterial burdens than vaccinated mice receiving isotype control antibody in the spleen, liver, 
and lung (figure 9B-D).  Vaccinated mice depleted of IFN-γ not only have higher bacterial 
burdens than vaccinated mice receiving isotype control antibody, they also have similar 
bacterial burdens as unvaccinated mice receiving anti-IFN-γ (figure 9B-D).  Unvaccinated 
mice receiving anti-IFN-γ had significantly higher bacterial burdens in all organs tested 
compared to unvaccinated mice receiving isotype control antibody and two of the 
unvaccinated mice administered anti-IFN-γ succumbed to the infection on day 5 post-
inoculation (figure 9B-D).  All mice receiving anti-IFN-γ have lung IFN-γ levels near the 
limit of detection (21.6 pg/mL) while mice receiving isotype control antibody have between 
1-5 ng/mL IFN-γ concentrations in the lung as measured by Luminex (data not shown) 
confirming successful depletion of IFN-γ.  These data indicate that IFN-γ production is 
critical during an intranasal secondary infection just as has previously been shown for 
primary infections with LVS (10, 11).  
IL-17A is dispensable during the secondary response to LVS  
Lethal secondary infection in LVS or LVS clpB vaccinated mice did not elicit a Th17 
response that was greater in magnitude compared to unvaccinated mice as determined by 
ICS.  We therefore hypothesized that IL-17A was not required for protection during 
secondary infection.  To test this hypothesis, we treated unvaccinated, LVS vaccinated, or 
LVS clpB vaccinated mice with 100 µg 17F3 (anti-IL-17A) or mouse IgG1 isotype control 
on day 0, 2, and 4 post-rechallenge.  Mice were then intranasally inoculated with 5x103 CFU 
LVS.  Mice were weighed daily and weight loss was reported as % of starting weight (figure 
10A).  The weight loss profiles of LVS and LVS clpB vaccinated mice were identical 
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regardless of treatment with anti-IL-17A or isotype control (figure 10A).  Unvaccinated mice 
also had identical weight loss profiles irrespective of antibody treatment (figure 10A).   
We then determined bacterial burdens in the spleen, liver, and lung on day 6 post-
rechallenge.  LVS and LVS clpB vaccinated mice had spleen and liver bacterial burdens near 
the limit of detection for both treatment groups (figure 10B-C).  In the lung, bacterial burdens 
were similar in LVS and LVS clpB vaccinated mice receiving anti-IL-17A compared to 
isotype control (figure 10D).  Bacterial burdens in the spleen, liver, and lung of unvaccinated 
mice were similar irrespective of antibody depletion (figure 10B-D).  Luminex analysis of 
clarified tissue homogenates determined IL-17A levels are below the detection limit in the 
spleen and lungs of mice receiving anti-IL-17A and isotype control antibody, irrespective of 
vaccination status (data not shown).  To confirm the Luminex results, we tested the clarified 
lung homogenate by IL-17A ELISA and found vaccinated mice had similar levels of IL-17A 
(70-80 pg/mL) irrespective of antibody treatment.  Unvaccinated mice had slightly higher IL-
17A levels (130-150 pg/mL), but again there was no difference in concentration between 
anti-IL-17A and isotype treated mice.  These data indicate IL-17A is produced at low levels 
in our model during the secondary infection, further supporting our conclusion that IL-17A is 
dispensable during a recall response.    
Altogether, our results indicate that the secondary immune response in LVS and LVS 
clpB vaccinated mice is nearly identical in terms of the absolute numbers of responding cells 
as well as the amount of cytokine produced.  These data indicate that primary infection with 
attenuated LVS clpB primes the immune system equivalently as LVS despite eliciting an 
altered primary response (16).  We also determined the importance of IFN-γ and IL-17A 
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during the secondary response and found IL-17A is dispensable while IFN-γ is absolutely 
required for survival during intranasal re-challenge. 
 
DISCUSSION 
Primary intranasal inoculation with LVS or LVS clpB elicits a robust IFN-γ and IL-
17A response in the lungs of infected mice (16).  Both of these cytokines are critical for 
controlling the primary infection.  IFN-γ-/- and IL-17-/- mice have increased bacterial burdens 
compared to wild-type mice and antibody depletion of either IFN-γ or IL-17A also increases 
bacterial burdens (10-12, 14, 15).  While the roles of IFN-γ and IL-17A during primary 
pneumonic tularemia are clear, it remains unknown whether these cytokines are also 
important during secondary infection.   
Route of primary infection influences survival during lethal secondary infection 
Intradermal vaccination with LVS does not provide protection during lethal aerosol 
challenge with SchuS4 or another lethal Type A strain (19, 20).  In order to achieve 
protective immunity for future intranasal challenge, mice must be inoculated intranasally (19, 
21).  Intradermal inoculation with LVS leads to a robust IFN-γ response in the lung by both 
CD4+ and CD8+ T cells that is greater in magnitude than mice inoculated intranasally (13).  
Despite eliciting a robust IFN-γ mediated immune response in the lung, intradermally 
inoculated mice are not protected during lethal intranasal challenge with SchuS4 (21).  
Because Th17 cells expand in the lung following LVS intranasal inoculation but not 
intradermal inoculation (13), one could hypothesize that memory Th17 cells are critical to the 
development of protective immunity in the lung.  Th17 cells are a critical component of the 
primary immune response to Francisella and other pathogens ((14) and reviewed in (22)).   
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The T cell response on day 4 post-re-challenge is dominated by IFN-γ producing T cells
 Using ICS, we identified IFN-γ and IL-17A producing T cells on day 4 post-re-
challenge.  In the lung, there were significantly more CD4+ and CD8+ T cells producing IFN-
γ in LVS and LVS clpB vaccinated mice compared to unvaccinated mice.  ΔMFI was used as 
a measure of how much IFN-γ is produced per cell, LVS and LVS clpB vaccinated mice have 
significantly higher IFN-γ ΔMFIs for CD4+ and CD8+ T cells compared to unvaccinated 
mice.  Clearly, previous infection with either LVS or LVS clpB primes both CD4+ and CD8+ 
T cells that produce IFN-γ in the lung upon re-challenge.  We also quantified the number of 
Th17 cells in the lungs and although there is a trend toward an increased number of Th17 
cells in LVS or LVS clpB vaccinated mice compared to unvaccinated mice, it does not reach 
statistical significance.  The IL-17A ΔMFIs were also not increased in LVS or LVS clpB 
vaccinated mice compared to unvaccinated mice.  These data suggest that Th17 cells do not 
play a critical role in the lung during secondary infection with LVS.  Instead, responding T 
cells in the lung produce IFN-γ.   
IFN-γ depletion in vaccinated mice worsens disease and increases bacterial burdens  
The intracellular cytokine staining experiments demonstrate that the secondary 
response to an intranasal infection is mediated by both CD4+ and CD8+ T cells producing 
IFN-γ.  Although Th17 cells in the lung are an important component of the lung’s primary 
immune response (13, 15, 23), this cell subset does not expand during secondary infection, 
suggesting that these cells are dispensable.  To further interrogate the importance of IFN-γ 
and IL-17A during secondary infection, we antibody depleted each cytokine during 
secondary infection.  LVS and LVS clpB vaccinated mice depleted of IFN-γ had significantly 
higher bacterial burdens and experienced increased weight loss compared to mice receiving 
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isotype antibody during re-challenge.  IFN-γ depletion in vaccinated mice caused them to 
behave like unvaccinated mice for both experimental read-outs.  This result demonstrated 
that IFN-γ is absolutely required for protective immunity during a secondary intranasal 
infection.  The requirement of IFN-γ during secondary infection has also been shown using 
several routes of LVS vaccination and then lethal challenge with LVS, SchuS4, or another 
Type A strain (19, 24, 25).     
IL-17A depletion in vaccinated mice does not alter disease course or increase bacterial 
burdens   
Depletion of IL-17A had no impact on weight loss in LVS and LVS clpB vaccinated 
mice compared to mice treated with isotype control antibody.  IL-17A depletion in LVS and 
LVS clpB vaccinated mice also did not alter bacterial burdens suggesting that IL-17A is 
dispensable for bacterial control during the secondary response.  Surprisingly, we did not 
observe an increase in bacterial burdens or weight loss profiles for unvaccinated mice 
receiving IL-17A depleting antibody compared to mice receiving isotype control antibody as 
other groups have shown using the very similar depletion regimens (14, 15).  This could 
suggest that the depletion antibody we used was not effective.  To test whether the anti-IL-
17A antibody could bind IL-17A, we performed an in vitro depletion experiment and found 
the antibody was capable of depleting IL-17A.  Additionally, we determined the 
concentration of anti-IL-17A and found the concentration we determined was almost 
identical to the one reported by the vendor.  Together, these data suggest the anti-IL-17A 
antibody was functional and should bind IL-17A in vivo.  Additionally, the dose 
administered to the mice was correct based on independent verification of the antibody 
concentration.   
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Because we have ruled out non-functional antibody, there are several possible 
alternative explanations for the observed result where naïve mice do not have increased 
bacterial burdens upon IL-17A depletion.  First, we used a different inoculation dose and 
delivery route (5000 CFU intranasally versus 1000 CFU  intratracheally (14)).  Second, the 
unvaccinated mice were age matched with the vaccinated mice and were 7-8 months old 
when they were inoculated while the other groups used young (6-8 weeks old) mice (14, 15).  
Finally, not all laboratory LVS stocks are identical thereby raising the possibility that slight 
differences in the infecting strain could affect virulence and/or impact the immune response.  
We could test the function of the in-hand depleting antibody by treating young mice during a 
primary LVS infection to recapitulate experiments described by Lin, et al and Markel, et al 
(15, 23).  We confirmed cytokine depletion by clarifying tissue homogenates used to 
determine bacterial burdens and subjecting these samples to Luminex analysis.  IL-17A 
levels were below detection limit for mice receiving IL-17A depleting antibody or isotype 
control.  These data indicate there was little IL-17A present in the lung irrespective of 
vaccination status and therefore little antigen for the anti-IL-17A antibody to deplete.  We 
also tested the clarified tissue homogenates by ELISA for a more sensitive determination of 
IL-17A concentration and found similar IL-17A concentrations in vaccinated mice 
irrespective of antibody treatment.  Unvaccinated mice had slightly higher IL-17A 
concentrations than the vaccinated mice (2-fold), but there were no differences between anti-
IL-17A and isotype control treatment.  We confirmed the antibody was functional and 
administered at the desired dose therefore, little IL-17A was produced in the lung of 
unvaccinated or vaccinated mice.            
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During lethal SchuS4 secondary challenge following intradermal vaccination with 
SchuS4 clpB, high levels of IL-17A are detectable in the lung during secondary aerosol 
infection and high IL-17 levels correlate with protection (26).  However, depletion of IL-17A 
did not significantly increase bacterial burdens compared to mice given isotype control 
antibody, suggesting this cytokine is not necessary for protective immunity in our 
experiments (26).  The authors did not examine whether IFN-γ was required for protection 
despite also detecting this cytokine at high levels in the lung and also finding it correlated 
with protection (26).  The primary T cell response to SchuS4 cannot be described in 
unmanipulated mice because they rapidly succumb to infection.  The Bosio laboratory has 
developed a convalescent model of SchuS4 infection where mice are intraperitoneally 
administered levofloxacin daily from day 3 until day 14 post-inoculation (27).  This model 
allowed the examination of the T cell response in the lung following primary intranasal 
inoculation with SchuS4.  They detected IFN-γ+ CD4+ and CD8+ T cells in the lung and 
spleens, with the peak response occurring on day 7 post-inoculation (27).  IL-17A was 
undetectable in lung and spleen tissue homogenates, indicating this cytokine is not produced 
at detectable levels in this model of primary SchuS4 infection (27).  More sensitive 
techniques, such as ICS, may allow the detection of Th17 cells and should be explored 
further in this model to determine whether primary intranasal inoculation with SchuS4 
induces a Th17 response.  This model could also be utilized to ask similar questions such as 
the requirement of IFN-γ and IL-17A for survival during secondary intranasal challenge with 
SchuS4.      
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Does the expression of lung T cell homing receptors differ in mice vaccinated 
intranasally or intradermally?   
Combined, our ICS and IL-17A depletion data suggest Th17 cells are not contributing 
to protective immunity to re-infection in the lung.  Because the presence of Th17 cells was a 
key difference during intranasal and intradermal primary infection, there must be an 
alternative explanation for why intradermally vaccinated mice are not protected during lethal 
intranasal challenge.  It is possible that intradermally vaccinated mice are not protected 
during an intranasal challenge because the site of T cell priming is critical for expression of 
lung homing receptors.  Therefore, despite the ability to produce large amounts of IFN-γ in 
response to Francisella antigens, T cells from intradermally vaccinated mice do not express 
the correct receptors to allow the T cells to traffic to the lung and control the secondary 
infection.  While skin and gut T cell homing receptors are well characterized, lung T cell 
homing receptors are less well defined.  Human lung resident memory T cells express the β1 
integrin, VLA-1, and the addressin, PSGL-1 (28).  It is unclear whether these homing 
receptors are expressed on mouse lung T cells.  These questions would be easier to answer in 
a system with MHCI or MHCII tetramer to examine homing receptor expression by 
Francisella-specific T cells.  We have identified an immunodominant CD4+ epitope and 
collaborators are in the process of cloning and expressing IAb presenting the LpnA peptide 
that can be used to identify Francisella-specific CD4+ T cells (29).  A CD8+ 
immunodominant epitope has not yet been identified.  In the absence of MHCI and/or 
MHCII tetramer, we could identify antigen experienced T cells by CD44hi and IFN-γ or IL-
17A expression.  It is highly likely that CD44hi T cells producing either IFN-γ or IL-17A 
following re-stimulation by LVS infected APCs are responding to LVS infection.  We could 
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then determine what homing receptor(s) these cells express and compare intranasally and 
intradermally infected mice.                 
Conventional T cell transfer experiments using T cells from immune mice do not confer 
protection   
To identify T cell population(s) that are required for protective immunity, 
immunologists transfer purified cell populations into naïve mice and challenge with the 
pathogen of interest.  Much effort has gone into developing a transfer system in a variety of 
Francisella models of infection (Karen Elkins, personal communication).  The only 
published adoptive transfer system that has successfully protected naïve mice during 
rechallenge is intraperitoneal injection of T cells followed 2 hours later by intraperitoneal 
injection of bacteria (ref).  While this system does distinguish between T cells isolated from 
naïve and immune mice, the peritoneum of the mouse has essentially been turned into a petri 
dish.  This system doesn’t require proper T cell trafficking as T cells encounter infected 
peritoneal macrophages and control the infection before bacteria can disseminate (Karen 
Elkins, personal communication).  If conventional T cell transfers were successful in our 
Francisella model, experiments could be designed to identify cell types critical for secondary 
protection.  For instance, CD4+ and/or CD8+ T cells could be purified from a specific tissue 
of an immune mouse and transferred into a naïve replete recipient that is subsequently 
lethally challenged.  This type of experiment would allow questions of where resident 
memory is located following primary intranasal or intradermal inoculation. 
Because conventional T cell transfers do not confer protection, yet those same T cells 
are required for protection if the mouse was left intact, we hypothesize the T cells fail to 
traffic properly following transfer.  We could begin to address T cell trafficking questions by 
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transferring T cells from an immune mouse into a congenically-marked recipient.  The 
presence of donor T cells in the spleen, lung, and lymph nodes would be determined by flow 
cytometry 24 hours after transfer.  These experiments would be improved if we could 
identify Francisella-specific T cells using tetramer.  This way, we would not be examining 
the ability of all T cells to home but could specifically address where Francisella-specific T 
cells traffic.    
As an alternative approach to avoid issues of T cell trafficking during transfer 
experiments, we could use parabiosis experiments to determine whether T cells could 
migrate between a pair consisting of an immune and naïve mouse through existing 
architecture.  For example, we predict that intransal inoculation of an immune mouse 
attached to a naïve mouse would confer protection on the naïve animal because the immune 
mouse would control the infection in their lung and decrease dissemination.  We found that 
LVS and LVS clpB vaccinated mice had spleen and liver bacterial burdens near the limit of 
detection.  These data, along with the near absence of a memory T cell response in the spleen 
indicates the infection is primarily contained in the lung.  Similarly, an immune mouse would 
control the infection and decrease the number of bacteria that disseminate to the attached 
naïve mouse.  Another potential experiment would involve challenging the naïve mouse in 
the pair intranasally.  If memory T cells had already or could traffic to the naïve mouse, we 
expect the naïve mouse to be protected.  If the memory T cells do not traffic properly, we 
expect the naïve mouse to succumb to the lethal infection.  If the naïve mouse was protected 
by trafficking memory T cells, we could also separate the mice prior to lethal infection to 
determine whether the T cells that conferred protection had already trafficked to the naïve 
mouse or if they migrated after infection.   
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The degree of IFN-γ+ CD4+ and CD8+ T cells and Th17 cell expansion during re-
challenge remains unclear   
We cannot state with certainty whether IFN-γ or IL-17 producing T cells expanded in 
the lungs or spleens of LVS and LVS clpB vaccinated mice because we haven’t definitively 
determined the number of resting memory T cells.  A preliminary experiment examining 
IFN-γ and IL-17A production in resting memory T cells stimulated ex vivo by LVS-infected 
CD45.1 splenocytes suggested the presence of IFN-γ producing memory T cells but not Th17 
cells in the lung.  These data are consistent with the ICS findings on day 4 post-re-challenge 
where IFN-γ+ CD4+ and CD8+ T cells were found at significantly higher numbers in LVS or 
LVS clpB vaccinated mice compared to unvaccinated mice and Th17 cells aren’t found at 
increased numbers.  It is possible that we examined the secondary T cell response at a time 
point before Th17 cells have expanded and are detectable using ICS.  Future studies should 
examine the T cell response at several time points post-re-challenge to determine the kinetics 
of the secondary response.  The antibody depletion experiments suggest that even if Th17 
cells do expand later in the secondary infection, this cell type isn’t required for survival.  
Future experiments should also examine the presence of resting memory T cells in the spleen 
and lung following primary intranasal and intradermal inoculation with LVS.  These data will 
allow a clearer understanding of whether T cell expansion occurs in the lung and spleen 
during secondary infection.       
Antibody responses are similar in LVS and LVS clpB vaccinated mice   
In addition to examining the T cell response, we determined whether primary 
infection with LVS or LVS clpB induced altered B cell responses that could impact survival 
during re-challenge.  LVS and LVS clpB vaccinated mice did not have significantly different 
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FT-specific IgG titers on day 28 or 120 post-inoculation suggesting the B cell response 
primed during both infections is similar.  Additionally, the banding patters were similar in 
LVS and LVS clpB vaccinated mice when LVS lysate was probed indicating similar antigens 
were recognized during both infections.  The patterns are not, however, identical (figure 2E).  
The differences could be explained by altered protein expression in LVS or LVS clpB 
bacteria during infection.  ClpB is a highly conserved chaperone protein involved in the 
stress response.  In its absence, protein expression could be altered because the bacteria 
cannot properly respond to stresses caused by the infection environment and therefore the 
host would be exposed to two different sets of antigens.   
Because Francisella lives intracellularly, the antibody response is not required for 
protection.  Indeed, CD4 knock-out mice have poor antibody responses (i.e. low titers) in the 
absence of T cell help, yet these mice still survive the primary infection and subsequent lethal 
secondary challenge (9).  B cell knock-out mice (BKO), which lack mature B cells, survive 
primary intradermal inoculation with LVS but have a lower LD50 than wild-type mice (18).  
During a secondary infection, B cell deficiency give a more pronounced phenotype with a 
two-log decrease in the LD50 compared to immune wild-type mice (18).  Transfer of immune 
serum into BKO mice does not ameliorate protection but transfer of B cells from immune 
mice does (18).  Together, these data suggest that the protection mediated by B cells is not 
antibody-dependent and instead is a consequence of another intrinsic function of B cells.  In 
human cases of tularemia, there is no correlation between antibody titers and protection 
during a secondary infection (30).  Therefore, while LVS infection in humans and mice does 
elicit an antibody response, this response is not required for protective immunity.   
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Model of primary and secondary immune response to LVS infection 
Overall, we propose the following model: during primary intranasal infection with 
LVS, IL-17A produced by innate and adaptive cells in the lung initially controls the infection 
until IFN-γ production by CD4+ and CD8+ T cells levels increase and clear the infection.  
Th17 cells do not expand in the spleen during primary infection in spite of the rapid 
dissemination of bacteria following inoculation (16).  During secondary intranasal infection 
with LVS, CD4+ and CD8+ T cells in the lung expand and produce IFN-γ.  Th17 cells do not 
expand in the lung during secondary infection.  The secondary response in the lung controls 
the infection and bacteria do not spread to distal organs like the spleen and the T cell 
response is not significantly different than unvaccinated mice.  Another important finding 
from these experiments was that there were no statistically significant differences between 
LVS and LVS clpB vaccinated mice for all parameters measured.  These data indicated that 
the protective immune response elicited by previous infection with either strain is nearly 
identical.  Because LVS clpB provides 100% protection during lethal challenge while 
causing less overall disease, this strain is an excellent vaccine candidate.      
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Figure 1
Figure 1.  Gating scheme for flow cytometry analysis.  Single cells were discriminated 
from doublets by plotting side scatter height (SSC-H) versus side scatter area (SSC-A).  
Cells were then selected by plotting SSC-A versus forward scatter area (FSC-A).  Live 
CD3
+
 T cells were then selected by plotting CD3 versus the Pacific Blue channel which 
included the live/dead stain and markers for antigen presenting cells.  CD45.1
-
 T cellls 
were the gated on by plotting CD3 versus CD45.1.  From the CD45.1
-
 gate, CD4
+
 and 
CD8
+
 T cells were selected.  Gates for IFN-γ and IL-17A positive cells were set based on 
isotype control staining.  For simplicity, only CD4
+
 IFN-γ is shown.  Change in mean 
fluorescent intensity (ΔMFI) for each sample was determined by subtracting the cytokine 
negative population from the cytokine positive population.  For each gate, the percent of 
the parent gate is indicated in bold (for example, CD3
+
 cells are 15.10% of the cells gate). 
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Figure 2.  Antibody responses are similar in LVS and LVS clpB infected mice.  B6 mice 
were intranasally inoculated with 5x10
2
 CFU LVS or 5x10
4
 CFU LVS clpB, or left 
uninfected.  On day 28 (A, B) or 120 (C, D) post-inoculation, sera was collected and the 
amount of LVS-specific IgG antibodies were determined using an ELISA.  Half-maximal 
titers were calculated for LVS and LVS clpB infected mice. n=7-11 mice/group.  Data are 
combined from 2 independent experiments.  Each sample was analyzed in duplicate.  A 
Mann-Whitney test was used to determine statistical significance.  E) LVS whole cell 
lysate was probed with sera from naïve, LVS, or LVS clpB mice collected 28 days post-
inoculation.  LVS-specific antibodies were detected using goat anti-mouse IgG secondary 
antibody.
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Figure 3
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Figure 3.  Previous infection with LVS or LVS clpB decreases bacterial burdens on day 
4 post-rechallenge.  B6 mice were intranasally inoculated with 5x10
2
 CFU LVS or 5x10
4
 
CFU LVS clpB, or left unvaccinated (Unvx).  On day 120 post-inoculation, all mice were 
challenged with 5x10
3
 CFU LVS.  On day 4 post-rechallenge, bacterial burdens were 
determined in the A) spleen, B) liver, and C) lung by plating serial dilutions of organ 
homogenate on chocolate agar.  n=3-4 mice/group.  Data are combined from 2 independent 
experiments.  The dashed line indicates the limit of detection of 50 CFUs.  Statistical 
significance was determined on log-transformed data using a one-way ANOVA with 
Tukey's post-test.
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Figure 4
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Figure 4.  LVS and LVS clpB vaccinated mice have similar spleen and lung cellularity 
as unvaccinated mice on day 4 post-rechallenge.  B6 mice were intranasally inoculated 
with 5x10
2
 CFU LVS or 5x10
4
 CFU LVS clpB, or left unvaccinated (Unvx).  On day 120 
post-inoculation, all mice were challenged with 5x10
3
 CFU LVS.  On day 4 post-
rechallenge, total cellularity was determined in the A) spleen or B) lung by trypan blue 
exclusion.  n=6 mice/group.  Data are combined from 3 independent experiments.  
Statistical significance was determined using a Kruskal-Wallis test with Dunn's correction.
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Figure 5
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Figure 5.  Vaccinated mice have increased numbers of lung IFN-γ producing CD4
+
 and 
CD8
+
 T cells compared to unvaccinated mice.   B6 mice were intranasally inoculated with 
5x10
2
 CFU LVS or 5x10
4
 CFU LVS clpB, or left unvaccinated (Unvx).  On day 120 post-
inoculation, all mice were challenged with 5x10
3
 CFU LVS.  On day 4 post-rechallenge, 
lung cells were restimulated with LVS infected B6-CD45.1 antigen presenting cells for 24 
hours.  Brefeldin A was added during the last 4 hours of culture.  The number of A) CD4
+
 
IFN-γ
+
 or B) CD8
+
 IFN-γ
+
 T cells in the lung was determined by flow cytometry.  To 
determine change in mean fluorescent intensity (ΔMFI) for each sample, the MFI of the 
IFN-γ negative population was subtracted from the MFI of the IFN-γ positive population 
for C) CD4
+
 or D) CD8
+
 T cells.  n=6 mice/group.  Data are combined from 3 independent 
experiments.  Statistical significance was determined using a Kruskal-Wallis test with 
Dunn's correction.    
183
Figure 6
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Figure 6.  Vaccinated mice do not have increased numbers of lung Th17 cells compared 
to unvaccinated mice.  B6 mice were intranasally inoculated with 5x10
2
 CFU LVS or 
5x10
4
 CFU LVS clpB, or left unvaccinated (Unvx).  On day 120 post-inoculation, all mice 
were challenged with 5x10
3
 CFU LVS.  On day 4 post-rechallenge, lung cells were 
restimulated with LVS infected B6-CD45.1 antigen presenting cells for 24 hours.  
Brefeldin A was added during the last 4 hours of culture.  A) Number of CD4
+
 IL-17A
+
 T 
cells in the lung were determined by flow cytometry.  B) Change in mean fluorescent 
intensity (ΔMFI) for each sample was determined by subtracting the MFI of the IL-17A 
negative population from the MFI of the IL-17A positive population.  n=6 mice/group.  
Data are combined from 3 independent experiments.  Statistical significance was 
determined using a Kruskal-Wallis test with Dunn's correction. 
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Figure 7
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Figure 7.  The IFN-γ mediated secondary response is nearly absent in the spleen.  B6 
mice were intranasally inoculated with 5x10
2
 CFU LVS or 5x10
4
 CFU LVS clpB, or left 
unvaccinated (Unvx).  On day 120 post-inoculation, all mice were challenged with 5x10
3
 
CFU LVS.  On day 4 post-rechallenge, spleen cells were restimulated with LVS infected 
B6-CD45.1 antigen presenting cells for 24 hours.  Brefeldin A was added during the last 4 
hours of culture.  The number of A) CD4
+
 IFN-γ
+
 or B) CD8
+
 IFN-γ
+
 T cells in the spleen 
was determined by flow cytometry.  To determine change in mean fluorescent intensity 
(ΔMFI) for each sample, the MFI of the IFN-γ negative population was subtracted from the 
MFI of the IFN-γ positive population for C) CD4
+
 or D) CD8
+
 T cells.  n=6 mice/group.  
Data are combined from 3 independent experiments.  Statistical significance was 
determined using a Kruskal-Wallis test with Dunn's correction.           
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Figure 8
A B
Figure 8.  The IL-17A mediated secondary response is absent in the spleen.  B6 mice 
were intranasally inoculated with 5x10
2
 CFU LVS or 5x10
4
 CFU LVS clpB, or left 
unvaccinated (Unvx).  On day 120 post-inoculation, all mice were challenged with 5x10
3
 
CFU LVS.  On day 4 post-rechallenge, spleen cells were restimulated with LVS infected 
B6-CD45.1 antigen presenting cells for 24 hours.  Brefeldin A was added during the last 4 
hours of culture.  A) Number of CD4
+
 IL-17A
+
 T cells in the spleen were determined by 
flow cytometry.  B) Change in mean fluorescent intensity (ΔMFI) for each sample was 
determined by subtracting the MFI of the IL-17A negative population from the MFI of the 
IL-17A positive population.  n=6 mice/group.  Data are combined from 3 independent 
experiments.  Statistical significance was determined using a Kruskal-Wallis test with 
Dunn's correction.                                         
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Figure 9
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Figure 9.  IFN-γ depletion increases bacterial burdens.  B6 mice were intranasally 
inoculated with 5x10
2
 CFU LVS or 5x10
4
 CFU LVS clpB, or left unvaccinated (Unvx).  On 
day 120 post-inoculation, all mice were challenged with 5x10
3
 CFU LVS.  A) Mouse 
weight was determined daily and is reported as the percentage of starting weight.  n=3-5 
mice/group.  Data are combined from 2 independent experiments.  On day 6 post-re-
challenge, bacterial burdens were determined in the B) spleen, C) liver, and D) lung by 
plating serial dilutions of organ homogenate on chocolate agar.  n=3-5 mice/group.  Data 
are combined from 2 independent experiments.  The dashed line indicates the limit of 
detection of 50 CFUs.  Statistical significance was determined on log-transformed data 
using a Student's t-test comparing anti-IFN-γ to isotype control within each group. 
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Figure 10
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Figure 10.  IL-17A depletion does not impact bacterial burdens.  B6 mice were 
intranasally inoculated with 5x10
2
 CFU LVS or 5x10
4
 CFU LVS clpB, or left unvaccinated 
(Unvx).  On day 120 post-inoculation, all mice were challenged with 5x10
3
 CFU LVS.  A) 
Mouse weight was determined daily and is reported as the percentage of starting weight.  
n=3-5 mice/group.  Data are combined from 2 independent experiments.  On day 6 post-re-
challenge, bacterial burdens were determined in the B) spleen, C) liver, and D) lung by 
plating serial dilutions of organ homogenate on chocolate agar.  n=3-5 mice/group.  Data 
are combined from 2 independent experiments.  The dashed line indicates the limit of 
detection of 50 CFUs.  Statistical significance was determined on log-transformed data 
using a Student's t-test comparing anti-IL-17A to isotype control within each group.
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 CHAPTER 4 
IDENTIFICATION OF EARLY INTERACTIONS BETWEEN FRANCISELLA AND THE 
HOST1 
 
 
OVERVIEW 
 The host’s adaptive immune response to Francisella tularensis is dependent on the 
route of inoculation.  Intradermal inoculation with F. tularensis live vaccine strain (LVS) 
results in many IFN-γ+ T cells in the lung whereas intranasal inoculation produces fewer 
IFN-γ+ T cells and instead many IL-17+ T cells in the lung.  Interestingly, at one day post 
inoculation, bacterial loads are similar in the spleen and lung regardless of the route of 
inoculation.  Due to the similar bacterial loads systemically, but very different host 
responses, we hypothesize that the adaptive immune response is influenced by local events at 
the site of infection immediately following inoculation.  To test this hypothesis, we identified 
the first cell type infected in the lungs of mice intranasally inoculated with F. novicida U112, 
LVS, or the highly virulent SchuS4 strain of F. tularensis using flow cytometry.  At four 
hours post-infection, we found that for all three strains of Francisella, alveolar macrophages 
are the primary cell type infected, to the exclusion of other myeloid cells and lung 
parenchyma.  In the skin, neutrophils, macrophages, and dendritic cells are infected with 
U112 or LVS 4 hours post-inoculation.  Following bacterial dissemination from the skin to 
                                                            
1 Contributing authors: Lydia Barrigan, Shraddha Tulhadar, Shaun Steele, Kristina Reibe, Ching-ju Chen, Ian 
Cumming, John Whitesides, Sarah Seay, Richard Frothingham, Greg Sempowski, Tom Kawula, and Jeffrey 
Frelinger 
  
 the lung, interstitial macrophages or neutrophils are infected indicating different cell types 
are infected in the lung following intranasal and intradermal inoculation. The lung has a more 
pro-inflammatory milieu following intradermal inoculation compared to intranasal 
inoculation, consistent with the development of a robust IFN-γ-mediated immune response 
after intradermal inoculation.  When alveolar macrophages are depleted using CD11c.DTR 
mice, lung bacterial burdens are higher on day 3 post-inoculation suggesting alveolar 
macrophages are necessary for controlling the infection early after inoculation.  Overall, we 
identified the early interactions between Francisella and the host following two different 
routes of inoculation.  We also identified the cytokines produced early after infection which 
likely play a role in shaping the subsequent adaptive immune response.        
 
INTRODUCTION 
Immune responses following bacterial infections are influenced by the route of 
infection (1, 2).  Cytokines produced by the innate immune response are critical in shaping 
the adaptive immune response (reviewed in (3)).  For example, if a naïve CD4+ T cell 
encounters antigen in the presence of IL-12, it will differentiate into Th1 effector T cell, but 
if it encounters IL-6 and TGF-β during antigen presentation, it will differentiate into a Th17 
effector T cell (3).  Our previous experiments in mice using intranasal or intradermal 
inoculation with Francisella tularensis subsp. holartica Live Vaccine Strain (LVS) 
demonstrated striking differences in the adaptive immune response in the lungs when these 
two inoculation routes were compared (2).  Upon either intradermal or intranasal inoculation 
with LVS, bacteria rapidly disseminate and are found in the spleen, liver, and lung 24 hours 
after inoculation (2).  After 3 days, equivalent bacterial burdens are found in the spleen and 
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 lungs of mice inoculated via either route (2).  Despite similar burdens early after inoculation, 
intradermally inoculated mice clear the infection more rapidly than intranasally inoculated 
mice and have an increased IFN-γ response.  Intradermal inoculation leads to significantly 
more CD4+ and CD8+ T cells producing IFN-γ in both the spleen and lung on day 7 post-
inoculation compared to intranasal inoculation (2).  Faster bacterial clearance in 
intradermally inoculated mice correlates with the increased IFN-γ-mediated immune 
response.  IFN-γ is required for controlling F. tularensis infection and administration of 
recombinant IFN-γ decreases bacterial burdens (4-6).  Intranasal infection leads to an 
expansion of Th17 cells, a CD4+ T cell population not found in the lungs of intradermally 
inoculated mice (2).  Altogether, we conclude T cell effector function is influenced by the 
inoculation route.  Thus, it is important to understand the initiation of the immune response 
and identify the earliest cells infected by Francisella as well as the cytokine environment 
induced upon inoculation.     
Francisella tularensis is a highly pathogenic, facultative intracellular, gram-negative 
coccobacillus.  Infection with F. tularensis causes the zoonotic disease tularemia which is 
endemic in regions of the United States and Europe.  F. tularensis subspecies holartica live 
vaccine strain (LVS) does not cause severe disease in humans (7).  Murine infection with 
LVS most closely resembles human infection (8).  The LD50 for intranasal inoculations is 
approximately 103 colony forming units (CFU) and approximately 106 for intradermal 
inoculation (9, 10).  While non-pathogenic in immunocompetent humans, F. novicida U112 
(U112) is highly virulent in mice with an LD50 for intranasal or intraperitoneal inoculation of 
<10 CFU (11, 12).  F. tularensis subspecies tularensis SchuS4 (SchuS4) is highly pathogenic 
in both mice and humans.  The route of Francisella infection contributes to the severity of 
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 tularemia in humans.  Approximately 90% of human tularemia cases are of the 
ulcerograndular type where bacteria are introduced through a cut in the skin or a bite from an 
arthropod vector (13).  The most severe form of tularemia is pneumonic tularemia which 
results from bacterial inhalation.  Before the use of antibiotics, pneumonic tularemia was 
fatal in 30-60% of cases when infection was caused by the highly virulent SchuS4 strain (13).  
Human disease can be caused by inhalation of as few as 10 organisms, highlighting the 
highly pathogenic nature of SchuS4 and intranasal infection (14).   
Due to similar bacterial burdens early after inoculation but very different adaptive 
immune responses for each inoculation route, we hypothesized that the adaptive immune 
response was shaped by events early after inoculation.  We therefore sought to identify host 
cells infected with F. tularensis early after inoculation.  Previously, we found alveolar 
macrophages comprised between 50-80% of cells infected with U112 or LVS 24 hours after 
intranasal inoculation (15).  Because infection for 24 hours had the potential of allowing for 
more than one round of infection, we were interested in identifying the infected cells 4 hours 
post-inoculation before any cell to cell spread.  We found alveolar macrophages were the 
primary cell type infected after intranasal inoculation and interstitial macrophages were 
infected in the lung following intradermal inoculation and bacterial dissemination to the lung.  
We also identified cytokines and chemokines produced in the lung early after inoculation or 
bacterial dissemination as well has how disease course is altered in the absence of alveolar 
macrophages.  Together, the work presented here helps us understand how events early after 
F. tularensis inoculation shape subsequent adaptive immunity.     
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 MATERIALS AND METHODS 
Bacteria  
Francisella novicida U112 was obtained from Colin Manoil (University of 
Washington).  F. tularensis subsp. holartica live vaccine strain (LVS) (29684) was obtained 
from American Type Culture Collection (Manassas, VA).  F. tularensis subsp. tularensis 
SchuS4 (SchuS4) (NR-643) was obtained from BEI Resources (Manassas, VA)  Bacteria 
were grown on chocolate agar supplemented with 1% IsoVitalex (Becton-Dickinson) at 37C̊.  
Bacterial inoculations were prepared by removing bacteria from a lawn grown on chocolate 
agar and resuspended in sterile PBS at an OD600=1 (equivalent to 1x107CFU/µL).  To 
achieve the desired dose, appropriate dilutions were made using sterile PBS.  Viable bacteria 
in each preparation were quantified by serial dilution and plating on chocolate agar.  
Mice   
C57Bl/6J (B6) mice were obtained from The Jackson Laboratory (Bar Harbor, ME).  
CD11c.diphtheria toxin receptor (CD11c.DTR) were obtained from Gunter Hammerling 
(German Cancer Research Center, Heidelberg, Germany) and then bred in-house.  All mice 
were housed in specific-pathogen free conditions at the University of North Carolina- Chapel 
Hill, Duke University, or the University of Arizona in accordance with their respective 
Institutional Animal Care and Use Committees.  Female mice used for experiments were 
between 7 to 12 weeks of age.   
Inoculation of Mice   
For intranasal bacterial inoculations, mice were anesthetized with 575 mg/kg 
tribromomethanol (Avertin) (Sigma) administered intraperitoneally.  Mice were then 
intranasally inoculated with 1 x 104 CFU U112 or LVS suspended in 50 μL PBS.  For 
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 intradermal inoculations, mice were inoculated with 5 x 105 CFU U112 or LVS in 25 µL at 
the base of the tail.  The inoculum was divided between 3 injection sites along the tail.  For 
diphtheria toxin (DT) treatment, CD11c.DTR mice were anesthetized with 0.25 mL of 7.5 
mg/mL ketamine and 0.5 mg/mL xylazine cocktail in PBS administered intraperitoneally and 
then intranasally inoculated with 8 ng diphtheria toxin (Sigma, St. Louis, MO) in 50 µL PBS.  
Depletion of alveolar macrophages was confirmed by flow cytometry.      
Single Cell Suspension of Mouse Lung 
B6 lungs were finely minced and placed into a sterile-filtered digestion mix of RPMI 
1640 (HyClone) containing L-glutamine (Gibco), sodium pyruvate (Gibco) and β-
mercaptoethanol (Gibco), 0.05 mg/mL collagenase (Worthington Biochemicals), 0.02 
mg/mL DNAse  (Sigma), and 125 U/mL elastase (Worthington Biochemicals). For 
intranasally inoculated mice, 50 µg/mL gentamicin (Sigma) was added to the digestion mix 
to kill extracellular bacteria.  The digestion mix was incubated in a 37°C water bath for 30 
minutes with occasional shaking.  The suspension was then strained through a 100 µM filter 
and cells pelleted by centrifugation at 300 x g for 5 minutes.  Red blood cells were lysed 
using ammonium chloride potassium lysis buffer (Gibco) and washed with RMPI 1640 
supplemented with 10% fetal calf serum (Atlas), L-glutamine, sodium pyruvate, and β-
mercaptoethanol.  The total number of viable cells was determined using a hemocytometer 
by trypan blue exclusion.        
Single Cell Suspension of Mouse Skin 
Tail skin was separated from the cartilage and placed dermis-side down in a petri dish 
containing 25 mg/mL trypsin (Invitrogen) and 50 µg/mL gentamicin.  Tails were incubated 
45 minutes at 37̊C and then the dermal and epidermal layers separated.  The epidermis was 
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 placed back in the 25 mg/mL trypsin and allowed to incubate 15 additional minutes.  
Epidermal cells were removed from the epidermis by washing and passed through a 100 µm 
filter.  The dermis was minced and placed in a sterile-filtered digestion mix composed of 
RPMI 1640, L-glutamine, sodium pyruvate, β-mercaptoethanol, 1000 U/mL collagenase 
(Worthington Biochemicals), 0.01 mg/mL DNAse (Sigma), 1000 U/mL hyluronidase 
(Worthington Biochemicals), and 25 µg/mL gentamicin (Sigma).  The dermis was digested 
for 2 hours in a 37̊C water bath with occasional shaking.  Dermal cells were then passed 
through a 100 µm filter and washed with RMPI 1640 supplemented with 10% fetal calf 
serum (Atlas), L-glutamine, sodium pyruvate, and β-mercaptoethanol.  The total number of 
viable cells was determined using a hemocytometer by trypan blue exclusion.              
Bead Enrichment of CD45+ cells 
Lung single cell suspensions were stained for 20 minutes on ice with CD45-APC 
(Clone 30-F11, Biolegend). After washing the cells to remove unbound antibody, IMag anti-
APC magnetic particles (BD) were used to enrich CD45-APC positive cells according to the 
manufacturer’s instructions.  Cells that did not bind the magnetic beads were considered 
CD45-APC negative.  CD45 enrichment was measured by flow cytometry.  Enriched 
eukaryotic cells were directly plated on chocolate agar containing 10 µg/ml ampicillin 
(Sigma) and the number of CFUs counted 72 hours later.   
Identification of infected lung populations    
Lung cells in a single cell suspension after intranasal inoculation with Francisella had 
Fc receptors blocked with 2.4G2  to prevent non-specific staining and were then stained with 
F4/80 PE (Clone BM8, eBioscience), CD11b Pacific Blue (Clone M1/70, Biolegend), and 
CD11c APC (Clone N418, eBioscience). Lung cells from intradermally inoculated mice had 
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 Fc receptors blocked with 2.4G2 and were then stained with F4/80 PE, CD11b Pacific Blue, 
CD11c APC, and GR-1 Pacific Orange (Clone, RB6-8C5, Invitrogen).  The cells were sorted 
using a Reflection cell sorter (iCyt/Sony) or FACS Aria (BD) into four populations based on 
surface marker expression (Table 1).  Sorted populations were plated directly on chocolate 
agar containing 10 µg/ml ampicillin without lysis and bacterial CFUs counted 24-72 hours 
later to enumerate the number of infected cells. 
Identification of infected epidermal and dermal populations   
Epidermal or dermal single cell suspensions after interdermal inoculation with 
Francisella were suspended in sterile PBS and then stained with 0.1 µg/mL Pacific Blue 
succimidyl ester (Invitrogen) for 8 minutes at room temperature.  Cells had Fc receptors 
blocked with 2.4G2 and were then stained with F4/80 PE, CD45 PE-Cy7 (Clone 30-F11, 
Biolegend), CD11b FITC (Clone M1/80, eBioscience), CD11c PerCP-Cy5.5 (Clone N418, 
Biolegend), GR-1 Pacific Orange, and CD207 (Clone eBioRMUL.2, eBioscience).  The cells 
were sorted using a FACS Aria (BD) based on surface marker expression (Table 2).  2x106 
naïve splenocytes were added to the sorted populations as carrier cells prior to centrifugation 
for 5 minutes at 300xg.  Cells were then  plated directly on chocolate agar containing 10 
µg/ml ampicillin without lysis and bacterial CFUs counted 24-72 hours later to enumerate the 
number of infected cells. 
Lung, epidermal, or dermal tissue culture   
Lungs were minced finely and placed in 1 mL complete RPMI 1640 containing 50 
µg/mL gentamicin in a 24 well plate.  Tail skin was separated from the cartilage and placed 
dermis-side down in a petri dish containing 10X trypsin (Invitrogen) and 50 µg/mL 
gentamicin.  Tails were incubated 45 minutes at 37̊C and then the dermal and epidermal 
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 layers separated.  Intact epidermal or dermal cell layers were placed in 1 mL complete RPMI 
1640 containing 50 µg/mL gentamicin in a 24 well plate.  1 hour after starting the culture, the 
gentamicin-containing media was removed and fresh media was added.  Tissue was cultured 
for 24 hours and then culture supernatant was collected.  Cells were removed by 
centrifugation at 300 x g for 5 minutes.  Culture supernatants were stored at -80 ̊C until 
Luminex analysis was performed.   
Luminex analysis   
A multiplex luminex bead-based approach was used to quantify 
cytokines/chemokines in the culture supernatant.  A 20-analyte assay panel was performed 
according to the manufacturer’s protocol (Invitrogen) using a BioPlex array reader (Bio-Rad 
Laboratories).  The assay reports pg/mL using integrated cytokine/chemokine standard 
curves.  The concentrations of the following analytes were determined:  FGF basic, GM-
CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p40/p70), IL-13, IL-17, KC, 
MCP-1, MIG, MIP-1α, TNFα, and VEGF.  A five-parameter non-linear logistic regression 
model was used to establish standard curve and to estimate the probability of occurrence of a 
concentration at a given point.  Standard outliers were removed from the analysis if the 
observed/expected % recovery was outside of the acceptable limits (70-130%).  Upper and 
lower levels of quantification were determined by the BioPlex Manager software based on 
goodness of fit and percent recovery.  Calculated pg/mL for experimental specimens were 
multiplied by the inherent assay dilution factor (df=2) and reported as final observed pg/mL. 
Statistical analysis   
Data were analyzed using a one-way ANOVA with Tukey’s post-test for cytokine 
levels.  CFU levels were log-transformed and then a Student’s t-test was used to determine 
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 significance.  GraphPad Prism (v5.04) was used for analysis.  Error bars show standard error 
of the mean.  Significance levels are indicated as follows: * p < 0.05; ** p < 0.01, *** p < 
0.001, **** p < 0.0001. 
 
RESULTS 
Identification of infected host cells early after inoculation   
The adaptive immune response to LVS is influenced by the route of infection despite 
similar bacterial burdens, and therefore antigen load, early after inoculation.  We 
hypothesized the adaptive immune response was shaped by these events occurring early after 
inoculation.  We therefore sought to identify infected cells early after inoculation.  We chose 
to use 4 hours after inoculation so that Francisella had sufficient time to infect the cells it 
initially targets, but not time for cell to cell spread.  We did not use GFP-expressing bacteria 
and flow cytometry to identify infected cells because there are few infected cells at 4 hours 
post-inoculation.  For example, an intranasal inoculum dose of 1x104 CFU yielded 
approximately 100 infected cells out of 1x107 host lung cells.  Additionally, intracellular 
replication of Francisella is just beginning at our chosen time point; therefore the GFP signal 
is low in infected cells.  Instead of using GFP-expressing Francisella to identify infected 
cells by flow cytometry, we took another approach.  The tissue of interest was digested into 
single cell suspensions in the presence of gentamicin to kill extracellular bacteria and stained 
with a variety of fluorophore-conjugated antibodies specific for surface markers that 
distinguish the cell populations of interest.  We then utilized FACS to sort individual cell 
populations of interest.  Purified cell populations were plated directly on chocolate agar 
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 without eukaryotic cell lysis and the resulting colonies counted.  A colony indicated a host 
cell of a specific type was infected with a live Francisella bacterium.                   
LVS infects myeloid-derived cells after intranasal inoculation   
Previous experiments identified a variety of lung cell types were infected with 
Francisella 24 and 72 hours post-intranasal inoculation (16).  Although the majority of 
infected cells 24 hours after intranasal inoculation with GFP-expressing Francisella strains 
were alveolar macrophages, alveolar type II epithelial cells were also identified as an infected 
cell type by flow cytometry (16).  Our initial experiments, therefore, sought to determine 
whether cells initially targeted by LVS were of the myeloid or non-myeloid lineage.  B6 mice 
were intranasally inoculated with 1x104 CFU LVS and sacrificed 4 hours later.  The lung 
single cell suspension was stained with anti-CD45-APC and anti-APC magnetic beads were 
used to positively select for myeloid-derived cells.  Figure 1A shows representative flow 
cytometry histograms of CD45 staining within the pre-enrichment, negative selection  
(CD45-), and positive selection (CD45+) samples.  Eukaryotic cells were directly plated on 
chocolate agar and the number of colonies within the CD45- and CD45+ pools were counted 
(figure 1B).  99% of the resulting LVS colonies were on the CD45+ plates indicating that 
LVS initially targets myeloid-derived cells for infection. 
Alveolar macrophages are the dominant infected cell type after intranasal inoculation   
Of the myeloid-derived cells in the lung, we selected alveolar macrophages, 
interstitial macrophages, and dendritic cells as the cell types most likely to be initially 
infected with Francisella.  These cell types were distinguished from one another by surface 
expression of F4/80, CD11c, and CD11b as shown in Table 1.  We also sorted an ‘other’ cell 
population that didn’t fit within the gates for alveolar macrophages, interstitial macrophages, 
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 or dendritic cells.  The lung gating scheme used for the sorts is shown in figure 2.  To 
identify infected cells in the lung early after intranasal inoculation, B6 mice were intranasally 
inoculated with 1x104 CFU U112, LVS, or SchuS4 and sacrificed 4 hours post-inoculation.  
The lung single cell suspension was stained for F4/80, CD11c, and CD11b and cell 
populations sorted based on expression of these surface markers.  Sorted eukaryotic cells 
were plated directly on chocolate agar and colonies counted (figure 3).  Approximately 90% 
of all infected cells were alveolar macrophages indicating these cells were initially targeted 
by Francisella after intranasal inoculation.  The remaining 10% of infected cells consisted of 
a mixture of interstitial macrophages, dendritic cells, and other.  The results were consistent 
across individual mice.  Alveolar macrophages were 86-96% of infected cells after U112 
inoculation, 71-93% of infected cells after LVS inoculation, and 93-96% of infected cells 
after SchuS4 inoculation.  Together, these data indicate alveolar macrophages are the 
dominant infected cell type after intranasal Francisella inoculation. 
Neutrophils are the dominant infected cell type in the skin after intradermal inoculation
 We next sought to determine what cells Francisella initially targets after intradermal 
inoculation.  Of the myeloid-derived cells in the skin, we selected dendritic cells, 
macrophages, neutrophils, and langerhans as the cells as the cell types most likely to be 
target by Francisella after intradermal inoculation.  Table 2 shows the surface markers used 
to distinguish these cell types.  The gating scheme used during the sorts is shown in figure 4.  
Non-myeloid derived cells  (CD45-) were the majority of cells within the skin and were also 
sorted to determine whether they were targeted by Francisella.  For intradermal inoculations, 
mice were inoculated with 5x105 CFU U112 or LVS at the base of the tail spread over three 
injection sites.  In order to recover approximately 100 infected cells, cells from two mice 
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 were combined prior to the sort into one sample.  In the epidermis, we found the majority of 
infected cells were neutrophils (figure 5).  Dendritic cells were also targeted by Francisella 
in the epidermis (figure 5).  In addition to neutrophils being the mostly likely cell typed 
infected with Francisella in the skin, neutrophils also had the highest percent infectivity of 
all sorted cell types by 10-100 fold.  Neutrophils were also the dominant infected cell type in 
the dermis (figure 6).  Macrophages were the other cell type targeted by Francisella in the 
dermis (figure 6).  Again, dermal neutrophils had the highest percent infectivity of all cell 
types in the dermis.  We had not expected naïve mouse skin to contain a large population of 
neutrophils but because so many neutrophils were infected after inoculation, we hypothesized 
that tissue damage and/or the presence of bacteria led to their recruitment.  To test this 
hypothesis, we inoculated mice with 50 μL PBS and sacrificed the mice 4 hours later.  We 
compared the % neutrophils of live CD45+ cells in the epidermis and dermis of untouched, 
naïve mice to mice that had been inoculated with PBS (figure 7).  We found a 3-4 fold 
increase in the % of neutrophils in the PBS inoculated mice suggesting that tissue damage 
caused by the injections leads to the recruitment of neutrophils to the skin.  Recruited 
neutrophils can then become infected with Francisella in the intradermal space.  Altogether, 
our data indicate neutrophils and dendritic cells are targeted by Francisella in the epidermis 
while neutrophils and macrophages are targeted by Francisella in the dermis.  Langerhans 
cells were not targeted by Francisella in either the epidermis or dermis.    
Interstitial macrophages and neutrophils are the dominant infected cell types in the 
lung after intradermal inoculation   
Because we observed very different adaptive immune responses in the lung after 
intranasal or intradermal inoculation, we hypothesized that there were different events 
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 occurring early after infection.  One possibility was different infected cell types in the lung 
depending on the route of infection.  We therefore sought to identify the infected cell type(s) 
after intradermal inoculation and bacterial dissemination to the lung.  Mice were 
intradermally inoculated with 5x105 CFU U112 or LVS.  Lung harvests were carefully timed 
such that infected cells were reproducibly found in the lung but we were still examining 
infected cells as soon after infection as practical.  Pilot experiments determined 48 hours 
post-inoculation was the time point that best fit these criteria.  Lung single cell suspensions 
were stained for F4/80, CD11b, CD11c, and GR-1 and sorted into the populations shown in 
table 1 and figure 2.  After intradermal inoculation and bacterial dissemination to the lung, 
interstitial macrophages and neutrophils are infected with Francisella (figure 8).  
Importantly, alveolar macrophages were not appreciably infected with Francisella in the lung 
after intradermal inoculation and bacterial dissemination.  These results indicate that different 
cell types are targeted by Francisella in the lung depending on the inoculation route.  
Intradermal inoculation leads to a pro-inflammatory lung cytokine/chemokine 
environment 
 Due to different cell types infected in the lung following intradermal or intranasal 
inoculation with LVS, we hypothesized that the cytokines and chemokines produced after 
inoculation would be different.  We intranasally inoculated B6 mice with 1x104 CFU LVS 
and harvested lung tissue 4 hours post-inoculation.  Alternatively, B6 mice were 
intradermally inoculated with 5x105 CFU and lungs were harvested 72 hours post-
inoculation.  Lungs were also harvested from naïve mice.  All lungs were minced in the 
presence of 50 μg/mL gentamicin.  Gentamicin was removed after 1 hour and the lung tissue 
was cultured overnight.  Culture supernatant was collected 24 hours after harvest and 
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 analyzed by Luminex.  The average lung cytokine and chemokine concentrations for each 
group are shown in table 3.  Intradermally inoculated mice had a pro-inflammatory lung 
milieu with significant increases in MIG, MCP-1, IP-10, and IFN-γ compared to naïve or 
intranasally inoculated mice (figure 9).  Intranasally inoculated mice had a significant 
increase in IL-10 production compared to naïve mice (figure 9).  These data indicate that the 
route of inoculation influences not only the types of cells that are initially infected but also 
the cytokine milieu of the lung.   
By culturing whole lung tissue after inoculation, we identified cytokines and 
chemokines produced by all cell types in the lung, not just the cells infected with LVS.  We 
attempted to determine the cytokines and chemokines produced specifically by alveolar 
macrophages after LVS inoculation using alveolar macrophages purified by flow cytometry 
sorting.  Naïve sorted alveolar macrophages produced cytokine in the absence of LVS 
infection, indicating these cells had become activated during the tissue processing or sorting 
process.  We were therefore unable to identify the cytokines and chemokines specifically 
produced by alveolar macrophages after intranasal inoculation. 
We also attempted to determine whether cytokine and chemokines were produced in 
the skin following intradermal inoculation.  4 hours post-inoculation we isolated epidermis 
and dermis from naïve, mock (PBS injected), U112 inoculated, and LVS inoculated mice and 
cultured whole tissue for 24 hours.  Luminex analysis of the culture supernatant showed that 
very little detectable cytokine or chemokine was produced by the epidermis or dermis.  We 
did detect high levels of IL-1α in the epidermal cultures, however, IL-1α is constitutively 
produced by epidermal cells, so this result is expected (17, 18).  We also detected FGF-basic 
(dermis), MIP-1α (epidermis), and VEGF (dermis), however all four groups of mice 
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 (including naïve mice) had similar levels indicating these molecules are produced 
constitutively by the skin and were not being made in response to the infection.   
Depletion of alveolar macrophages increases bacterial burdens in the lung 
 Since alveolar macrophages are the dominant infected cell type in the lung early after 
intranasal inoculation, we sought to determine how disease course would change in the 
absence of alveolar macrophages.  To deplete alveolar macrophages, we utilized the 
CD11c.diphtheria toxin receptor (CD11c.DTR) mouse which expresses DTR under control 
of the CD11c promoter.  Alveolar macrophages express high levels of CD11c and therefore 
would also express high levels of DTR, causing alveolar macrophages sensitive to diphtheria 
toxin depletion.  We administered diphtheria toxin (DT) intranasally so that only alveolar 
macrophages were depleted and not systemic dendritic cells, which also express CD11c.  We 
titrated the dose and timing of DT treatment so that alveolar macrophages were nearly absent 
prior to inoculation.  Initial experiments indicated that nearly all alveolar macrophages were 
depleted 24 hours after DT treatment.  However, when mice were inoculated with LVS 24 
hours after DT treatment, mice succumbed within 3 days to neutrophilic pneumonia.  We 
then re-analyzed our flow cytometry data from the initial titration experiments and found a 5-
10 fold increase in neutrophils in DT-treated mice compared to PBS-treated mice.  We then 
waited longer after DT treatment to allow time for the number of neutrophils to decrease.  On 
day 5 post-DT-treatment, alveolar macrophages were still 95% depleted while neutrophils 
were increased only 2-fold (figure 10).  Importantly, spleen and lung dendritic cells were 
present in similar frequencies as untreated mice indicating the DT-treatment did not deplete 
these populations 5 days post-treatment (figure 10).  Therefore, we treated CD11c.DTR mice 
intranasally with DT 5 days prior to inoculation. 
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  To determine whether the absence of alveolar macrophages affected bacterial 
burdens, we intranasally inoculated DT-treated CD11c.DTR mice with LVS and determined 
bacterial burdens in the spleen, liver, and lung on days 3, 7, and 10 post-inoculation (figure 
11).  On day 3 post-inoculation in the lung, DT-treated mice had significantly higher 
bacterial burdens compared to PBS-treated mice (figure 11A).  Burdens continued to trend 
higher in the lung on days 7 and 10 post-inoculation in DT-treated mice compared to PBS-
treated mice, but did not reach statistical significance (figure 11).  Burdens also trended 
higher in the spleen in DT-treated mice compared to PBS-treated mice for all three time 
points, but statistical significance was not reached (figure 11).  PBS- and DT-treated mice 
had similar liver burdens on days 3, 7, and 10 post-inoculation.  These results indicate that 
the absence of alveolar macrophages does not significantly affect bacterial burdens in distal 
organs (spleen and liver).  The increase in bacterial burdens in the lung on day 3 post-
inoculation in mice lacking alveolar macrophages suggests that alveolar macrophages help 
control the initial infection. 
Interstitial macrophages are infected with LVS in the absence of alveolar macrophages 
 We next sought to determine what cell type(s) were infected with LVS in the absence 
of alveolar macrophages in DT-treated CD11c.DTR mice.  CD11c.DTR mice were treated 
with DT 5 days prior to intranasal inoculation with LVS.  4 hours post-inoculation, mice 
were sacrificed, lungs digested into a single cell suspension, and then single cells were 
stained for flow cytometry sorting.  Alveolar macrophages, interstitial macrophages, 
dendritic cells, and neutrophils were sorted according to the markers described in table 1 and 
the gating scheme shown in figure 2.  When alveolar macrophages are at greatly reduced 
numbers, interstitial macrophages are the dominant infected cell type 4 hours post-
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 inoculation (figure 12).  However, even with significant alveolar macrophage depletion, 
nearly 10% of infected cells were alveolar macrophages indicating the remaining cells could 
still be infected with LVS.  When alveolar macrophages were infected, they were infected at 
a higher rate (0.029% of sorted alveolar macrophages were infected) compared to interstitial 
macrophages which were present at much higher numbers (0.0059%)   Neutrophils 
comprised a small percent of all infected cells and were only infected in 2 of 7 mice (figure 
12).  Alveolar macrophages were infected in 3 of 7 mice whereas interstitial macrophages 
were infected in all 7 mice indicating interstitial macrophages were the preferential target of 
LVS in the absence of abundant alveolar macrophages.     
The lung has a more pro-inflammatory milieu in the absence of alveolar macrophages 
 We next sought to determine whether the cytokine milieu was altered in the absence 
of alveolar macrophages early after LVS inoculation.  We hypothesized there would be an 
altered milieu because bacterial burdens were increased in the lungs in the absence of 
alveolar macrophages.  B6 or DT-treated CD11c.DTR mice were intranasally inoculated with 
LVS and lungs harvested 4 hours post-inoculation.  Lungs were minced and cultured for 24 
hours before culture supernatant was collected and analyzed by Luminex.  The average lung 
cytokine and chemokine concentrations for each group are shown in table 4.  We found a 
significant increase in the concentrations of IL-12, MCP-1, MIG, and VEGF in mice 
CD11c.DTR mice treated with DT and therefore lacking alveolar macrophages compared to 
naïve B6 mice or LVS infected B6 mice (figure 13).  IL-6 levels were significantly increased 
in LVS infected CD11c.DTR mice compared to B6 mice.  GM-CSF was also elevated in 
CD11c.DTR mice but the increase did not reach statistical significance.  Although we 
observed a different lung cytokine/chemokine milieu upon LVS inoculation in the absence of 
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 alveolar macrophages, we did not isolate tissue from naïve, DT-treated CD11c.DTR mice to 
determine whether the changes we observe are due to the LVS infection or simply caused by 
the DT-treatment.  For example, the high levels of GM-CSF could be driving monocyte 
differentiation into alveolar macrophages to re-populate the lung and may not be a 
consequence of LVS infection.  Further studies are necessary to clearly address whether 
depletion of alveolar macrophages alters the lung environment prior to LVS inoculation.   
 
DISCUSSION 
 Francisella is capable of infecting a variety of cell types upon inoculation (15, 16, 19, 
20).  The early interactions between the host and pathogen set the stage for the adaptive 
immune response.  We and others have shown the route of inoculation influences the type of 
adaptive immune response that develops (2, 21).  We were particularly interested in the early 
interactions between Francisella and the host following intranasal and intradermal 
inoculation because of differential adaptive immune responses.  Intranasal and intradermal 
inoculation with LVS leads to similar bacterial burdens early after inoculation, yet the 
adaptive immune responses are very different (2).  We hypothesized early events after 
inoculation, such as the cells infected with Francisella immediately after inoculation, were 
shaping the adaptive immune response.  We therefore sought to identify the cells that were 
infected with Francisella after inoculation that were likely responsible for shaping 
subsequent adaptive immunity. 
 We identified infected cells by sorting individual populations using flow cytometry.  
We did not use GFP-expressing bacteria because we had very few infected cells and it would 
therefore be difficult to identify dimly fluorescent cells among millions of host cells, many 
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 with significant autofluorescence.  This technique also only identified host cells infected with 
live Francisella.  Experiments using flow cytometry and GFP-expressing bacteria do not 
determine whether the intracellular bacterium is alive.  We had to intranasally inoculate mice 
with 1x104 CFU to have detectable infected cells after sorting.  This inoculum dose is 20-fold 
higher than our typical LVS intranasal inoculation dose.  We do not believe the higher dose 
altered the distribution of infected cell types, the higher dose likely just increased the overall 
number of infected cells.     
 All three strains of Francisella predominantly infected alveolar macrophages 
following intranasal inoculation (figure 3).  Alveolar macrophages are the resident 
macrophages of the airway and interact with inhaled antigens.  It is therefore not surprising 
that inhalation of Francisella leads to infection of alveolar macrophages.  Other pathogens, 
like Mycobacterium tuberculosis, Mycoplasma pulmonis, and Legionella pneumophila, target 
alveolar macrophages upon infection as well (22-25).  Experiments conducted by the Dow 
group and reported in Bosio, et al. found that LVS infects pulmonary dendritic cells 1 hour 
post-intratracheal inoculation with 5x104 CFU using flow cytometry to detect CFSE labeled 
bacteria inside of host cells (19).  A potential explanation for the seemingly disparate results 
between the two experiments is the use of different surface markers to define airway 
dendritic cells and alveolar macrophages.  Bosio, et al. defined dendritic cells as CD11c+, 
DEC-205+, CD11b-, and GR-1- and alveolar macrophages as CD11c-, DEC-205-, CD11b+, 
and GR-1+ (19).  We defined alveolar macrophages as CD11chigh and CD11bmid (table 1).  
The markers described by Bosio, et al. for alveolar macrophages are a better fit with how we 
define interstitial macrophages (table 1).  More recently, the Dow group reported in Guth, et 
al. that alveolar macrophages express high levels of DEC-205 and CD11c, giving this 
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 macrophage cell subset a more dendritic cell-like surface phenotype (26).  Therefore, the 
more recent work by the Dow group indicates that what they defined as dendritic cells in 
2005 are actually alveolar macrophages.  Thus, our results are consistent with the results 
described by Bosio, et al. where alveolar macrophages are the primary cell type targeted by 
Francisella after pulmonary infection.   
Because alveolar macrophages were infected following intranasal inoculation with 
LVS, we sought to determine whether disease course was altered in the absence of alveolar 
macrophages.  Alveolar macrophages express high levels of CD11c (figure 2) and can 
therefore be depleted in CD11c.DTR mice upon intranasal treatment with diphtheria toxin 
(DT).  We chose to use CD11c.DTR mice so that alveolar macrophages are specifically 
depleted.  Alveolar macrophages can also be depleted by intranasal administration of 
liposomal clodronate, however this treatment is non-specific and depletes >90% of lung and 
airway antigen presenting cells (19).  Depletion of alveolar macrophages led to a significant 
increase in bacterial burdens in the lung on day 3 post-inoculation.  Burdens continue to trend 
higher in the lung on days 7 and 10 post-inoculation but the increases did not reach statistical 
significance.  Bacterial burdens were also not significantly increased in the spleen or liver at 
all three time points.  These data suggest that alveolar macrophages help control bacterial 
burdens at the primary site of infection but do not play a role in bacterial dissemination.   
Alveolar macrophages have been shown in other models to be either protective or 
detrimental during infection (19, 22, 27-29).  CBA/J mice succumb rapidly (day 3) to 
Klebsiella pneumoniae in the absence of alveolar macrophages and have significantly higher 
bacterial burdens in the plasma and lung suggesting that alveolar macrophages control 
bacterial replication in the lung (27, 29).  B6 mice, normally resistant to Mycoplasma 
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 pulmonis, were more susceptible to infection in the absence of alveolar macrophages, 
indicating alveolar macrophages are important for host defense during Mycoplasma infection 
(28).  In a Mycobacterium tuberculosis model, mice lacking alveolar macrophages were less 
susceptible to infection and had decreased mycobacterial burdens in the lung and liver 
suggesting the presence of alveolar macrophages is detrimental during infection (22).  Bosio, 
et al. found depletion of alveolar macrophages with clodronate followed 18 hours later by 
intratracheal inoculation with a lethal dose of LVS led to decreased bacterial burdens and an 
increase in mean time to death (19).  It is possible that the difference in bacterial burdens 
observed in untreated and clodronate treated mice was due to the absence of cells to infect 
because nearly all antigen-presenting cells were reported to be depleted (19).  In our model of 
alveolar macrophage depletion, there are still other cells available for infection which could 
account for our different results.  Additionally, Bosio, et la. inoculated mice with a high dose 
that killed untreated mice by 6 days, indicating there is little, if any, contribution of the 
adaptive immune response.  In our model, the inoculation dose is half of the reported LD50 
for intranasal inoculation and all infected mice survive (9, 10).  The increase in bacterial 
burdens on day 3 post-inoculation and then similar burdens on day 7 and 10 suggests that 
there are defects in the innate immune response in the absence of alveolar macrophages but 
that the adaptive immune response is able to mediate bacterial clearance whether or not mice 
had alveolar macrophages upon LVS inoculation.  Future experiments should examine 
whether the adaptive immune response changes in the absence of alveolar macrophages 
during the primary response.     
 Francisella infects neutrophils, macrophages, and dendritic cells in the epidermis and 
dermis of the tail following intradermal inoculation (figure 5, 6).  Neutrophils are recruited to 
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 the skin upon tissue damage during PBS injection (figure 7).  We therefore suggest a model 
where dendritic cells (epidermis) or macrophages (dermis) are resident cells infected with 
Francisella and that recruited neutrophils become infected with Francisella when they 
encounter bacteria in the intradermal space.  It is not clear how Francisella disseminates 
from the site of inoculation on the tail to the lung.  The long-held paradigm was that 
Francisella was strictly an intracellular pathogen in vivo and was carried to distal sites within 
host cells (30).  Forestal, et al. was the first refute this dogma by describing cell-free LVS 
and SchuS4 in the plasma of infected mice (31).  U112 has also been found non-cell 
associated in mouse plasma (32).  To test whether Francisella disseminates as free bacteria 
in the bloodstream, mice could be treated with gentamicin to kill extracellular bacteria and 
bacterial burdens in distal organs monitored.  If the time course of infection and bacterial 
burdens are similar in gentamicin and vehicle treated mice, these data would suggest that 
while Francisella can survive extracellularly, the bacteria disseminate within host cells.  The 
dosage of gentamicin would need to be carefully titrated for such an experiment so that the 
dose is high enough to kill extracellular bacteria but low enough so that the gentamicin does 
not enter host cells and kill intracellular bacteria. 
 While we did not pursue experiments to determine the underlying mechanisms 
responsible for bacterial dissemination, we identified interstitial macrophages and neutrophils 
as the dominant infected cell types in the lung after intradermal inoculation and bacterial 
dissemination (figure 8).  We carefully timed the lung harvest after intradermal inoculation 
so that we were identifying infected cells soon after bacteria disseminated to the lung.  When 
the cytokine milieus were compared at time points early after bacterial entry into the lung (4 
hours post-intranasal, 72 hours post-intradermal inoculation), we found intradermal 
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 inoculation led to a more pro-inflammatory environment compared to naïve or intranasally 
inoculated mice (figure 9).  These results are consistent with a more robust Th1 response in 
the lung during the adaptive immune response following intradermal inoculation (2).                                   
If the cytokine and chemokines produced in DT-treated CD11c.DTR mice are due to 
the infection, the presence of a pro-inflammatory environment is consistent with the infection 
of interstitial macrophages (figures 8, 9, and 12).  Intradermally inoculated mice did not have 
infected alveolar macrophages following bacterial dissemination (figure 8).  Intradermally 
inoculated mice also had a more pro-inflammatory lung milieu compared to intranasally 
inoculated mice (figure 9).  The presence of a pro-inflammatory lung milieu in DT-treated 
CD11c.DTR mice where interstitial macrophages are the dominant infected cell type (figure 
12) is consistent with previous findings.  However, if the lung milieu is more pro-
inflammatory, we would expect better control of the infection which we did not observe on 
day 3 post-inoculation in the lung.  It is possible that the lung milieu is initially pro-
inflammatory, but changes by day 3.  Additional experiments are necessary to determine 
whether the lung milieu is altered on day 3 post-inoculation in mice lacking alveolar 
macrophages.  We also need to determine how the lung milieu changes upon depletion of 
alveolar macrophages because it is likely many of the changes observed were not due simply 
to the presence of LVS.  For instance, we did observe an increase in GM-CSF concentration, 
but the increase did not reach statistical significance.  GM-CSF is necessary for expressing 
high levels of CD11c and is therefore likely involved in the re-population of lung alveolar 
macrophages (26).   
Overall, we have identified alveolar macrophages are initially infected with 
Francisella in the lung intranasal and macrophages, dendritic cells, and neutrophils are 
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 infected in the skin after intradermal inoculation.  We also determined interstitial 
macrophages are infected with Francisella in the lung following bacterial dissemination in 
the skin.  We had previously observed a differential adaptive immune response following 
intranasal and intradermal inoculation, despite similar bacterial burdens early after 
inoculation.  We predict there would be differences in the innate immune response in the 
lung that was contributing to the development of two distinct T cell responses and this was 
the case; different types of cells were infected following each inoculation route and the lung 
cytokine milieu was also different.  We have begun to examine the immune response in the 
absence of alveolar macrophages during intranasal inoculation.  Bacterial burdens are higher 
in the lung on day 3 post-inoculation in the absence of alveolar macrophages but are not 
increased later in infection.  Additional experiments are necessary to determine whether the 
lung’s cellular composition and cytokine milieu are altered on day 3 post-inoculation and 
whether this results in differences in the adaptive immune response.  The work presented 
here does increase our understanding of the early interactions between the host and 
Francisella for two commonly studied routes of inoculation.             
                    
 
 
  
217
Figure 1
CD45
%
 o
f 
m
a
x
Pre-enrichment
A
B
1%
Positive selectionNegative selection
CD45+ 
CD45-
99%
CD45
+
 
38.1%
CD45
-
 
61.3%
CD45
-
 
97.5%
CD45
+
 
0.4%
CD45
-
 
9.2%
CD45
+
 
88.4%
Figure 1.  LVS infects myeloid-derived cells following intranasal inoculation.  B6 mice 
were intranasally inoculated with 1x10
4
 CFU LVS.  4 hours post-infection mice were 
sacrificed and lungs were removed and digested into a single cell suspension.  Cells were 
stained with CD45 APC and then CD45+ cells were enriched using magnetic beads.  A) 
Representative flow cytometry analysis of CD45 enrichment.  B) CD45+ and CD45- 
populations were directly plated on chocolate agar and the number of colonies were 
counted 72 hours later.  Data are represented as the % of CFUs within a population out of 
all recovered colonies from 4 infected mice in 2 independent experiments.    
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Table 1
Table 1. Identification of lung cell types 
Cell type Surface markers
a
 
Alveolar macrophages F4/80
high
, CD11c
high
, CD11b
mid
  
Interstitial macrophages F4/80
high
, CD11c
var
, CD11b
high
 
Dendritic cells F4/80
low
, CD11c
high
, CD11b
low
 
Other F4/80
low
, CD11c
low
, CD11b
var
 
Neutrophils F4/80
low
,CD11b
high
, GR-1
high
 
a
 mid, medium level; var, variable level 
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Figure 2
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Figure 2. Lung gating scheme for sorting.  Single cells were discriminated from doublets 
by plotting side scatter height (SSC-H) versus side scatter area (SSC-A).  Cells were 
selected by plotting SSC-A versus forward scatter area (FSC-A).  F4/80
-
 and F4/80
+
 cells 
were gated on by plotting FSC-A versus F4/80.  From the F4/80
+
 gate, alveolar 
macrophages (AMs) were discriminated from interstitial macrophages (IMs) by plotting 
CD11c versus CD11b.  Of the F4/80
-
 cells, dendritic cells were identified by plotting 
CD11c versus CD11b and neutrophils were identified by plotting CD11b versus GR-1.  
For each gate, the percent of the parent gate is indicated in bold (for example, AMs are 
4.6% of the cells within the F4/80+ gate).
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Figure 3
Figure 3.  Alveolar macrophages are the primary infected cell type in the lung after 
intranasal inoculation with Francisella.  B6 mice were intranasally inoculated with 1x10
4
 
CFU U112, LVS, or SchuS4.  4 hours post-inoculation mice were sacrificed and lungs 
were removed and digested into a single cell suspension and stained for sorting.  Alveolar 
macrophages, interstitial macrophages, dendritic cells, and other cell populations were 
sorted and directly plated on chocolate agar.  Resulting colonies were counted 24-72 hours 
later.  Data are represented as the % of CFUs within a population out of all recovered 
colonies from 2 mice (U112), 6 mice (LVS), or 3 mice (SchuS4) from 1 (U112), 3 (LVS), 
or 2 (SchuS4) independent experiments.  
U112 LVS
SchuS4
Alveolar 
macrophages
Interstitial 
macrophages
Dendritic cells
Other
90.7% 88.6%
94.4%
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Table 2
Table 2. Identification of skin cell types 
Cell type Surface markers 
Dendritic cells CD45
high
, F4/80
low
, CD11c
high
 
Macrophages CD45
high
, F4/80
high
, 
CD11b
high
, GR-1
high
 
Neutrophils CD45
high
, F4/80
low
, CD11b
high
, 
GR-1
high
 
Langerhans CD45
high
, F4/80
high
, CD207
high
 
Non-myeloid CD45
low
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Figure 4
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Figure 4.  Epidermis and dermis gating scheme for sorting.  Single cells were 
discriminated from doublets by plotting foward scatter height (FSC-H) versus forward 
scatter area (FSC-A).  Cells were selected by plotting side scatter area (SSC-A) versus 
FSC-A.  Live cells were selected using a 1-D histogram.  CD45+ cells were gated on by 
plotting FSC-A versus CD45.  F4/80
-
 and F4/80
+
 cells were gated on by plotting FSC-A 
versus F4/80.  From the F4/80
+
 gate, macrophages were gated on by plotting CD11b 
versus GR-1 and Langerhans were gated on by plotting CD11b versus CD207.  Of the 
F4/80
-
 cells, dendritic cells were identified by plotting CD11c versus CD11b and 
neutrophils were identified by plotting CD11b versus GR-1.  For each gate, the percent of 
the parent gate is indicated in bold (for example, macrophages are 85.2% of the cells 
within the F4/80+ gate).
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Figure 5
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Figure 5.  Neutrophils and dendritic cells are the primary cell types infected with U112 
or LVS in the epidermis after intradermal inoculation.  B6 mice were intradermally 
inoculated with 5x10
5
 CFU U112 or LVS in 50 µL PBS at the base of the tail.  4 hours 
post-inoculation, mice were sacrificed and the tails removed.  Cells from two mice were 
combined for each sample.  Epidermis and dermis layers were separated, digested into a 
single cell suspension, and stained for sorting.  Dendritic cells, macrophages, neutrophils, 
Langerhans and non-myeloid cells were sorted and directly plated on chocolate agar.  
Resulting colonies were counted 24-72 hours later.  Data are represented as the % of CFUs 
within a population out of all recovered colonies from 6 samples (U112 or LVS) from 2 
(U112) or 3 (LVS) independent experiments.                 
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Figure 6
Figure 6.  Neutrophils and macrophages are the primary cell types infected with U112 
or LVS in the dermis after intradermal inoculation.  B6 mice were intradermally 
inoculated with 5x10
5
 CFU U112 or LVS in 50 µL PBS at the base of the tail.  4 hours 
post-inoculation, mice were sacrificed and the tails removed.  Cells from two mice were 
combined for each sample.  Epidermis and dermis layers were separated, digested into a 
single cell suspension, and stained for sorting.  Dendritic cells, macrophages, neutrophils, 
Langerhans and non-myeloid cells were sorted and directly plated on chocolate agar.  
Resulting colonies were counted 24-72 hours later.  Data are represented as the % of CFUs 
within a population out of all recovered colonies from 6 samples (U112 or LVS) from 2 
(U112) or 3 (LVS) independent experiments.                 
U112 LVS
75.2%
22.6%
55.0%
44.0%
Dendritic Cells
Macrophages
Neutrophils
Langerhans Cells
Non-myeloid
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Figure 7
Figure 7.  Neutrophils traffic to the skin following PBS inoculation.  B6 mice were 
intradermally inoculated with 50 µL PBS at the base of the tail or left naive.  4 hours post-
inoculation, mice were sacrificed and the tails removed.  Epidermis and dermis layers were 
separated, digested into a single cell suspension, and stained for flow cytometry analysis.  
The % of neutrophils in the live CD45+ gate was determined.  n=2 mice.  Data are from 1 
experiment.        
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Figure 8
Figure 8.  Interstitial macrophages and neutrophils are the primary cell types infected 
with U112 or LVS in the lung after intradermal inoculation.  B6 mice were intradermally 
inoculated with 5x10
5
 CFU U112 or LVS in 50 µL PBS at the base of the tail.  48 hours 
post-inoculation mice were sacrificed and lungs were removed and digested into a single 
cell suspension and stained for sorting.  Alveolar macrophages, interstitial macrophages, 
dendritic cells, and neutrophil cell populations were sorted and directly plated on chocolate 
agar.  Resulting colonies were counted 24-72 hours later.  Data are represented as the % of 
CFUs within a population out of all recovered colonies from 4 mice (U112 or LVS) from 1 
(U112 or LVS) experiment per strain.    
U112 LVS
Alveolar 
macrophages
Interstitial 
macrophages
Dendritic cells
Neutrophils
43.2%
70.8%54.6%
27.2%
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Table 3 
 
Table 3.  Average lung cytokine and chemokine 
concentrations after two different routes of LVS 
inoculation (pg/mL) 
 Intradermala Intranasalb Naive 
FGF basic 69.47 69.47 69.47 
GM-CSF 127.25 702.00 349.78 
IFN-γ 137.30 17.21 17.21 
IL-1α 28.55 28.55 28.55 
IL-1β 24.51 24.51 24.51 
IL-2 11.77 11.61 11.42 
IL-4 30.93 30.93 30.93 
IL-5 37.25 129.75 152.33 
IL-6 549.35 823.18 600.25 
IL-10 81.15 154.10 63.95 
IL-12 10.87 11.03 16.78 
IL-13 22.81 22.81 22.81 
IL-17 3.54 3.54 3.54 
IP-10 243.00 19.19 19.19 
KC 1708.88 1785.48 1460.70 
MCP-1 1025.65 102.65 47.79 
MIG 1270.45 3.65 7.75 
MIP-1α 32.10 45.60 42.38 
TNF-α 17.42 17.42 17.42 
VEGF 665.5 296.63 391.53 
a Lungs harvested 72 post-intradermal inoculation 
b Lungs harvested 4 hours post-intranasal inoculation 
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Figure 9
Figure 9.  Intradermal inoculation induces a pro-inflammatory environment in the 
lung.  B6 mice were intranasally inoculated with 1x10
4
 CFU LVS, intradermally 
inoculated with 5x10
5
 CFU LVS, or left naive.  4 hours post-intranasal inoculation or 72 
hours post-intradermal inoculation, mice were sacrificed and lungs removed.  Minced 
lungs were cultured for 24 hours.  Culture supernatant was collected and analyzed using a 
Luminex-based assay.  n=4 mice/group.  Data are from 1 experiment.  An ANOVA with 
Tukey's post-test was used to determine statisical significance for each cytokine or 
chemokine.  Statistical significance is indicated by stars after the fold change when two 
groups differed. 
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Figure 10
Figure 10.  Intranasal diphtheria toxin treatment depletes alveolar macrophages.  
CD11c.DTR mice were intranasally inoculated with 8 ng of diphtheria toxin in 50 µL 
PBS.  5 days after treatment, lungs were removed, digested into a single cell suspension 
and strained for flow cytometry analysis.  The % A) alveolar macrophages, B) dendritic 
cells, C) interstitial macrophages, D) neutrophils, and E) spleen dendritic cells was 
determined of live cells was determined.  Each dot represents one mouse.  Data are 
representative of 2 independent experiments.  
A B
C D
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Figure 11
Figure 11.  Bacterial burdens increase in the lung early after LVS inoculation in the 
absence of alveolar macrophages.  B6 were intranasally inoculated with 50 µL PBS or 
CD11c.DTR mice were intranasally inoculated with 8 ng diphtheria toxin (DT) in 50  µL 
PBS.  5 days later, all mice intranasally inoculated with 5x10
2
 CFU LVS.  On days 3, 7, 
and 10 post-inoculation, bacterial burdens were determined in the A) lung, B) spleen, and 
C) liver by plating serial dilutions of organ homogenate on chocolate agar.  n=4-7 
mice/group for each time point.  Each dot represents one mouse.  Data are from 1 
experiment for day 7 and combined from 2 independent experiments for days 3 and 10.  
Statistical significance was determined on log-transformed data using a Student's t-test.  D) 
Weight loss was determined daily and is reported as a percentage of the starting weight.    
D
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Figure 12.  Interstitial macrophages are the dominant infected cell type in the absence 
of alveolar macrophages.  CD11c.DTR mice were intranasally inoculated with 8 ng 
diphtheria toxin (DT) in 50 µL PBS.  5 days later, mice intranasally inoculated with 1x10
4
 
CFU LVS.  4 hours post-inoculation were sacrificed and lungs removed and digested into 
a single cell suspension and stained for sorting.  Alveolar macrophages, interstitial 
macrophages, dendritic cells, and neutrophils were sorted and directly plated on chocolate 
agar.  Resulting colonies were counted 72 hours later.  Data are represented as the % of 
CFUs within a population out of all recovered colonies from 7 mice from 2 independent 
experiments.   
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Table 4 
 
Table 4.  Average lung cytokine and chemokine 
concentrations in the presence or absence of alveolar 
macrophages following intranasal LVS inoculation (pg/mL) 
 Naïve B6 LVS B6  (+ AMs) 
LVS CD11c.DTR  
(-AMs) 
FGF basic 24.63 24.63 24.63 
GM-CSF 348.66 286.62 2714.79 
IFN-γ 10.80 10.80 10.80 
IL-1α 14.40 14.40 14.40 
IL-1β 11.80 11.80 11.80 
IL-2 8.27 8.27 8.27 
IL-4 14.59 14.59 20.38 
IL-5 858.12 521.89 602.90 
IL-6 2026.12 1030.81 2893.26 
IL-10 6.26 6.26 6.26 
IL-12 39.43 23.94 73.17 
IL-13 11.56 11.56 11.56 
IL-17 8.31 8.31 8.31 
IP-10 147.98 74.19 108.30 
KC 2111.13 2014.51 2167.38 
MCP-1 183.79 163.37 369.29 
MIG 2.44 3.64 33.48 
MIP-1α 13.76 13.76 13.76 
TNF-α 8.70 8.70 8.70 
VEGF 101.72 115.97 624.17 
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Figure 13.  LVS inoculation in the absence of alveolar macrophages induces a pro-
inflammatory environment in the lung.  B6 were intranasally inoculated with 50 µL PBS 
or CD11c.DTR mice were intranasally inoculated with 8 ng diphtheria toxin (DT) in 50  
µL PBS.  5 days later, B6 and CD11c.DTR mice intranasally inoculated with 1x10
4
 CFU 
LVS or B6 mice were left naive.  4 hours post-intranasal inoculation, mice were sacrificed 
and lungs removed.  Minced lungs were cultured for 24 hours.  Culture supernatant was 
collected and analyzed using a Luminex-based assay.  n=4 mice/group.  Data are from 1 
experiment.  An ANOVA with Tukey's post-test was used to determine statisical 
significance for each cytokine or chemokine.  Statistical significance is indicated by stars 
after the fold change when two groups differed.
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CHAPTER 5 
IDENTIFICATION OF FRANCISELLA NOVICIDA MUTANTS THAT FAIL TO INDUCE 
PROSTAGLANDIN E2 SYNTHESIS BY INFECTED MACROPHAGES1,2 
 
 
OVERVIEW 
Francisella tularensis is the causative agent of tularemia.  We have previously shown 
that infection with F. tularensis Live Vaccine Strain (LVS) induces macrophages to 
synthesize prostaglandin E2 (PGE2).  Synthesis of PGE2 by F. tularensis infected 
macrophages results in decreased T cell proliferation in vitro and increased bacterial survival 
in vivo. Although we understand some of the biological consequences of F. tularensis 
induced PGE2 synthesis by macrophages, we do not understand the cellular pathways 
(neither host nor bacterial) that result in up-regulation of the PGE2 biosynthetic pathway in F. 
tularensis infected macrophages.  We took a genetic approach to begin to understand the 
molecular mechanisms of bacterial induction of PGE2 synthesis from infected macrophages.  
To identify F. tularensis genes necessary for the induction of PGE2 in primary macrophages, 
we infected cells with individual mutants from the closely related strain Francisella 
tularensis subspecies novicida U112 (U112) two allele mutant library. Twenty genes were 
identified that when disrupted resulted in U112 mutant strains unable to induce the synthesis 
                                                            
1 Contributing authors: Matthew D. Woolard, Lydia M. Barrigan, James R. Fuller, Adam S. Buntzman, Joshua 
Bryan, Colin Manoil, Thomas H. Kawula, and Jeffrey A. Frelinger 
 
2 This work was published in Frontiers in Microbiology: Front. Microbio. 4:16. Doi:10.3389/fmicb.2013.00016 
© Woolard, Barrigan, Fuller, Buntzman, Bryan, Manoil, Kawula and Frelinger.  Reprinted with permission.   
of PGE2 by infected macrophages.  Fourteen of the genes identified are located within 
the Francisella pathogenicity island (FPI).   Genes in the FPI are required for F. tularensis to 
escape from the phagosome and replicate in the cytosol, which might account for the failure 
of U112 with transposon insertions within the FPI to induce PGE2.  This implies that U112 
mutant strains that do not grow intracellularly would also not induce PGE2. We found that 
U112 clpB::Tn grows within macrophages yet fails to induce PGE2, while U112 pdpA::Tn 
does not grow yet does induce PGE2. We also found that U112 iglC::Tn neither grows nor 
induces PGE2.  These findings indicate that there is dissociation between intracellular growth 
and the ability of F. tularensis to induce PGE2 synthesis.  These mutants provide a critical 
entrée into the pathways used in the host for PGE2 induction.  
 
INTRODUCTION 
Francisella tularensis is a facultative intracellular bacterium and the causative agent 
of tularemia.  F. tularensis has a low infective dose, high morbidity, and can persist in the 
environment (1).   F. tularensis has also been produced as a bioweapon (2), and is classified 
as a Category A Select Agent. There are four major subspecies of F. tularensis: F. tularensis 
subspecies tularensis, F. tularensis subspecies holarctica, F. tularensis subspecies 
mediasiatica, and F. tularensis subspecies novicida.  F. tularensis, F. holarctica (including 
the Live Vaccine Strain (LVS)) and F. novicida all cause a fulminate disease in mice that is 
similar to tularemia in humans (3).  There are clear differences in virulence between strains 
in mice.  F. novicida, F. holarctica and F. tularensis can have and LD50 of less than 10 
organisms in intranasally inoculated mice, while F. holarctica LVS LD50 in mice is much 
higher (4).   Each strain varies in its capacity to cause disease in humans.  F. novicida is 
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highly attenuated in humans, only causing disease in immuno-compromised individuals (5, 
6).  F. holarctica is highly infectious in humans, but causes a milder form of tularemia 
compared to F. tularensis. F. holarctica LVS is highly attenuated for disease in humans but 
can cause disease in immunocompetent individuals (1, 7, 8).  Though each strain has a 
different level of virulence in humans, they share high nucleotide sequence identity.   F. 
novicida shares 95% nucleotide sequence identity with F. tularensis and F. holarctica (9), 
suggesting that homologous proteins function via similar mechanisms.   
Key to F. tularensis’ virulence is its ability to escape the phagosome and replicate 
within the cytosol of host cells.  Previous studies have identified over 200 genes that are 
necessary for intracellular growth of F. tularensis (10-14). Some of the genes required for 
escape from the phagosome and intracellular growth reside within the Francisella 
pathogenicity island (FPI) (15).  The FPI is a set of 16 genes that are highly conserved among 
all subspecies of F. tularensis (15).  The FPI likely encodes a secretion system that is related 
to the recently discovered type VI secretion systems (T6SS) (16, 17). The T6SS is involved 
in the virulence of several bacterial pathogens (18-21).  Several regulators of FPI expression 
have been described. Two of the best studied are MglA and SspA, which positively regulate 
the transcription of FPI genes (22-24).  The mechanisms by which FPI proteins promote F. 
tularensis escape and intra-macrophage growth are unknown. There is evidence that 
translocated products of T6SS in other bacteria are capable of modulating host immune 
responses (18, 25-27). Though FPI gene products are clearly involved in phagosome escape 
and intracellular growth, the ability of these gene products to induce immunomodulatory 
responses has not been demonstrated to date.   
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PGE2 synthesis induced by LVS from host cells alters both innate and adaptive 
immune responses. We demonstrated that F. tularensis LVS was capable of inducing 
macrophages to synthesize PGE2 and that this was independent of intracellular growth of F. 
tularensis (28).  In vitro, LVS induced PGE2 synthesis inhibits T cell proliferation and skews 
their phenotypic development from IFN-γ+ T cells to IL-4+ T cells (28). Through an indirect 
mechanism PGE2, induces ubiquitin mediated degradation of MHC II which results in 
decreased MHC II protein levels on the surface of macrophages (29).  Decreased MHC II 
surface expression would decrease the antigenic stimulatory capacity of these macrophages, 
likely making them less capable of activating F. tularensis specific T cells.   T cells are 
required for both clearance of F. tularensis and generation of long-term immune protection 
(30), thus the biological activity of PGE2 would be beneficial to F. tularensis survival in vivo.  
LVS-induced PGE2 synthesis during respiratory tularemia inhibits the generation of 
beneficial T cell response. The inhibition of PGE2 synthesis in vivo by indomethacin leads to 
increased number of IFN-γ+ T cells and decreased bacterial burden (31). It is clear that 
induction of PGE2 synthesis is an important immune modulation mechanism utilized by F. 
holarctica to persist in the host.   
Presently, none of the F. tularensis product(s) responsible for the induction of PGE2 
synthesis in eukaryotic cells are known.  Several bacterial products have been identified that 
are capable of inducing PGE2 synthesis. Bacterial peptidoglycan, LPS, and CpG DNA can 
up-regulate prostaglandin synthesis through interactions with TLR2, TLR4, and TLR9 
respectively (32-36). It is not known if F. tularensis is capable of inducing PGE2 through a 
similar mechanism. To date, few F. tularensis TLR ligands have been identified.  F. 
tularensis LpnA and FTT1103 have been reported to be TLR2 ligands and DnaK a TLR4 
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ligand (37-39).  F. tularensis LPS fails to or only weakly stimulates a cytokine response by 
host cells (40, 41).  If F. tularensis LPS does stimulate host cells, it is likely in a TLR4 
independent manner. Both TLR2 and TLR4 deficient macrophages produce PGE2 after 
infection (Woolard et al. unpublished). 
In this study we demonstrate that along with LVS, F. novicida U112 (U112), and F. 
tularensis tularensis Schu S4 (Schu S4) induce PGE2 synthesis by macrophages. We tested a 
F. novicida (U112) comprehensive transposon mutant library to identify genes necessary for 
induction of PGE2 synthesis by infected bone marrow-derived macrophages.  This library 
allowed us to identify 20 genes that when disrupted result in U112 strains that are unable to 
induce the synthesis of PGE2 by infected macrophages. Identified genes included genes of 
the FPI and regulators of the FPI.  All genes identified are highly conserved among all 
sequenced strains of F. tularensis (17, 23, 42, 43).  We also demonstrate that the ability of F. 
novicida to induce PGE2 synthesis is likely not dependent on phagosome escape nor 
intracellular growth.  This work likely suggests that the FPI is involved in immune 
modulation along with previously established mechanisms of phagosomal escape and 
intracellular growth.   
 
MATERIALS AND METHODS 
Bacteria and mouse strains 
The F. tularensis subspecies holarctica LVS was obtained from ATCC (29684; 
American Type Culture Collection (Manassas, VA) (44), the F. tularensis subspecies 
novicida U112 strain was previously published (45), and the F. tularensis subspecies 
tularensis Schu S4 strain (catalog no. NR-643) was obtained from the Biodefense Emerging 
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Infections Research Resources Repository (Manassas, VA). The two allele transposon library 
was previously described (46).  For all studies, except for the original screen, F. novicida was 
propagated on tryptic soy agar supplemented with 0.1% cysteine while the F. novicida 
transposon mutants where propagated on the same agar with the addition of 20 µg/ml of 
kanamycin.  F. holarctica LVS and F. tularensis Schu S4 where propagated on chocolate 
agar.  Inocula were generated by collecting plate grown bacteria and diluting them in PBS to 
reach an OD600 of 1.00.  Inocula where then diluted into appropriate cell culture medium for 
inoculation.    
The F. novicida two allele transposon library was previously described (Gallagher et 
al., 2007).  The LVS ΔmglA, LVS ΔsspA, LVS ΔmglA pmglA, and LVS ΔsspA psspA were 
previously published (47). The dotU deletion construct was made by splice overlap extension 
PCR retaining the start and stop codons of dotU and fusing the first four and last two codons 
in frame and retaining 0.8 kb of flanking sequence. The constructs were cloned into the 
suicide vector pMP590 and sequenced to confirm the integrity of the DNA sequence. The 
LVS dotU mutant was generated by allelic exchange, selection for plasmid co-integrates, and 
counter selection on sucrose containing media to identify plasmid and dotU allele resolution 
as described (48). The following primers were utilized to generated the SOE fragment; 
FTL0119 5’ ext 5’-GAGTTTTTTCCACCTCTGAGGATGTTTC,  FTL0119 5’ int 5’-
GAAAGACTTTAAAGAGATAGAATAATAAGGGTAAGAGGAGATTTATATGAGTCA
GATAATATC,  FTL0119 3’ int 5’-CTCCTCTTACCCTTATTATTCTATCTCTTTAAAGT 
CTTTCATTTATAATATCCTTTATATAGAG, FTL0119 3’ ext 5’-CATACATATTTAACC 
AAGTATTAGAAGATAATGGCTCAG.  Loss of the wild type and retention of the deletion 
dotU alleles were confirmed by PCR.  Since dotU is duplicated in the LVS genome, a second 
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round of mutagenesis was performed on the single dotU mutant strain to create an LVS dotU 
double deletion strain. Plasmids for complementation were created by ligating cloned region 
of dotU into the PKK MCS plasmid. dotU expression from the PKK MCS plasmid was 
regulated by the putative PI promoter.  The following primers were used: FTL0119 forward 
5’-CTTAATTAAATGAAAGACTTTAAAGAGATAGAAATTATTCTAGATATTATAA 
AAC, FTL0119 reverse 5’-TGTCGACCCAGCTTAATAAAATTAGTAAGCTTAAAAGA 
AACAGTC.   
C57Bl/6J (B6) mice were purchased from the Jackson Laboratory (Bar Harbor, ME).  
All animals used in this study were maintained under specific pathogen-free conditions in the 
American Association of Laboratory Animal Care-accredited University of North Carolina 
Department of Laboratory Animal Medicine Facilities or American Association of 
Laboratory Animal Care-accredited Louisiana State University Health Science Center at 
Shreveport Animal Medicine Facilities. All work was approved by each facility’s Animal 
Care and Use Committee (UNC #04-200, LSUHSC P10-010). 
Generation of bone marrow-derived macrophages 
Bone marrow cells from B6 mouse femurs were cultured in 30% L cell conditioned 
medium as previously described (28). Briefly bone marrow cells were flushed from B6 
mouse femurs and incubated for 7 days on nontissue culture-treated 15-cm2 dishes with L 
cell-conditioned medium as a source of GM-CSF. Following differentiation, nonadherent 
cells were removed by multiple washes with PBS and bone marrow-derived macrophages 
were removed from plates by incubation with 10 mM EDTA in PBS. Since L cell condition 
media and FBS batches can affect the amount of PGE2 induction by infected macrophages 
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we utilized the same L cell conditioned media and FBS batches for each series of 
experiments to minimize variability in PGE2 synthesis between experiments.   
Bone marrow-derived macrophage infections 
BMDM were plated in 96 well flat bottom plates (105/well).  Macrophages were 
allowed to adhere for two hours.  Macrophages were mock infected or infected with LVS, 
Schu S4, U112, or U112 transposon insertion strains at different MOIs as indicated.  Bacteria 
were centrifuged onto the macrophage monolayer at 300 g for 5 min to allow closer contact 
and more efficient infection.  Two hours after inoculation, extracellular bacteria were killed 
by the addition of 50 µg/ml of gentamicin for 45 minutes.  Supernatants were removed and 
cells were washed with antibiotic free complete medium.  Fresh antibiotic free complete 
medium was added and cells were incubated for 24 hours.  Supernatants were then collected 
and spun at 300 g for 10 minutes to remove eukaryotic cells.  Supernatants were sterilized by 
UV.  Representative supernatants were plated onto chocolate agar after UV treatment to 
ensure complete killing of F. tularensis.  Supernatant was then stored at -80o C until needed. 
Identification of transposon insertion strains 
The transposon library has previously been described (46).  In brief, the 3,050-
member library includes two insertion alleles for 1488 genes the majority of total Francisella 
ORFs. The alleles chosen were primarily insertions positioned between 5% and 70% within 
the ORF and are thus likely to represent null mutations.  After single-colony purification, the 
mutants were arrayed in 96-well format and sequence-mapped to confirm their identities.  
See table 2 of (46) for the summary of this information.    
The two allele mutant library was screened in a 96 well format.  Transposon insertion 
strains were grown up in 96 well deep well plates containing 1 ml of Tryptic Soy broth 
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containing 15µg/ml carbenicillin, 20 µg/ml kanamycin, and supplemented with 0.1% l-
cysteine-HCl.  After over-night growth an aliquot of supernatants from each transposon 
insertion strain was taken and OD600 was determined.  MOI were normalized by average 
plate OD600.  B6 BMDM was inoculated at an MOI of 500:1 to guarantee sufficient inocula 
in each well to induce PGE2 synthesis.  In our experience increasing MOI inocula increases 
the number of macrophages infected. Twenty four hours after inoculation supernatants were 
collected and then stored at -80oC until needed.   
PGE2 assay 
PGE2 in cell culture supernatants was measured using a commercial PGE2 enzyme 
immunoassay kit (Assay Design, Ann Arbor, MI) as per manufacturer’s instructions. 
Transposon insertion strains were deemed defective in the ability to induce of PGE2 when the 
levels of PGE2 by any transposon insertion strain were 3 standard deviations below the mean 
of the entire plate. 
Bacterial growth assay 
Macrophages were mock infected or infected with U112, U112 clpB::Tn, U112 
pdpA::Tn, or U112 iglC::Tn strains at an MOI of 100:1.    At 4 and 24 hours post-inoculation, 
supernatants were removed.  100 µl of 0.05% sodium dodecyl sulfate in PBS was used to 
lyse the BMDM. Samples were transferred to tubes containing 900 µl PBS and vortexed on 
high setting for one minute.  Samples were serially diluted and plated on chocolate agar to 
determine bacterial numbers.  
Confocal and transmission electron microscopy  
J774.1 macrophages (from ATCC #TIB-67) were seeded on coverslips at a density of 
6x105 cells/well.  Prior to infection, bacteria were carboxyfluorescein succinimidyl ester 
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(CFSE) labeled as previously described (49) with the following modifications:  CFSE was 
added to bacteria at a final concentration of 5 µM and incubated for 20 minutes at 37˚C.  
Macrophages were inoculated with CFSE-labeled U112, U112 clpB::Tn, U112 pdpA::Tn, or 
U112 iglC::Tn mutants at an MOI of 200:1.  Bacteria were centrifuged onto the macrophages 
at 300 g for 5 min.  Two hours after inoculation, extracellular bacteria were killed by the 
addition of 25 µg/ml of gentamicin for 45 minutes and then media was replaced with 
antibiotic free media.  At four hours post-inoculation, LAMP-1 association with bacteria was 
determined as previously described (50).  Briefly, wells were washed with PBS and fixed for 
20 minutes at room temperature with 2% (w/v) formaldehyde and 1% (w/v) sucrose in PBS.  
Cells were permeabilized using methanol.  Coverslips were blocked with 5% bovine serum 
albumin, incubated overnight at 4oC with anti-mouse LAMP-1 (1D4B eBioscience), washed 
three times with PBS, and stained with donkey anti-rat IgG Alexafluor594 secondary 
antibody (Invitrogen) for two hours at room temperature.  After three PBS washes, the 
coverslips were mounted in DAPI-containing mounting media (Vector Laboratories, Inc.) to 
label the DNA.  Cells were imaged using a Leica SP2 Laser Scanning Confocal Microscope 
using a 63x oil immersion lens.  A minimum of 20 cells per strain were captured.  To remove 
subjectivity in determining co-localization of bacteria with LAMP-1 images were analyzed 
using Volocity software (Improvision/Perkin Elmer) to determine bacterial association with 
LAMP-1. Co-localization was determined by the shared of red and green pixels at the same 
location.  To determine whether a bacterium resided in a LAMP-1 positive vesicle, the voxel 
spy tool was used closely examine whether the LAMP-1 red pixels surrounded the CFSE 
green pixels that labeled the bacterium.  If the red pixels surrounded greater than 50% of the 
green pixels, the bacterium was categorized as residing within a LAMP-1+ vesicle. 
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B6 BMDMs were inoculated with U112, U112 clpB::Tn, U112 iglC::Tn, or U112 pdpA::Tn 
at an MOI of 500:1 at an MOI of 500:1 to maximize the number of infected BMDMs.  2 
hours after inoculation, the media was removed and replaced with media containing 50 
μg/mL gentamicin (Sigma-Aldrich, St. Louis, MO).  Gentamicin-containing media was 
removed 1 hour after treatment and replaced with antibiotic-free media.  4 hours post-
inoculation, the BMDM monolayer was fixed using gluteraldehyde and post-fixed with 
osmium tetroxide.  Images were obtained using a Phillips CM-12 transmission electron 
microscope using 25,000x magnification.      
Statistical analysis 
Student’s t tests were used for statistical analysis between two group experiments. 
Multi group comparisons were done by ANOVA followed by Dunnett’s Multiple 
Comparison Test. When appropriate, data were logarithmically transformed before statistical 
analysis and confirmed by a demonstrated increase in power of the test after transformation 
of the data.  Data analysis on the rescreen (figure 2) was accomplished by one-way ANOVA 
analysis followed by Student’s t test. A p value ≤ 0.05 was considered statistically 
significant. 
 
RESULTS 
F. tularensis subspecies novicida and tularensis induced the synthesis of PGE2 by 
infected macrophages 
We have previously demonstrated that F. tularensis subspecies holarctica LVS 
induces PGE2 synthesis in infected macrophages. To enable the use of the two allele 
transposon mutant library we needed to determine if the ability to induce PGE2 synthesis by 
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infected macrophages is shared among Francisella subspecies. We tested both F. novicida 
U112 and F. tularensis Schu S4 for their ability to induce B6 bone marrow-derived 
macrophages (BMDM) to synthesize PGE2 upon infection.  We inoculated BMDM with 
LVS, U112, or Schu S4 at an MOI of 100:1.  All strains tested were capable of inducing 
synthesis of PGE2 by infected macrophages (figure 1).  This demonstrates that the ability to 
induce PGE2 synthesis is conserved among F. tularensis strains. 
Screening the two allele mutant library identifies several genes necessary for the 
Francisella induction of PGE2 by infected macrophages 
Since we demonstrated that U112 induced macrophage synthesis of PGE2, we used 
the F. novicida two allele transposon mutant library (46) to identify mutants that were unable 
to induce PGE2 synthesis.  During the initial testing of the 3050 F. novicida U112 transposon 
mutants, we defined a F. novicida U112 transposon mutant as defective in induction of PGE2 
synthesis by infected BMDM when BMDM produced relative PGE2 amounts that were three 
standard deviations lower than the plate average amount of PGE2.  The use of the three 
standard deviation rule allowed us to minimize the likelihood (0.3%) of identifying false 
positives.   The initial screen identified 33 genes that when disrupted made F. novicida 
unable to induce PGE2 synthesis by infected macrophages.  This included 10 genes located in 
the FPI.  We retested all U112 transposon insertion mutants with transposon insertions in the 
identified 33 genes.  Furthermore, since the initial screen identified 10 genes of the FPI, we 
included all FPI transposon mutants within the two allele transposon mutant library in this 
rescreen to ensure these genes important in pathogenesis were carefully evaluated.  BMDM 
were inoculated with individual transposon insertion strains (89 mutants representing the 
original 33 genes identified and 10 genes from the FPI not originally identified) at an MOI of 
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200:1 and PGE2 levels were measured 24 hours post-inoculation (figure 2).  We utilized an 
MOI of 200:1 since we have previously demonstrated this MOI results in a reproducible 
significant increase in detectable PGE2 from infected macrophages (28).  Each U112 
transposon mutant was tested a minimum of four times. No difference was noted between 
strains with insertions in the same gene; as such the values were combined for representation 
in figure 2. We were able to confirm 20 genes that when disrupted resulted in F. novicida 
strains that did not induce the synthesis of PGE2 by infected BMDM (figure 2).  With the 
exception of mglA and rpoB, which were only represented once, each gene identified encodes 
a product involved in the induction of PGE2 that was represented at least twice in the U112 
two allele transposon mutant library. The genes identified in the screen of the two allele 
mutant library are summarized in Table 1. The identified genes were located in the FPI or 
were genes that encode some of the previously identified regulators of the FPI (sspA, mglA, 
mglB, and trmE) with the exception of rpoB and clpB (17, 22, 23, 42, 51).  These genes are 
highly conserved in all F. tularensis subspecies sequenced to date (17, 23, 42, 43). Of note: 
not all genes encoded within the FPI are necessary for U112 induced PGE2 synthesis as 
pdpA::Tn, pdpD::Tn, and pdpE::Tn were able to induce PGE2 synthesis similarly to wild type 
U112.  Thus the screen identified 20 F. novicida genes that are necessary for the induction of 
PGE2. 
F. tularensis LVS mutant strains with deletions of mglA, sspA or dotU do not induce 
PGE2 synthesis from infected macrophages 
To begin to address if the genes identified in U112 also encode products that 
contribute to LVS to induce PGE2 synthesis by infected macrophages we utilized clean 
deletion mutants. Two of the genes identified in the screen of the two allele library, U112 
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mglA::Tn and U112 sspA::Tn, encode positive transcriptional regulators (22-24).  We also 
identified several genes of the FPI, including dotU. DotU is necessary for stabilization of the 
FPI secretion apparatus, and mutants lacking dotU do not have a functional FPI secretion 
system (52).   To examine the possibility that LVS mutants lacking mglA, sspA or dotU do 
not to induce PGE2 synthesis, we tested these mutant strains for induction of PGE2 synthesis 
by BMDMs.  BMDM were inoculated with LVS, LVSΔmglA, LVSΔmglA (pmglA), 
LVSΔsspA, LVSΔsspA (psspA), LVSΔdotU, or LVSΔdotU (pdotU) at an MOI of 200:1.  
Twenty-four hours after inoculation the levels of PGE2 were determined.   Neither 
LVSΔmglA, LVSΔsspA nor LVSΔdotU mutant strains induce significant PGE2 synthesis 
from infected macrophages (figure 3).  This phenotype was reversed by trans 
complementation with the appropriate plasmid (figure 3) suggesting that U112 and LVS 
induce PGE2 synthesis through similar mechanisms.  
Dissociation of intracellular growth and induction of PGE2 by Francisella 
Escape from the phagosome and replication in the cytosol of host cells are critical for 
F. tularensis survival.  All of the genes identified in this screen have been identified in other 
screens examining disease pathogenesis and intracellular growth (10-12, 14, 53, 54).  Thus, it 
may be that failures to either escape the phagosome or replicate explains why these F. 
novicida mutants did not to induce PGE2 synthesis. Previous studies that examined infection 
of macrophages by F. novicida pdpA::Tn and ΔpdpA strains demonstrated that PdpA is 
required for escape from the phagosome (50, 55).  Similarly, IglC has been shown to be 
required for F. novicida and F. holarctica phagolysosomal escape (56, 57).  In contrast, F. 
holarctica mutants with a transposon insertion in clpB escape the phagosome and replicate 
(43).  The characterization of the trafficking phenotypes of Francisella strains with mutations 
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in clpB, pdpA, and iglC suggested we could use the two allele mutant library clpB::Tn, 
pdpA::Tn, and iglC::Tn mutant strains as tools to investigate the requirement of escape and 
intracellular growth for PGE2 induction. We understand these experiments do not prove that 
these genes are necessarily involved in the induction of PGE2, but rather eliminate or confirm 
if either the act of escaping the phagosome or replicating in the cytosol is what is necessary 
and sufficient to induce PGE2 synthesis in macrophages.     
To determine the intracellular localization of these strains, we inoculated the J774.1 
macrophage cell line, as we and others have successfully used this cell line in the past to 
examine intracellular localization of F. tularensis (48, 58), at an MOI of 500:1 with CFSE 
labeled U112, U112 clpB::Tn, U112 iglC::Tn, and U112 pdpA::Tn and examined their 
association with LAMP-1 using confocal microscopy (figure 4).  A high MOI was used to 
ensure our ability to identify intracellular bacteria and their respective intracellular 
localization.  We confirmed that U112 infected J774 cells synthesize increased amounts of 
PGE2 upon both U112 and LVS infection compared to uninfected samples (data not shown).   
We analyzed the associations of bacteria and LAMP-1 using Volocity image software and 
showed the percentage of bacteria associated with LAMP-1 by pixel association (figure 4a).   
We found only 34% of U112 remained associated with LAMP-1 four hours post-inoculation.  
Similarly, 34% of U112 clpB::Tn remained associated with LAMP-1 four hours post-
inoculation.  In contrast, U112 iglC::Tn and U112 pdpA::Tn resided mainly in the 
phagosome four hours post-inoculation displaying 71% and 70% LAMP-1 association, 
respectively.  We confirmed the intracellular localization of U112 clpB::Tn, U112 iglC::Tn, 
and U112 pdpA::Tn by transmission electron microscopy (figure 4b)  These data indicate 
U112 clpB::Tn, U112 iglC::Tn, and U112 pdpA::Tn have intracellular trafficking patterns 
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that are similar to those of previously published clpB, iglC, and pdpA transposon insertion 
strains (43, 50, 55-57).  As noted above, these data show that the U112 pdpA::Tn mutant is 
able to induce PGE2 even though it was diminished in its ability to escape the phagosome.  If 
PGE2 synthesis induction required phagosomal escape, we would expect U112 pdpA::Tn 
would not induce PGE2 synthesis, as seen with U112 iglC::Tn. However, pdpA::Tn does 
induce PGE2 at similar levels to wild-type U112 (figure 2).Thus our data suggest PGE2 
induction is unaffected by intracellular trafficking/localization.   
To determine if intracellular growth was required for F. novicida induction of PGE2 
synthesis we inoculated BMDM at an MOI of 100:1 with U112, U112 clpB::Tn, U112 
pdpA::Tn, and U112 iglC::Tn and counted intracellular CFUs over time. We used an MOI 
100:1 to maximize differences in intracellular CFUs at 4 and 24 hours post-inoculation.  At 
higher MOIs extensive cell death of BMDMs by 24 hours post-inoculation made it difficult 
to measure intracellular growth (data not shown).  The number of intracellular bacteria was 
determined at 4 and 24 hours post-inoculation, while the concentration of PGE2 in 
supernatants was determined at 24 hours post-inoculation.  The U112 clpB::Tn strain grew 
within BMDM similarly to wildtype U112, while the U112 pdpA::Tn and U112 iglC::Tn 
strains failed to grow in BMDM (figure 5).  In fact, there were fewer intra-macrophage U112 
pdpA::Tn and U112 iglC::Tn bacteria at 24 hours post-inoculation than at 4 hours post-
inoculation.  Wild type U112 and U112 pdpA::Tn were able to induce PGE2 synthesis, while 
U112 clpB::Tn and U112 iglC::Tn did not.  The fact that pdpA::Tn induced PGE2 synthesis 
without intra-macrophage growth and clpB::Tn did not induce PGE2 synthesis while still able 
to grow in the macrophage demonstrates dissociation between intracellular growth and the 
ability of F. novicida to induce infected BMDM to synthesize PGE2.       
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 DISCUSSION 
The induction of PGE2 synthesis by LVS infected macrophages disrupts T cell 
responses allowing LVS to persist in the host (28, 31).  We demonstrate here that induction 
of PGE2 synthesis by infected bone marrow-derived macrophages is conserved among F. 
novicida, F. holarctica, and F. tularensis.  Synthesis of PGE2 by U112 infected macrophages 
allowed us to screen the comprehensive U112 two allele transposon mutant library to identify 
Francisella genes that are potentially involved in the induction of PGE2 synthesis by 
Francisella infected macrophages.  Our screen identified 20 genes that when disrupted 
resulted in strains that failed to induce PGE2 synthesis by F. novicida infected BMDM. These 
20 genes are highly conserved in all sequenced Francisella subspecies (17, 23, 42, 43).   
Eighteen of the genes identified in this study either mapped to the FPI or represent positive 
transcriptional regulators of the FPI (17).  17 of the 20 identified genes have been 
demonstrated to be involved in mouse virulence (14, 54). Most, but not all of these genes, 
encode proteins that have been implicated in escape from the phagosome and intracellular 
growth (14, 54).  The data presented here suggest these gene products may be responsible for 
the induction of PGE2 biosynthesis in infected BMDM independent of their role in 
phagosomal escape and intracellular growth.   
The FPI likely encodes a secretion system. The FPI proteins PdpB, VgrG, DotU, 
IglA, and IglB proteins are homologous to T6SS proteins from other bacterial pathogens (16, 
52, 59, 60).   The FPI was initially identified in F. novicida via mutations in iglA and iglC 
that resulted in F. novicida strains that no longer replicated within macrophages (61).  Recent 
work has identified the FPI genes that encode proteins required for intracellular growth  and 
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include pdpA, pdpB, dotU, vgrG, iglABCDEFHJ, and potentially iglG and iglI  (56, 59, 62-
66).  The genes pdpC, pdpD, pdpE, and anmK are not required for intracellular growth (59).  
Our screen demonstrated that disruptions in FPI genes dotU, vgrG, pdpBC, and 
iglABCGEDFGHIJ resulted in U112 strains unable to induce PGE2 synthesis by infected 
macrophages.  At this time we are unsure whether all gene products are necessary, or 
whether some mutants where identified due to polar effects of transposon insertions.  This is 
possible as the FPI is believed to be organized in  two operons (17).  Future work will be 
necessary to define which FPI gene products are truly necessary for induction of PGE2 
synthesis from infected macrophages. Disruptions in pdpADE and anmK did not impair the 
bacteria’s ability to induce synthesis of PGE2. We were  not surprised that pdpD and anmK 
mutants are not impaired, as we believe the mechanism of induction of PGE2 synthesis is 
conserved between Francisella strains.  The anmK gene is not present in LVS while the 
pdpD is truncated in LVS and presumably nonfunctional (16).  The deletion of pdpE from F. 
novicida had no effect on the bacteria’s ability to grow in macrophages or cause disease. At 
this time the role of PdpE in FPI function is unknown (59).  PdpA is involved in both 
intracellular growth and virulence. However PdpA is not believed to be a component of the 
FPI secretion system (50, 55) which may explain why the pdpA::Tn mutant is still capable of 
inducing PGE2 synthesis.  Some of the transposon mutants (pdpE::TN, pdpD::Tn, and 
anmK::Tn) were capable of inducing enhanced PGE2 secretion from infected macrophages.  
The mechanism behind this is unknown and future work will be done to examine this 
phenomenon.   Regardless, it is clear that disruption of F. novicida’s genes in the FPI 
diminishes its ability to induce PGE2 synthesis from infected macrophages. 
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There are 6 genes located outside of the FPI that when disrupted resulted in strains 
unable to induce the synthesis of PGE2 from U112 infected macrophages.  Four of those 
(trmE, sspA, mglA, and mglB) have previously been identified to encode positive 
transcriptional regulators of genes found both in FPI and outside the FPI (22-24, 42, 50, 55). 
The work of the Dove laboratory has clearly identified other transcriptional regulators which 
include CaiC, CphA, PigR, and SpoT in F. tularenisis LVS(42). The two allele mutant 
library lacks transposon insertional mutants in spoT and pigR, while the caiC  and the cphA  
transposon mutant strain induced PGE2 synthesis from macrophages.  This result suggests 
differential transciprional regulation of the FPI between U112 and LVS; however future 
work would be required to corroborate this observation.  RpoB is a component of the RNAP 
catalytic core responsible for the transcription of genes (67).  The U112 rpoB::Tn was likely 
identified due to a general disruption of transcription.  The fact the rpoB::Tn mutant failed to 
induce PGE2 synthesis would predict finding other components of the RNAP catalytic core.  
However, the two allele library did not contain mutants with transposon insertions in either 
rpoA or rpoD, while rpoC::Tn and rpoZ::Tn mutants strains induced PGE2 synthesis.  ClpB, 
a stress response protein, has been previously demonstrated to be important in Francisella 
disease pathogenesis.  A U112 clpB mutant was identified due to a delay in intramacrophage 
growth, while a disruption of clpB in F. holarctica LVS resulted in a strain that could grow 
in vitro in macrophages, but failed to effectively multiply in mice (43, 61). We did not 
observe a intramacrophage growth defect of the the two allele clpB::Tn.   In Listeria 
monocytogenes and Porphyromonas gingivalis, ClpB homologs are necessary for virulence 
during animal infections (68, 69).  ClpB/ClpV homologs have been identified in other T6SS 
where their AAA+ ATPase activity supply energy for the protein secretion process (19, 21, 
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70, 71).  ClpB regulates the protein levels of DnaK, FTL_0525, FTL_0311, FTL_0588, and 
FTL_0207 (43).  Since none of these genes were identified as necessary for induction of 
PGE2 synthesis, it would suggest ClpB may have other unidentified functions.   It has not 
been demonstrated to regulate the protein levels of the FPI.  Future work will be needed to 
define the mechanism of ClpB mediated induction of PGE2 synthesis from infected 
macrophages, and whether this is through regulation of FPI genes, function of FPI gene 
products, or through a FPI independent mechanism.   
Infection of macrophages with U112, LVS, or Schu S4 results in the induction of 
PGE2.  This demonstrates that the ability to induce PGE2 synthesis from infected 
macrophages is conserved among F. tularensis subspecies.  In fact, U112 and Schu S4 
induce more PGE2 than LVS at similar doses. This difference in PGE2 induction may be 
partially responsible for difference in virulence in these different subspecies.  While we have 
previously demonstrated differences in innate immune responses to Schu S4, LVS, and U112 
in intranasally inoculated mice, it is unknown if these different responses are due to 
differences in PGE2 induction (72). Further work will address this difference in PGE2 
induction and the potential effect of PGE2 on disease pathogenesis.  The demonstration that 
inactivation of FPI genes in F. novicida results in the inability to induce PGE2 biosynthesis 
and the fact that the FPI is highly conserved among all subspecies of F. tularensis would 
suggest that the mechanism of PGE2 induction is conserved among these subspecies. The fact 
that LVS mglA, sspA and dotU mutant strains did not induce PGE2 synthesis further suggests 
the likelyhood that F. tularensis subspecies tularensis, F. tularensis subspecies holarctica, 
and F. tularensis subspecies novicida have conserved mechanisms of induction of PGE2 
synthesis.  However, we cannot discount the possibility that F. tularensis subspecies 
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tularensis may possess additional mechanisms for induction of PGE2 synthesis that F. 
novicida or F. holarctica do not.   
The FPI is necessary for the organism to escape the phagosome and replicate in the 
cytosol (59, 64-66).  The reason the transposon insertion mutants we identified in U112 
failed to induce PGE2 synthesis may be due to their failure to escape the phagosome and 
subsequently replicate.  Failure to escape the phagosome may create a physiologic barrier 
between F. tularensis and the eukaryotic molecule that is responsible for sensing and 
responding to F. tularensis.  There are many intracellular receptors that can recognize 
bacterial products (73).  ASC, a component of the inflammasome, and AIM2 (which 
recognizies F. tularensis DNA) are crucial for control of Francisella intra-macrophage 
growth in vitro and infection in vivo (74-76).  Inflammasome activation is also capable of 
inducing eicosanoid production (77). However, we believe that failure to escape into the 
cytosol is not the reason the transposon insertion mutant strains we identified in this study 
failed to induce PGE2 synthesis by infected macrophages.  In other studies, pdpA::Tn and 
ΔpdpA F. novicida mutants fail to fully escape the phagosome (50, 55, 76).  The U112 
pdpA::Tn strain in the U112 two allele mutant library does not escape the phagosome to the 
same level as wildtype U112.  Recently, 92 transposon mutant strains from the two allele 
mutant library were identified that did not  escape the phagosome (10). We showed all of 
these strains were able to induce PGE2.  Thus it is unlikely that the mutants we did identify 
failed to induce PGE2 solely because they failed to escape from the phagosome.    Future 
work that identifies both the F. tularensis effector molecule and the corresponding eukaryotic 
binding partner will allow us to more definitively dissociate F. tularensis trafficking and 
induction of PGE2 synthesis from Francisella infected macrophages.  
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Previous studies have identified 201 genes outside the FPI that are required for 
Francisella intra-macrophage growth (10, 11, 13, 53).  U112 strains with insertions in any 
one of these 201 genes were all capable of inducing PGE2 synthesis from infected 
macrophages.  We did not identify known F. tularensis auxotrophs as being defective in the 
ability to induce PGE2.  Transposon insertions in purA, purF, carA, carB, and pyrB produce 
strains that have a defect in intracellular growth yet are able to induce macrophage synthesis 
of PGE2 (53, 78, 79).  Our studies using U112, U112 clpB::Tn, U112 pdpA::Tn, and U112 
iglC::Tn strains demonstrate dissociation between intra-macrophage growth, the ability of F. 
tularensis to fully escape the phagosome, and the ability to induce PGE2.  These data also 
confirm our earlier report that UV inactivation of LVS, which inhibits replication, did not 
impact LVS’s ability to induce PGE2 synthesis from infected macrophages (28).  Further 
characterization and understanding of the molecular interactions between F. tularensis and 
eukaryotic cells that lead to the induction of PGE2 will provide new insight into tularemia 
pathogenesis.   
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Figure 1
Figure 1. LVS, U112 and Schu S4 induces the synthesis of PGE2 from bone marrow-
derived macrophages.   Bone marrow-derived macrophages were either mock inoculated 
or inoculated with LVS, U112, or Schu S4 at an MOI of 200:1.  24 hours after inoculation 
supernatants were collected and PGE2 concentration was determined.  Data represents three 
independent experiments and expressed as the mean ± standard error. * denotes statistical 
difference (p≤0.05) from uninfected BMDM.
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Figure 2
Figure 2. Identification of U112 genes necessary for the induction of PGE2 from bone 
marrow-derived macrophages.  Bone marrow-derived macrophages were inoculated with 
U112 or individual transposon insertion strains at an MOI of 200:1. 24 hours after 
inoculation, supernatants were collected and PGE2 concentration was determined.  Each 
transposon insertion mutant strain was tested 4 times. Bars represent the mean of all 
independent transposon insertions mutants within the same gene ± standard error. * 
denotes statistical difference (p≤0.05) from U112 inoculated BMDM. 
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Table 1
Table 1. Genes required for Francisella induction of PGE2 
synthesis in Francisella infected macrophages. 
ORF Gene  Function (postulated) 
FTN_0549 sspA Regulate virulence genes 
FTN_1290 mglA Regulate virulence genes 
FTN_1291 mglB Regulate virulence genes 
FTN_1298 trmE tRNA modification, GTPase activity 
FTN_1310 pdpB Unknown 
FTN_1311 iglE Unknown 
FTN_1312 vgrG Secreted 
FTN_1313 iglF Unknown 
FTN_1314 iglG Unknown 
FTN_1315 iglH Unknown 
FTN_1316 dotU Unknown 
FTN_1317 iglI Unknown 
FTN_1318 iglJ Unknown 
FTN_1319 pdpC Unknown 
FTN_1321 iglD Replication in cytosol 
FTN_1322 iglC Escape from phagosome 
FTN_1323 iglB Unknown 
FTN_1324 iglA Unknown 
FTN_1568 rpoB DNA directed RNA polymerase subunit beta 
FTN_1743 clpB Chaperone, ATPase activity 
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Figure 3
Figure 3.  mglA, sspA,  and dotU are necessary for LVS induction of PGE2 synthesis.  
Bone marrow-derived macrophages were inoculated with LVS, LVSΔsspA, LVSΔsspA 
(psspA), LVSΔmglA, LVSΔmglA (pmglA), LVSΔdotU, or LVSΔdotU (pdotU) at an MOI 
of 200:1.  24 hours after inoculation the levels of PGE2 were determined. Samples were 
analyzed in triplicate.  Data represents three independent experiments and expressed as the 
mean ± standard error.  * denotes statistical difference (p≤0.05) from LVS inoculated 
BMDM.
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Figure 4
Figure 4.  Induction of PGE2 does not require full escape from the phagosome.  A) 
Bacterial association with LAMP-1 was scored using Volocity (n= at least 20 imaged cells 
per strain with an average of one bacterium per macrophage). Co-localization was 
determined by the shared of red and green pixels at the same location.  Data represents 
three independent experiments and expressed as the mean ± standard error. *, denotes 
statistical difference (p≤0.05) from U112 infected cells. B) BMDMs were inoculated with 
U112, U112 clpB::Tn, U112 iglC::Tn, or U112 pdpA::Tn at an MOI of 500:1. Association 
of the bacterium with the phagosomal membrane was determined 4 hours post-inoculation 
using transmission electron microscopy.  Open arrowheads denote bacteria no longer 
surrounded by an intact phagosomal membrane.  Filled arrowheads denote bacteria 
surrounded by a phagosomal membrane.
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Figure 5
Figure 5.  Dissociation of intracellular growth and the induction of PGE2 from bone 
marrow-derived macrophages. A) Bone marrow-derived macrophages were inoculated 
with U112 , U112 clpB::Tn, U112 iglC::Tn, or U112 pdpA::Tn at an MOI of 100:1.  CFU 
were determined at 4hr and 24hr post-inoculation. Data represents three independent 
experiments and expressed as the means ± standard error. * denotes statistical difference 
(p≤0.05) from corresponding 4 hour sample. # BMDM denotes statistical difference (p≤ 
0.05) from 24 hour U112 infected BMDM (n=3).  B) Bone marrow-derived macrophages 
were inoculated with U112 , U112 clpB::Tn, U112 iglC::Tn, or U112 pdpA::Tn at an MOI 
of 100:1.  24 hours after inoculation supernatants were collected and PGE2 concentration 
was determined.  Data represents three independent experiments and expressed as the 
mean ± standard error. * denotes statistical difference (p≤0.05) from U112 infected 
BMDM.
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CHAPTER 6 
CONCLUDING REMARKS 
 
Survival of bacteria, viruses, fungi, and parasites has required these organisms to 
evolve sophisticated mechanisms to evade and/or subvert host immunity.  The host’s immune 
response is not singly focused; therefore, pathogens must evade many potential assaults from 
the host and have accordingly developed multiple mechanisms to do so.  These mechanisms 
are shared among organisms, allowing the study of one pathogenic organism to provide 
insight into how similar organisms also evade host immunity.  The study of host-pathogen 
interactions, specifically immune evasion, increases our understanding of pathogenicity as 
well as identifies critical aspects of host immunity necessary for pathogen clearance and the 
development of protective immunity.  These studies are increasingly important as the human 
population continues to encounter existing and emerging pathogens to which new therapies 
and/or vaccines must be developed to successfully combat infection.      
  Francisella tularensis utilizes a variety of immune evasion strategies to suppress or 
evade both the host’s innate and adaptive immune response.  Our laboratory is particularly 
interested in the immune consequences of prostaglandin E2 (PGE2) production following F. 
tularensis subsp. holartica live vaccine strain (LVS) infection.  We identified 20 genes 
necessary for the induction of PGE2 synthesis and secretion by F. novicida U112 in bone 
marrow-derived macrophages.  We also determined that PGE2 induction does not require the 
U112 to escape the phagosome.  These data are presented in Chapter 5 and were published in 
Frontiers in Microbiology in 2013 (1).  One of the genes necessary for inducing PGE2 
synthesis and secretion is clpB.  ClpB is a conserved chaperone protein of the AAA+ family 
of ATPases.  We hypothesized LVS clpB would be attenuated in vivo because a more robust 
IFN-γ-mediated adaptive immune response would form in the absence of PGE2-mediated 
suppression.  Importantly, LVS clpB does not have an intracellular growth defect compared 
to wild-type LVS.  Intranasal inoculation with LVS clpB revealed this strain was attenuated.  
While we did observe decreased PGE2 concentrations in the BALF of LVS clpB infected 
mice compared to LVS infected mice, LVS clpB induced altered innate and adaptive 
immunity as well.  LVS clpB fails to suppress early pro-inflammatory cytokine production in 
the lung following intranasal inoculation, in stark contrast to LVS inoculation.  The adaptive 
immune response in LVS and LVS clpB mice was similar in terms of the frequency of 
responding cells, but T cells from LVS clpB infected mice produced more IFN-γ and IL-17A 
as measured by mean fluorescent intensity.  Despite its attenuation, LVS clpB induces a 
protective immune response.  Because LVS clpB does not have an intracellular growth 
defect, we attribute its attenuation to the failure to suppress host immunity.  Our work 
revealed a new class of bacterial attenuation caused by altered host immunity and identified 
clpB as a gene necessary to suppress early pro-inflammatory cytokine production by the host.  
These data are presented in Chapter 2 and were published in Infection and Immunity in 2013 
(2).     
 The altered adaptive immune response in LVS clpB infected mice raised the 
possibility that the secondary immune response in LVS and LVS clpB infected mice could be 
different.  We therefore characterized the T cell response in mice previously infected with 
LVS or LVS clpB during a lethal challenge with LVS.  Mice vaccinated with LVS and LVS 
clpB had similar secondary T cell responses that were exclusively IFN-γ-mediated.  During 
primary intranasal infection, Th17 cells significantly expand in the lung but were not 
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detectable during the secondary response in numbers greater than unvaccinated mice.  We 
therefore used monoclonal antibody treatment to deplete either IFN-γ or IL-17A during the 
secondary response to determine the importance of these cytokines for survival during a 
lethal infection.  Vaccinated mice treated with anti-IFN-γ had significantly higher bacterial 
burdens than isotype treated vaccinated mice, indicating IFN-γ was critical for controlling the 
infection.  Anti-IL-17A depletion in vaccinated mice had no impact on bacterial burdens 
indicating IL-17A is dispensable during a secondary infection.  These studies contributed to 
our knowledge of the secondary immune response during pneumonic tularemia and revealed 
that while IL-17A is necessary during the primary response to intranasal LVS infection, it is 
dispensable for protection during re-infection. 
 Finally, we sought to identify early interactions between Francisella and the host 
following intranasal or intradermal inoculation.  Intranasal and intradermal inoculation with 
LVS induces two different adaptive immune responses despite similar bacterial burdens in 
the lung and spleen early after inoculation.  We hypothesized that the adaptive immune 
response was shaped by events occurring early after inoculation.  We therefore sought to 
identify the cell types infected with Francisella in the lung and skin after intranasal or 
intradermal inoculation, respectively.  Alveolar macrophages are infected in the lung 
following intranasal inoculation whereas macrophages, dendritic cells, and neutrophils are 
infected in the skin.  Following bacterial dissemination from the skin to the lung, interstitial 
macrophages and neutrophils are the dominant infected cell types indicating the route of 
inoculation influences the types of cells that become infected with Francisella.  The lung 
milieu is more pro-inflammatory after intradermal inoculation and bacterial dissemination to 
the lung compared to lungs early after an intranasal inoculation.  We also examined how 
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disease course changed when alveolar macrophages were depleted and found increased 
bacterial burdens in the lung on day 3 post-inoculation, suggesting alveolar macrophages are 
necessary to control an intranasal LVS infection.  These data are described in Chapter 4. 
 Overall, our work has identified clpB as a gene required for multiple immune evasion 
strategies used by Francisella to persist in the host (inducing PGE2 and suppression of host 
pro-inflammatory responses).  ClpB is a chaperone protein; therefore, it is unlikely that ClpB 
itself is the effector molecule responsible for immune evasion.  Instead, we hypothesize ClpB 
is involved in insuring proper folding or trafficking of the true effector molecules.  Our 
laboratory is pursuing the targets of ClpB that induce PGE2 and prevent activation of a pro-
inflammatory cytokine response as well as the host pathways involved in the pro-
inflammatory response.  We are taking advantage of the ability of Francisella to evade host 
immunity to learn more about Francisella pathogenesis as well as key players in the host’s 
immune response.  Additionally, since ClpB is highly conserved among other bacterial 
species, identifying ClpB’s targets and their role in immune evasion could increase our 
knowledge of pathogenesis in other organisms as well.    
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